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Abstract
Syntheses of Mono- and Diamide Cross-bridged Cyclens and Syntheses of Bifunctional 
Chelators Based upon Cross-bridged Tetraamine Macrocycles
By 
Yijie Peng
University of New Hampshire, September 2004
The syntheses of two diamide cross-bridged cyclens (22 and 23) and three 
monoamide cross-bridged cyclens (24, 25, and 26) are presented. Metal (Li(I), Zn(II), 
and Cu(II)) coordination studies of 26 are also presented. Evidence suggests that ligand 
26 forms intermolecular complexes through the oxygen of an amide with Li(I), Zn(II), 
and Cu(II), and 26 could form complex with Li(I) through the nitrogen of an amide.
0  O
A  n lM  N ^ R  .N N ^ R
_  N N N N
RY  v y
o
oo- d -m =  24 R=Me
25: R=Ph
23 R_Ph 26: R=H
Appropriate cross-bridged tetraamine macrocycles are promising bifunctional 
chelators (BFC). Improved synthesis of one BFC (36) is presented, alternative synthesis 
o f one BFC (39) is also presented, the synthesis of a precursor of one BFC (42), the
xvii
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CHAPTER I
SYNTHESES OF MONO- AND DIAMIDE CROSS-BRIDGED
CYCLENS
I. Introduction
Amides are a class of molecules important to several chemical disciplines. Not 
only do they comprise a major functional group in organic chemistry, but also they 
provide the linkage between adjacent amino acid residues in proteins and polypeptides. 
Sigel and Martin provided a summary of the structure and stability of metal carboxamide 
complexes with a strong emphasis on metal complexes containing proteins and peptides.1 
Experimental stability constant data, kinetic information, spectroscopy (IR and NMR) 
measurements and some data from x-ray crystal structures were provided regarding the 
changes in the amide bond lengths upon metal coordination and the effect of metal 
coordination upon amide bond rotation. It has been presumed that most metals complex 
with the oxygen atom of an amide. According to Hay,2 the monodentate binding of amide 
ligands to metals occurs predominantly through the carbonyl oxygen atom rather than the 
amide nitrogen atom. Out o f the 227 instances examined where monodentate amides 
were bound to metal ions, in 223 cases the amide was bound to the metal through the 
carbonyl oxygen atom. There are a few examples in which multidentate ligands bearing 
amide functionality are bound to the metal through the amide’s nitrogen. Common 
chelate rings occur in these ligands, and most are primary and secondary amides that
1
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exhibit deprotonation of the amide nitrogen.2 Only one example presents spectroscopic 
and crystallographic proof of coordination of the amide nitrogen in tertiary amides.
Amide isomerization plays an important role in protein folding, where it can be 
the rate-determining step with proline-containing polypeptides and proteins.4 Peptidyl 
prolyl isomerases (PPIases), including cyclophilin and FKBP, are "rotamase" enzymes 
that catalyze protein folding in vitro and in vivo through the isomerization of proline 
residues.5 The catalysis of amide bond isomerization by Bnjmsted acids is a'Well-
6 7documented reaction that proceeds through a putative N-protonated intermediate. ’
On the other hand, the catalysis of amide bond isomerization by Lewis acid (metal 
ion) complexation with the nitrogen atom of an amide still remains to be clarified. It has 
been presumed that coordination with the oxygen of an amide should increase the barrier 
to rotation around the C-N bond and enhance its double bond character. Coordination 
with the nitrogen of an amide is expected to reduce the resonance delocalization of the 
nitrogen lone pair, decrease the barrier to rotation around C-N bond, and weaken its 
double bond character (Figure 1.1). The N-coordination should catalyze amide bond 
isomerization.
R P  R _ F  R P~
N- ^  -  -  ^ -  'N—^
R R R R R R
Figure 1.1 Resonance structures of an amide
Polyamine macrocycles are able to tightly binding and stabilize a variety of main 
group and transition metal cations. Metal complexes of these ligands exhibit extra 
thermodynamic stability that is not found for acyclic ligands, which is attributed to the
2
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macrocyclic effect. This effect has been attributed to the macrocycles having both a 
larger enthalpy and a smaller entropy of complexation than their nearest open-chained
some flexibility in their coordination geometries. This flexibility allows the ligands to 
adopt isomeric geometries about the same metal. As a result of this mixed 
stereochemistry, modifications have been made to “pre-organize” these ligands to favor 
specific coordination geometries.
Wainwright made a structural modification to the parent polyamine macrocycles 
"cyclen" and "cyclam" ligands (1 and 2, Figure 1.2) whereby two adjacent nitrogens (i.e., 
those without intervening nitrogens) were bridged with an ethylene (-CH2 CH2 -) unit (3 
and 4, Figure 1.3), reinforcing the tendency towards trans-coordination (square planar or 
octahedral tetraequatorial) of transition metal ions.9a’9b Hancock later carried out further 
investigations of the coordination chemistry of ligands of this type.10
A new class of "cross-bridged" tetraamine ligands, which have nonadjacent 
nitrogens bridged with an ethylene unit, was first reported in 1990 by Weisman and
o
analogues. Depending upon the detailed structure of the ligand, macrocycles also have
1 (cyclen) 2 (cyclam) 3 4
Figure 1.2 Cyclam and cyclen Figure 1.3 Wainwright’s structures
Wong.11 The first cross-bridged tetraamine ligand ‘dimethyl cross-bridged cyclam’ was 
shown to be strongly basic and a good Li+ complexer. Cross-bridged tetraaza
3
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macrocycles adopt a cis-folded coordination geometry when coordinated with small 
metal cations. The bridge creates a bicyclic system of two fused triaza macrocycles that 
conjointly bind a metal cation. A cavity or cleft is created by this bridging in an 
arrangement that can be equated to a clam shell. The free ligands are flexible, but when 
complexed to metal cations “they can adopt low energy conformations having all four
19nitrogen lone pairs convergent upon the cleft of the ligand”. Figure 1.4 illustrates the 
cleft created by the cross-bridged arrangement and the low energy conformation of these 
ligands upon metal complexation.11,13
-R
-R
Figure 1.4 A clam shell arrangement and the cw-folded coordination 
geometry of the cross-bridged tetraaza macrocycles 
Therefore, if  we convert one or two secondary amines (R=H) to amides 
(R=COR’), the geometry of the cross-bridged tetramines might allow the amide 




Scheme 1.1 Hypothetical structure of amide cross-bridged derivative’s metal complex
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II. Background
Tabushi and coworkers 14 have synthesized the 13- to 15-membered macrocyclic 
dioxotetraamines, 1,4,7,10-tetraazacyclotridecane-l 1,13-dione (5, Figure 1.5), 1,4,8,11- 
tetraazacyclotetradecane-12,14-dione (6, Figure 1.5), and 1,4,8,12- 
tetaazacyclopentadecane-9,11-dione (7, Figure 1.5), and Kimura and coworkers15,16 have 
studied their Cu(II) complexes. All three ligands form the neutral amide-ionized Cu(L-2H) 
species.
Figure 1.5 13,14, and 15-Membered macrocyclic dioxo tetraamines
Lectka and coworkers used specially designed ligands (8a, 8b and 8c) to study 
their Cu(II) complexes. They found that the amide rotation barrier was lowered up to 6 





Scheme 1.2 Cu(II)-catalyzed amide isomerization
5
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However, Konig and coworkers studied the binding properties of urea or amide 
derivatives of 1,4,7,10-tetraazacyclododecane, and found that Zn(II) and Cu(II) didn’t
17 18coordinate the nitrogen of the tertiary amide at all (Figure 1.6). ’
Hxr - \ H
2 C I0 * '
7  '  HN N "
H \___ / Y  '
OH \ / H
9 M=Zn(ll) 10a  M-Zn(ll)
v ’ 10b  M=Cu(ll)






4 CI°2-  4CI° 2" r N M/NA J
H \ / 'HN NH' \___ / H
11a M=Zn(ll) 12a  M=Zn(ll)
11b M=Cu(ll) 12b  M=Cu(ll)
Figure 1.6 Metal complexes of amide- and urea-functionalized cyclens
Weisman and Wong recently studied new class o f cross-bridged tetraamine 
ligands. They have developed a series o f  refined methods to synthesize different 
derivatives of cross-bridged tetraamine ligands and have studied their metal 
complexes.11,12’13
6
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Our approach to synthesize diamide derivatives of cross-bridged cyclens is based 
upon previous synthetic work in the group. The synthesis of di-N-H-cross-bridged cyclen 
(l,4,7,10-tetraazabicyclo[5.5.2]tetradecane, 17)  was first reported by Weisman, Wong 
and coworkers in 1996 (Scheme 1.3).13 The synthetic route involves the condensation of 
cyclen with glyoxal to give a bisaminal 1 4  followed by highly regioselective dialkylation 
with benzyl bromide to give the bisquatemary salt 15. By allowing the bis-quatemary salt 
to react with sodium borohydride, a reductive ring expansion leads to N-benzyl protected 
cross-bridged cyclen 16. Debenzylation of the cross-bridged cyclen then leads to the key 
intermediate 17 having two secondary amines which are available for acylation.
/ N H H N  OHC-CHO| PhCH2Br ( x s ) _  NaBH4 (xs)
NH HN CH3CN N'T^N CH3CN 95% Et0H
\ I V ± U  Ph — ' V_hJ 2Br"
13 14 15
I \ A ph I \ /---\  £
N P*1 it in o /p H /r HN. . m N '^^RS  A  A H2, 10/oPd/C  ^ /  v. A  acylation / Ns  Ns  K
N N H 0A c NH N
 I___________________________ \___ I r y \_/
O
16 17
Scheme 1.3 The synthesis of key intermediate 17 toward the
diamide cross-bridged cyclens
The synthesis ofN-H, N-methyl cross-bridged cyclen (4-methyl-1,4,7,10- 
tetraazabicyclo[5.5.2]tetradecane, 21) which is the key intermediate for mono-amide 
cross-bridged cyclen was carried out by Daniel C. Hill, a former student of Weisman and 
Wong (Scheme 1.4).19 In the first step of the synthetic sequence, cyclen was condensed
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
with glyoxal to form the cis-fused tetracyclic bisaminal 14. Selective monoalkylation 
with benzyl bromide followed by another monoalkylation with methyl iodide forms a bis- 
quatemized ammonium salt 19. Reaction of the bis-quatemary salt with reducing agent 
sodium borohydride leads to N-benzyl, N-methyl cross-bridged cyclen 20. Debenzylation 
of the cross-bridged cyclen then leads to the key intermediate 21 having one secondary 
amine which is available for acylation. Hill had difficulties obtaining pure compound 21. 
Therefore, we needed to address that problem in order to prepare monoacyf,derivatives.








^ i ' . N .  Ph CH3I ( x s ) / Nq ;
\ H / Br‘
CH3CN
18











AN . N . r
N N
20 21
Scheme 1.4 The synthesis of key intermediate 21 toward the
monoamide cross-bridged cyclens
The details o f the synthesis of mono- and diamide cross-bridged cyclens will be 
described in the Results and Discussion section of this chapter. Furthermore, attempted 
complexations with Li(I), Cu(II) and Zn(II) will also be discussed.
8
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II. Results and Discussion
A. Diamide Derivatives of Cross-bridged Cyclen
The strategy outlined in Scheme 1.3 was used to synthesize two diamide cross­
bridged cyclens (Scheme 1.5). We started from commercially available cyclen, and 
followed the synthetic route that was developed by Weisman, Wong and coworkers to 
make key intermediate 17, di-N-H cross-bridged cyclen.12 NMR spectra of intermediates 




















/TTW ^ dl,N. „N^ Ph
























Scheme 1.5 The synthesis of diamide cross-bridged cyclens
1. The Synthesis and Characterization of 4.10-Diacetvl-tetraazabicvclor5.5.21tetradecane 
(22)
Treatment of the key intermediate 17 with excess acetic anhydride gave the solid 
product 22 in good yield (85%) after basic extraction (Scheme 1.6). The compound was 
characterized by NMR, 1R, and high resolution FAB mass spectrometry (HRFABMS).
9
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c T )NH N acetic anhydride 85%




Scheme 1.6 The synthesis of compound 22 
It should be noted that there are two conformational diastereomers, one has time- 







Scheme 1.7 Schematic representation of two conformational 
diastereomers of compounds 22 and 23
1 1 ^Two sets of peaks appear in the H NMR spectrum, and 14 peaks in the C NMR
spectrum, which is one less than we predicted. The isomer which has Cs symmetry should
have 8 carbon peaks, and the isomer which has C2 symmetry should have 7 carbon peaks.
Thus, two peaks overlap by coincidence.
2. The Synthesis and Characterization of 4.10-Dibenzovl-tetraazabicvclo|~5.5.21- 
tetradecane (23)
10
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Treatment of the key intermediate 17 with excess PhCOCl in CH2 CI2  gave crude 
23 which was recrystallized from acetone to give the desired product as white crystals in 
moderate yield (50%) (Scheme 1.8). The compound was characterized by NMR, IR and 
CHN analysis.
OX
.N  HN PhCOCl N \  Ph
* N S |^
\ I 50% Ph Y  \ I
O
17 23
Scheme 1.8 The synthesis of compound 23 
Like diamide 22, 23 also has two conformational diastereomers. One has Cs 
symmetry; the other has C2 symmetry (Scheme 1.7). There are 20 peaks in its 13C NMR 
spectrum, which is a smaller number than predicted. The isomer which has Cs symmetry 
should have 11 carbon peaks, and the isomer which has C2 symmetry should have 10 
carbon peaks. The total should thus be 21 peaks, so two aromatic carbon peaks are 
accidentally coincident.
B. Mono amide Derivatives of Cross-bridged Cvclen
The synthetic strategy outlined in Scheme 4 was used to synthesize the 
monoamide cross-bridged cyclen via the key intermediate 21 (Scheme 1.9). Starting from 
commercially available cyclen and following the synthetic route that was developed by 
Weisman, Wong and Hill led to compound 20, precursor to the key intermediate 21.19
1 1
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Scheme 1.9 The synthesis of monoamide cross-bridged cyclen
However, the debenzylation failed to give pure 21 by using the conditions that 
Dan Hill used (Scheme 1.10). As previously mentioned, Hill was never able to obtain 
pure 2 1  using his conditions. 19
J. Ki/^ P h  I ^
| / NN H2i 10%Pd/C r ' N^ HN^i
>  N ' HOAc L n k NJ
 / rt  1
20 21 
Scheme 1.10 The attempted debenzylation
We analyzed the NMR spectrum of 21 that we obtained in the reaction, and we 
found the same impurity of unknown identity as reported by Hill. Thus, modifications 
had to be made in order to get pure 21. After we tried a number of different methods 
(Table 1.1), we finally found reliable debenzylation conditions (Table 1.1, entry 5). The 
hydrogenolysis (atmospheric pressure) of N-benzyl, N-methyl cross-bridged cyclen 20
12
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was carried out using 10% Pd/C in a 1% (v/v) solution of conc. HC1 in methanol at room 
temperature. After the workup with base followed by benzene extraction, the crude 
product was converted to an HC1 salt which was recrystallized from hot absolute EtOH. 




/ \ I---- \
\___ / \___ /
30%
20 21
Scheme 1.11 The Synthesis of the key intermediate 21
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1. The Synthesis and Characterization of 4-Formvl-10-methvl-tetraazabicvclor5.5.21- 
tetradecane (26)
During the investigation of the debenzylation of 20, we were very surprised to 
find that we obtained cross-bridged cyclen monoformamide 26 when we used HCO2 H as 
the hydrogen donor according to a literature procedure 2 0 ,2 1  (Table 1.1, entry 1). After we 
optimized the reaction conditions, we were able to synthesize the compound in good
14
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yield (85%) (Scheme 1.12). The compound was characterized by NMR, IR, and high 
resolution FAB mass spectrometry (HRFABMS).
O
10%Pd/C





/ \  /
H
/  \ /
20 26
Scheme 1.12 The synthesis of compound 26
One possibility for formation of 26 is that initially formed monomethyl cross­
bridged cyclen reacts with HCO2 CH3 , which is formed in situ via the reaction of HCO2H 
and CH3 OH. Alternatively, the mechanism could involve Pd/C catalyst. Control 
experiments were needed to discern between these possibilities. We did two control 
experiments: one was treatment of N-methyl, N-H cross-bridged cyclen 21 with 5% 
HCO2 H in MeOH; the other was treatment of 21 with 10 % Pd/C, and 5% HCO2 H in 
MeOH. Both control reactions gave the monomethyl cross-bridged cyclen 26 (Scheme 
13). Although the results don’t rule out the second possible mechanism, they strongly 
suggest the first mechanism.
15
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N N MeOH N N
/ \  / rt / \ __ /
14 h
21 2 6
.N  HN 10% Pd/C N \
N 5 % H C 0 2H
/  \___ / MeOH /  \___ /
rt
21 1 4 h 26
O
Scheme 1.13 Investigation of possible mechanism
2. The Synthesis and Characterization of 4-Acetvl-10-methvl-tetraazabicvclor5.5.21- 
tetradecane (24)
Treatment of the monomethyl cross-bridged cyclen 21 with excess acetic 
anhydride formed the desired product 24 in good yield (80%) after basic extraction 
(Scheme 1.14). The compound was characterized by NMR, IR and high resolution FAB 
mass spectrometry (HRFABMS).
. n n .  acetic anhydride N ^|
N N 80% N N
/ \  I_______________________y \__ I
HN.
21 24
Scheme 1.14 The synthesis of compound 24
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3. The Synthesis and Characterization of 4-Benzovl-10-methvl-tetraazabicvclor5.5.21-
tetradecane (25)
Treatment of the monomethyl cross-bridged cyclen 21 with PhCOCl in CH2 CI2 
yielded the desired product 25 in excellent yield (99%) after basic extraction (Scheme 
1.15). The compound was characterized by NMR, IR and high resolution FAB mass 
spectrometry (HRFABMS).
O
r ~ \  ' A
.N  HN PhCOCl Ph
S  CH2CI2
/  \ j 99% /  \ j
21 25
Scheme 1.15 The synthesis of monoamide 25
C. Metal Coordination Studies of 4-Formvl-10-methvl-tetraazabicvclol5.5.21 
tetradecane 26
As mentioned in the Introduction and Background sections of this chapter, the 
amide derivatives of cross-bridged cyclen were postulated to have a good chance of 
binding metal ions through the nitrogen of the amide. There are several methods which 
can determine whether the ligand binds the metal through the nitrogen of amide. 3 Amide 
rotational barriers of free ligand and metal complex can be measured by dynamic NMR 
spectroscopy. Of course the most compelling evidence for N-coordination is the X-ray 
structure of the complex. A convenient method is IR . 2 ,3 If the N-coordinated complex is 
formed, there will be a strengthened C-O  bond, and the amide carbonyl stretch will shift
17
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to higher frequency than that of free ligand. Although NMR is a powerful tool for 
investigation of complexation, typically it can’t definitively confirm whether the ligand 
binds the metal through the nitrogen or through the oxygen. The following metal 
complexes were mainly studied by IR and NMR (where possible), since we had no luck 
obtaining X-ray-quality crystals of these complexes.
1. Lithium complexation of 4-Formyl-10-methvl-tetraazabicvclo|~5.5.2] tetradecane 
(26*LiC104)
Equimolar amounts of ligand 26 (0.167 M) and LiC104  were dissolved in CD3 CN 
in an NMR tube. NMR analysis of this mixture indicated that complexation had occurred, 
but the results were more complicated than we had expected. For example, 13C NMR 
showed at least two groups of peaks. One set is sharp, and the other is dynamically 
broadened. After three more equivalents o f LiC104  were added, the sharp set of peaks 
increased, and the broadened set of peaks decreased (Figure 1.7A and Figure 1.7B).
18
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26 (0.167 M) + leq LiC104  in CD3CN
150 1 0 0 50
26 (0.167 M) + 4eq LiC104  in CD3CN
150 1 0 0 50
26 in CD3CN
150 1 0 0 50
Figure 1.7A Comparison of full I3C{'H} NMR spectra of26 with and without added
LiC104
19
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
26 (0.167 M) + leq LiC104  in CE)3CN
6 5  6 0  5 5  5 0  4 5  4 0  3 5
26 (0.167 M) + 4eq LiC104 in CD3CN
I
6 5  6 0  5 5  5 0  4 5  4 0  3 5
26 in CD3CN
i  i r | | r - T r --|—j -"| —i | | j | | [ |—|—
6 5  6 0  5 5  5 0  4 5  4 0  3 5
Figure 1.7B Comparison of 1 3C{*H} NMR upfield spectra of 26 with and without added
LiC104
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We are sure that there was no free ligand left after the addition of 1 equivalent of 
LiClCU, since the chemical shifts are different from those of free ligand. There are 12 
sharp peaks including one O O  peak and at least 9 dynamically broadened peaks 
including one C=0 peak apparent in the 13C NMR spectrum. Although we don’t know 
what kinds of complexes we have based upon the NMR data, we can rule out some 
possibilities, Simple intramolecular O-coordination can be ruled out, because this kind of 
coordination would be expected to exhibit Cs time-averaged symmetry on the NMR time 
scale, which will lead to 7 peaks at most. The r|2-CO amide binding mode can be
2 13eliminated, because in this kind of r\ -coordination the C=0 resonance in C NMR 
should dramatically move to higher field . 2 2  Solvent was removed under reduced pressure 
to give solid product, and the IR of the solid product was compared with the IR of free 
ligand. The amide carbonyl stretch actually shifts to lower frequency by 26.7 cm" 1 (Table
1.2) upon addition of excess UCIO4 , This strongly suggests that the dominant (sharp 
peaks in l3C NMR at higher concentration of LiC1 0 4 ) complexes cannot be amide N- 
coordinated, but O-coordinated. However, the dominant (broadened peaks in l3C NMR at 
lower concentration of LiC1 0 4 ) complex could be amide N-coordinated. As we discussed 
in the Introduction section of this chapter, coordination with the nitrogen of an amide is 
expected to decrease the barrier to rotation around C-N bond, which could cause the 
peaks to broaden on the NMR time scale. After addition of three more equivalent of 
UCIO4 , the magnitude of broad set o f peaks decreased, and the sharp set of peaks 
increased, which could mean that the amide N-coordination was weak. So we decided to 
screen less oxophilic late transition metals cations, including Zn(II) and Cu(Il).
21
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Table 1.2 Carbonyl stretching frequencies (oc=o, cm'1) in ligand 26 and its complexes 















1680.7 1654.0 1669.3 1671.7 1665.1 none
Ao c=o
-26.7 -11.4 -9 -15.6 . . .
Auc=o -  uc=o o f its metal complexes - t>c=o of ligand 26
2. ZnfH) complexation of 4-Formvl-10-methvl-tetraazabicvclof5.5.2]tetradecane 
(26«Zn(C104)2)
Equimolar amounts of ligand 26 (0.191 M) and Zn(C104 )2 *6H20  were heated to 
reflux in methanol solution for 40 h, the solvent was removed to give solid product. NMR 
analysis indicated that Zn(II) complexes were formed. The 13C NMR spectrum showed
one major set o f peaks, although a minor set of peaks was still visible. Comparison of the
11 C NMR resonance signals with those of free ligand showed significant changes upon 
metal ion binding, but no significant changes if  compared to the Li(I) complexes (Figure 
1.8 A and Figure 1.8 B). The amide carbonyl stretch shifted to lower frequency by 11.4 
cm ' 1 (Table 1.2). We have to draw the same conclusion as for Li (I) complexes. The 
Zn(II) complexes formed are intermolecular amide O-coordination complexes.
22
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26 (0.191 M) + 4 eq LiC104  in CD3CN
150 1 0 0 50
26 (0.191 M ).+ leq Zn(C104 ) 2 in CD3CN
ill
150 1 0 0 50
26 in CD3CN
*#» Wl
150 1 0 0 50
Figure 1.8A Comparison of full ^C l'H } NMR spectra of 26 + 4eq LiC104, 26 + leq
Zn(C104 ) 2  and 26
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26 (0.191 M) + 4eq LiC104  in CD3CN
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26 (0.191 M) + leq Zn(C104 ) 2 in CD3CN
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Figure 1.8B Comparison of i3 C{'H) NMR upfield spectra of 26 + 4eq LiC104, 26 + leq
Zn(C1 0 4 ) 2  and 26
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3. Cu(II) complexation of 4-Formyl-10-methvl-tetraazabicvclof5.5.21 tetradecane
(26«Cu(C104)2)
The ligand 26 was refluxed with an equimolar amount of Cu(C1 0 4 )2 *6 H2 0  in 
methanol. To investigate a possible participation of the amide moiety in metal ion 
coordination, IR spectra were carefully compared. We were surprised to find that the 
amide carbonyl stretch had disappeared. After recrystallization (ether diffusion), the blue 
crystalline product was subjected to CH&N analysis, consistent with Cu(C1 0 4 )2 *(2 6 - 
C0 )»H2 0  and confirming that the formyl group was gone. We decided to do two more 
complexation experiments with the ligand to rule out some possible factors.
In a first experiment, anhydrous CuCl2  was used instead of Cu(C1 0 4 )2 #6 H2 0 , all 
other conditions remaining the same. This time, the IR of the complex formed showed the 
amide carbonyl stretch at 1665.1 cm'1, which is 15.6 cm ' 1 lower than the free ligand 
stretch, and almost the same as that of the Zn(ClC>4 ) 2  complex. In a second experiment, 
anhydrous ZnCl2 was used instead of Zn(C]0 4 )2 *6 H2 0  to complex the ligand. The IR and 
NMR spectra of 26*Zn(C104)2 and 26»ZnCl2 were carefully compared. No significant 
changes upon the change of counterion could be detected. It can be assumed that Zn(II) 
and anhydrous Cu(II) salts form the same type of complex with free ligand 26. Therefore, 
it is believed that 26«CuC12 formed an intermolecular amide O-coordinated complex. In 
our initial experiments, 26«Cu(C104)2*6H20  formed the same complex. Then Cu(II) can 
act as a Lew is acid to  catalyze am ide hydrolysis, and then the n itrogen subsequently  
coordinated the Cu(II) to form a more stable complex (Scheme 1.16).
25
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VWl
Scheme 1.16 Lewis acid-catalyzed amide hydrolysis
D. Conclusions
Two diamide cross-bridged cyclens (22 and 23) and three monoamide cross­
bridged cyclens (24, 25, and 26) were synthesized. A method was developed to 
synthesize compound 2 1  which is the key intermediate in the synthesis of monoamide 
cross-bridged cyclens.
Metal (Li(I), Zn(II), and Cu(II)) coordination of compound 26 was investigated. 
We anticipated that this ligand can form metal complexes through the nitrogen and not 
the oxygen of the amide. In the Li(I) coordination study, the ligand 26 could form 
complex with Li(I) through the amide nitrogen, but the binding was weak. After more 
addition of Li(I) salt, they converted to the more stable intermolecular amide O- 
coordinated complex. Under our conditions, the evidence suggested that our ligand forms 
intermolecular coordination complexes with Zn(II) and Cu(II) through the oxygen of an 
am ide.
26
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CHAPTER II
SYNTHESES OF BIFUNCTIONAL CHELATORS BASED UPON 
CROSS-BRIDGED TETRAAMINE MACROCYCLES
I. Introduction
Radiopharmaceuticals are drugs containing a radionuclide, and are designed for 
diagnostic or therapeutic purposes, such as to deliver small doses of ionizing radiation to 
the disease sites in the body. Radiopharmaceuticals are mostly small organic or inorganic 
compounds with definite composition. They can also be macromolecules, such as 
monoclonal antibodies and antibody fragments. Biodistribution of radiopharmaceuticals 
can be determined either by their chemical and physical properties or by receptor binding 
or other biological interactions. Radiopharmaceuticals which act through receptor binding, 
are called receptor-based target-specific radiopharmaceuticals. 2 3 ,2 4 ,2 5
The use of radiometal-labeled small complexes and biomolecules as diagnostic 
agents is a relatively new area o f medical research. In the late 1940s and early 1950s, the 
use of nuclear technology for medical purposes began with nuclear reactors, accelerators, 
and cyclotrons being applied to medical isotope production. Within the last 15 years, 
there has been a considerable amount of research in the area of radiometal-labeled 
receptor targeting agents. Receptor ligands can be larger biomolecules such as peptides or 
smaller organic molecules such as dopamine or folic acid. The radiometal is connected to 
these biomolecules via a bifunctional chelator (BFC) , 2 5 ,2 6  which consists of a chelate to 
complex the radiometal and a functional group for attachment to the biomolecule
27
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(targeting molecule) by forming amide, thiourea, urea, Schiff base, or thioether linkages 
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\23,27Figure 2.1 Diagrammatic representation of a bifunctional chelator (BFC)
'IV
The first BFCs2 8  described were analogs of EDTA and DTPA (27 and 28, Figure
9Q in2.2), such as 29 (Figure 2.3). ’ Octreotide, an 8 -amino acid somatastatin (SS) analog 
has been labeled with 11 ’ in using DTPA as a BFC, and is approved for human use in the 
USA and Europe as a diagnostic imaging agent for neuroendocrine tumors. This 
development has spurred the search for new target-specific radiopharmaceuticals. 
Currently, the field of radiometal-labeled radiopharmaceuticals for imaging and therapy 
of disease is rapidly growing. New therapeutic targeting molecules are being developed
91 9A 97at a rapid pace. ’ ’
HO2C— \  / — \  / —C 0 2H 
N N
ho2c^  ^ c o 2h
H 02C— \  /  v / — \  c o 2h
N N N
ho2c^  ^ co2h^ co2h
27 (EDTA) 2 8 (DTPA)
Figure 2.2 Structures of EDTA and DTPA
The functionalized polyaminopolycarboxylic acids have served as good 
bifunctional chelators for radiolabeling biomolecules, especially with ’"in, but they are 
less applicable for chelation of many other radionuclides such as Cu and Y that are
28
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superior for diagnostic and therapeutic applications. 2 7  Studies have shown that Cu
complexes o f these analogs of EDTA and DTPA are insufficiently stable in vivo. 3 1 ,3 2  It’s
• • • well known that Cu(II) binds readily and strongly to proteins, particularly albumin.
EDTA and DTPA derivatives don’t bind Cu(II) well enough to prevent competitive
binding of Cu(II) by albumin. Therefore, it seems that stable complexes cannot be formed
by using either EDTA or DTPA as bifunctional chelating agents to label antibodies with
Cu(II). It has also been shown that 9 0Y-DTPA is not very stable in vivo, and; free 90Y
accumulates in the bone. 34
H







Figure 2.3 Structure of [ ' 1 'ln]DTPA-octreotide (OctreoScan)
New bifunctional chelating agents composed of polyazamacrocycles began to 
draw attention in the 1980s. Generally, macrocyclic complexes are less sensitive to acid 
dissociation and are more kinetically inert at lower pH.35'36 In 1985 Moi and coworkers33 
synthesized a new BFC composed of a 14-membered macrocyclic ring with four 
carboxymethyl-substituted nitrogens (32, Figure 2.4), which is a derivative of 1,4,8,11 - 
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) (30, Figure 2.4). Even though
29
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Cu(II)-32 is less thermodynamically stable than Cu(II)-EDTA or Cu(II)-DTPA, it 
decomposes in human serum at a rate of about 1 % per day which is much lower than that 
of Cu(II)-EDTA or Cu(II)-DTPA . 3 3 ,3 7  In 1989 Craig and coworkers3 2  also reported that 
1,4,7,10 tetraazacyclododecane-l,4,7,10-tetraacetic acid (DOTA) (31, Figure 2.4) forms 
a more kinetically inert complex with 90Y than DTPA. Therefore TETA- and DOTA- 
based BFCs have been investigated and have been used to radiolabel a number of 
different cancer-associated antibodies. 9 0 Y-DOTA-peptide conjugates for radioimaging 
and radiotherapy are in clinical trials, 3 8 and ^Cu-TETA-peptide conjugates are also
•>Q
being evaluated as radioimaging agents for neuroendocrine tumors.
II. Background
There are several strategies for the design of receptor-based target-specific 
metalloradiopharmaceuticals. These include the integrated approach, the bifunctional
HOOC /N  N. COOH HOOC /N  N. COOH
HOOa /N  N ' /COOH HOOC^ "N N. XOOH
30 (TETA)
HOOC /N  Isk COOH
H O O a /N  Nr /COOH
31 (DOTA) 32
Figure 2.4 TETA, DOTA and a TETA Derivative 32
30
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approach and the peptide-hybrid approach. 2 3 ,2 4  “The integrated approach involves the 
replacement of part of a known high affinity receptor ligand with the requisite ‘unnatural’ 
metal chelate in such a way that there are minimal changes in size, conformation, and 
receptor binding affinity. The bifunctional approach uses a high affinity receptor ligand 
as the targeting biomolecule, a bifunctional chelator (BFC) for conjugation of the 
biomolecule and chelation of the radionuclide. In the peptide-hybrid approach, the 
radionuclide is chelated by a tripeptide sequence containing an N4 , N3 S, or N2 S2 donor 
set. ” 23 However, the bifunctional approach is the most popular approach for the 
development of receptor-based target-specific radiopharmaceuticals. There are several 
requirements for an ideal BFC. The BFC has to be able to withstand radiolysis because a 
large dose of P-radiation can produce very reactive free radicals and result in a significant 
amount of decomposition of the metal chelate during process and transportation. The 
BFC must form a metal chelate with high thermodynamic stability and kinetic inertness 
at biological pH in order to keep the metal chelate intact under physiological conditions. 
Decomposition of the metal chelate produces free radiometal ion, which may damage 
healthy cells. The conjugation group of the BFC should be easily attached to the 
biomolecule. 2 3 '2 4
The most common way to increase the thermodynamic stability and kinetic 
inertness of a metal complex is to use a polydentate chelator. Compared to open-chained 
analogues, polydentate macrocyclic ligand metal complexes exhibit extra thermodynamic
o
stability , which is attributed to the macrocyclic effect: a larger enthalpy and smaller 
entropy of formation. Three common tetraaza macrocycles that we are interested in are 
cyclen, 13-ane-N4, (sometimes called homocyclen) and cyclam (Figure 2.5). These
31
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macrocycles also have flexibility in their coordination geometries. The flexibility allows 
macrocycles to coordinate many different metals, but it also allows the ligands to adopt 
isomeric geometries about the same metal. As a result of this mixed stereochemistry, 
modifications have been made to “preorganize” these ligands to favor specific 
coordination geometries. The higher the degree of preorganization of an uncoordinated 
ligand, the more stable the metal complex. 2 3 ,3 9 ,4 0  Preorganization of the ligand framework 
also tends to improve the kinetic inertness, 41 which is the determining factor for the 
release of radionuclide from the metalloradiopharmaceutical.
.NHHN .NHHN .N H  HN
NH HN NH HN NH HN
1 (cyclen) 33 (13-ane-N4) 2 (cyclam)
Figure 2.5 Cyclen, 13-ane-N4, and cyclam
As discussed in Chapter one, Weisman and Wong made a structural modification 
to the parent polyamine macrocycles cyclen, 13-ane-N4, and cyclam ligands whereby two 
nonadjacent nitrogens were bridged with an ethylene (-CH2 CH2 -) unit (17,34 and 35, 
Figure 2.6)"’12'13'19. These cross-bridged tetraaza macrocycles adopt a cis-folded 
coordination geometry when coordinated with small metal cations. Figure 2.7 illustrates 
the cleft created by the cross-bridged arrangement and the low energy conformation of 
these ligands upon metal complexation. For example, the copper (II) complex of the
32
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dimethyl cross-bridged cyclam was found to be over eight orders of magnitude more
stable to acid decomplexation than its closest unbridged analog.42
cN . HN .N  H N . N H N .
NH 'N '  NH N NH N '
17 34 35
Figure 2.6 Cross-bridged cyclen 17, cross-bridged 13-ane-N4 34, 
and cross-bridged cyclam 35
Figure 2.7 A clam shell arrangement and the cis-folded coordination 
geometry of the cross-bridged tetraaza macrocycles
A further enhancement of the already high kinetic stability of these cross-bridged 
ligand copper(II) complexes can be realized through the attachment of ionizable pendant 
arms at the two secondary nitrogens. As shown by a number of X-ray studies, these 
pendent arms can serve to fully envelop a six coordinate cation as well as neutralize a 
dicationic charge. The latter property is desirable for optimal 6 4 Cu(II) complex 
biodistribution and clearance characteristics. 12 ,4 3 4 4
33
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Analogs of TETA are currently the most common chelators used for copper
radionuclides. However, nearly all radio-Cu(II) complexes (e.g. radio-Cu(II)-TETA) 
exhibit in vivo instability due to transchelation of the Cu(II) to proteins. 4 S ’4 6  A current
challenge in the development of copper radiopharmaceuticals is to design appropriate 
macrocyclic chelators that can form complexes with copper radionuclides that exhibit a 
high kinetic stability in vivo. Results on the complex of Cu(II) with the ligand, 4,11 - bis- 
(carboxymethyl)-l ,4,8,11 -tetraazabicyclo[6.6.2]hexadecane (CB-TE2A) (34>, Figure 2.8) 
indicate the ligand can be radiolabeled in high radiochemical purity and that the labeled 
complex was found to be highly stable in rat serum for 24 hours. As a neutral complex it 
cleared rapidly from all tissues and had more optimal clearance properties than 6 4Cu- 
TETA. 64Cu-36 behaves ideally in vivo, suggesting that 36 itself or other bifunctional 
chelators based on 36 will have significant potential as a labeled copper radionuclide for 
diagnostic imaging and targeted radiotherapy. 4 4 ,4 8
36 (CB-TE2A)
Figure 2.8 Structure of 36
36 as a BFC was conjugated with a special biomolecule (e.g. Y3-TATE, which is 
a well-characterized SSTr2 ligand and a good model for evaluating novel BFC-peptide 
conjugates).The bioconjuget, 36-Y3-TATE (37, Figure 2.9), was then labeled with
34
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^CuCII). It was determined that 6 4 Cu-37 has better microPET data for imaging cancer 
than 6 4 Cu-TETA-Y3-TATE (38, Figure 2.10), which is superior in tumor uptake and 
biological clearance in a tumor-bearing rat model. Therefore, 36 is a superior chelator for
wn
38
Figure 2.10 Structure of TETA-Y3-TATE
Thus, appropriate cross-bridged tetraamine macrocycles are promising BFCs, and 
36 shows excellent results for diagnostic imaging. In Figure 2.11 are listed known BFCs 
based upon cross-bridged ligands whose syntheses needed to be improved as well as new 
designed BFCs based upon the cross-bridged tetraamine macrocycles (Figure 2.11). Our 
general strategy for synthesis of BFCs based on the pendant-arm cross-bridged 
tetraamine motif requires BFC precursor targets having a remote unprotected carboxyl
64Cu due to improved liver and blood clearance, resulting in higher tumor/tissue ratios 
compared to the 6 4 Cu-labeled TETA conjugate. Modifications to 36 to reduce the net 
positive charge of the Cu(II) complex may further improve the biodistribution.4 9
OH
37
Figure 2.9 A BFC application of 36
35
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group for bioconjugation (peptide or protein coupling) and carboxyls for coordination 
protected as t-butyl esters. After conjugation, the esters are to be deprotected to carboxyl 
groups for radiolabelling with metal. Synthetic designs also must minimize 
stereochemical complications. Dr. Carolyn Anderson’s group and collaborators at the 
Washington University School of Medicine then carry out bioconjugation and evaluate 
the efficacy of the bioconjugates as carriers of cancer diagnostic and therapeutic copper, 
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Figure 2.11 The structures o f targeting molecules
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Scheme 2.1 The synthesis of 36-4HC1
An alternative synthesis was needed. We proposed the following retrosynthetic 
pathway for 36 (Scheme 2.2).
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Scheme 2.2 Retro-synthetic routes for 36
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The ligand 39 was originally developed by Condon50 in our research group
(Scheme 2.3).
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Scheme 2.3 Condon’s synthesis of 39«1TFA
An alternative synthesis could be realized as indicated in Scheme 2.4.
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Scheme 2.4 Retro-synthetic routes for 39
Condon’s initial work on a benzo-annelated cross-bridged cyclam had focused on 
utilizing the synthetic approach developed by Weisman, Wong and coworkers toward 
cross-bridged tetraazamacrocycles with dibenzocyclam, which has been reported in the 
literature. 5 ' ,5 2 ’5 3 ’5 4 Needing this ligand for his study, Condon had worked out the protocol 
for the synthesis of dibenzocyclam 56 shown in Scheme 2.5. 50
38
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NH2CH2CH2NH2 
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Scheme 2.5 The Synthesis of dibenzocyclam 56 
Having the dibenzocyclam ligand 56 in hand, Condon performed a glyoxal 
condensation to obtain the cis-fused glyoxal adduct 57, and also carried out the synthesis
of one example o f a cross-bridged dibenzocyclam (Scheme 2.6) 50
NH HN
NH HN
40% aq glyoxal 









Scheme 2.6 The synthesis of cross-bridged dibenzocyclam 59
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With the synthesis of dibenzo biaminal 57 in hand, we proposed the following 
retrosynthetic pathway for 44 (Scheme 2.7).
CH2CH2C02H CH2CH2C02Bn
N O f  
& \ ? °
44
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Scheme 2.7 Retro-synthetic routes for 44
Bist’s5 5 initial work on the C-substituted cross-bridged tetraazamacrocycles in our 
group had focused on utilizing the synthetic approach of Weisman, Wong and coworkers 
toward cross-bridged tetraazamacrocycles. She performed a pyruvaldehyde condensation 
with cyclen to obtain the cis-fused pyruvaldehyde adduct 6 6  which was finally converted 
to C-substituted cross-bridged cyclen 6 8  (Scheme 2.8) . 5 5
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Scheme 2.8 The synthesis o f C-substituted cross-bridged cyclen 6 8  
We are encouraged by the example of C-substituted cross-bridged cyclen 6 8 . It 
envisioned that we can use same synthetic strategy to approach our BFC 40. The 
retrosynthetic pathway for 40 is shown in Scheme 2.9.
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Scheme 2.9 Retro-synthetic route for 40
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Condon5 0  also had worked on the N-carbo-tert-butoxymethyl cross-bridged cyclen 
73, which is a very useful compound due to its secondary amine. The precursor 72 was 
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Scheme 2.10 Toward the synthesis o f mono-tert-butyl cross-bridged cyclen 73 
We are encouraged by the debezylation method that we developed earlier for 
synthesizing N-methyl cross-bridged cyclen 21 (Chapter one). Therefore, our retro- 
synthetic pathway toward BFC 41 is proposed based upon compound 72 (Scheme 2.11).
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Scheme 2.11 Retro-synthetic routes for BFC 41 
It is also envisioned that we could use same strategy to approach BFC 43, 45 and 
46. Scheme 2.12 shows the retro-synthetic pathway for BFC 43, 45 and 46.
42
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Scheme 2.12 Retro-synthetic route for BFC 43,45 and 46
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Scheme 2.13 The synthesis of cross-bridged 14-ane-N4 34
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With the synthesis of 34 in hand, we proposed the following retrosynthetic 
pathway for 42 (Scheme 2.14).
HO'
,N N (V




Scheme 1.14 Retro-synthetic route for 42 
The successes and failures of our synthetic approaches to the BFCs of Figure 2.11 
will be discussed in the Results and Discussion section.
III. Results and Discussion
A. The Synthesis and Characterization of the Bis-(trifluoroacetic acid) Salt of 4.11- 
Bis-(carboxvmethvD-1.4.8.11-tetraazabicvclol6.6.21hexadecane (36+2TFA)
The synthetic strategy which was outlined in Scheme 2.2 was used to synthesize 
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Scheme 2.15 The synthesis of 36«2TFA
44
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Di-N-H cross-bridged cyclam 35 which was originally synthesized by Weisman, Wong 
and Hill was allowed to react with a slightly excess of tert-butyl bromoacetate in CH3CN 
to give the desired product 51 as a white solid in excellent yield (93%), 51 was 
characterized by NMR, IR, and high resolution FAB mass spectrometry (HRFABMS). 51 
was then stirred in 1:1 (v:v) solution of TFA: CH2 CI2 for 48 h. Solvent removal gave oil, 
which crystallized after removal o f residual solvent under vacuum. This solid passed 
elemental analysis as a di-TFA salt. Compound 36’s proton and carbon NMR spectra 
were consistent with this formulation.
This method was preferred over the former method which was developed by 
Hill. 1 2 ,1 3 ,1 9  The deprotection of t-butyl ester is much easer than the deprotection of ethyl 
ester.
B. The Synthesis of 4-(tert-Butvl)carboxvmethvl-1 Q-(2-hvdroxv-benzvO-l.4.7.10- 
tetraazabicvclol5.5.21tetradecane (83) and The Attempted Synthesis of 3-flO-tert- 
Butoxvcarbonvlmethvl-1.4.7.10-tetraazabicvclo 15.5.21 tetradec-4-vlmethvD-4- 
hvdroxv-benzoic acid (41)
Compound 41 (Figure 2.12) was a good candidate for BFC. The synthetic 
strategy which was outlined in Scheme 2.11 was used to synthesize the target.
HO.
41
Figure 2.12 The Structure of BFC 41
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Before we tried to synthesize desired BFC 41, we first tried a model compound. 
This approach has at least two advantages, one is that we can check the method that we 
try to use to make the desired compound; the other is that we can use the model 
compound to perform the coordination chemistry to check if the desired BFC has good 
kinetic and thermodynamic properties in coordination chemistry. The model compound 
83 was synthesized as indicated in Scheme 2.16.
The precursor o f N-carbo-tert-butoxymethyl cross-bridged cyclen 72 was synthesized by 
following the method that was developed by Condon5 0  (Scheme 2.10), and its selective 
debenzylation was performed by using the acidic condition hydrogenolysis that we 
developed earlier for synthesizing N-methyl cross-bridged cyclen 21 (Chapter One) as 
indicated in Scheme 2.16. The compound 73 was characterized by NMR, IR, and high 
resolution FAB mass spectrometry (HRFABMS). And then the mono-tert-butyl cross­
















Scheme 2.16 The synthesis of model compound 83 of BFC 41
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triacetoxyborohydride was then added. After base extraction, solvent removal gave the 
desired product in moderate yield (40%). The compound 83 was characterized by NMR, 
IR, and high resolution FAB mass spectrometry (HRFABMS).
Having synthesized the model compound 83, it was envisioned that the BFC 41 












Scheme 2.17 Attempted synthesis of BFC 41
Before its reductive alkylation was attempted, we needed to synthesize the 3- 
formyl-4-hydroxy benzoic acid 8556 first. We used a Duff reaction5 7 to synthesize the 
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Scheme 2.18 The synthesis of 85
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4-Hydroxy benzoic acid 84 and hexamethylene tetramine were dissolved in 
HOAc. The mixture was refluxing for 5 hours, and 33% aq H2 SO4  solution was added 
into the mixture, the resulting mixture was refluxed for an additional 1 hour. After CHCI3 
extraction, solvent removal gave white solid product 85 in 39% yield.
The reductive alkylation was then attempted. We used the same procedure as we 
developed for synthesis of the model compound 83. The mono-tert-butyl cross-bridged 
cyclen 73 and 3-formyl-4-hydroxy benzoic acid 85 were mixed in CH2 CICH2 CI, and 
sodium triacetoxyborohydride was then added (Scheme 2.17). The workup was difficult, 
because the product should be an amino acid if we made the compound. The solution’s 
pH was adjusted to try to precipitate, or to extract with organic solvent such as CeH6  and 
CHCI3 , but that approach failed. Finally, all solvents were removed under reduced 
pressure to generate the crude product. NMR shows that we made the compound 41, and 
also shows some unknown impurities. We tried to isolate the product by chromatography, 
but it failed. Because the desired BFC is too polar, in the future we might isolate the 
product by reverse phase chromatography.
C. The Synthesis and Characterization of Hydrochloride Salt of 4-Carboxvmethvl- 
1.4.7.10-tetraazabicvclol5.5.21tetradecane (87*4HC1).
During the investigation of BFC 41 we found that we could easily synthesize the 
monoionizable cross-bridged cyclen 87, which is a very interesting ligand for metal 
complexation study.
87 was synthesized by acidic hydrolysis as indicated in Scheme 2.19.
48
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Scheme 2.19 The synthesis of 87 
The cross-bridged cyclen 72 was dissolved in a solution of 4.4% HCOOH in MeOH, and 
10% Pd/C as catalyst was also added into the mixture. After workup, the, solvent was 
removed under reduced pressure to give pure product in excellent yield (99%). 8 6  was 
characterized by NMR, IR, and high resolution FAB mass spectrometry (HRFABMS). 8 6  
was then dissolved in 6  M HCI and allowed to reflux for 3 days. Solvent removal gave 
the product as a white solid HCI salt, the mass calculation indicated that there are four 
HCI molecules. The compound 87 was characterized by NMR, IR, and high resolution 
FAB mass spectrometry (HRFABMS).
D. Attempted Synthesis of C-functionalized BFC 40
40 (Figure 13) was a good candidate for BFC. The synthetic strategy which was 
outlined in Scheme 2.9 was used to approach the target.
HO„n
40
Figure 2.13 The Structure of BFC 40
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According to the strategy, first step is that cyclen reacts with 4,5-dioxopentanoic 
acid (91). Compound 91 isn’t commercially available, but 91 is a known compound, and 
can be prepared in two steps using a published method5 8 which starts from commercially 
available laevulinic acid and benzaldehyde (Scheme 2.20). Laevulinic acid and 
benzaldehyde were dissolved in dry benzene, and acetic acid and dry piperidine were also 
added to the mixture. The resulting solution was then refluxed for 72 hours. After workup, 
solvent removal gave white crystalline product 90 in 81% yield. The melting point and 
'H NMR were consistent with the reported spectra, and l3C NMR was also consistent 
with the formulation. After we made the benzylidene laevulinic acid 90, we followed the 
literature ozonolysis to give the 4,5-dioxopentanoic acid 91 in 90% yield (calculated 








1. 0 3, -78 °C
2. CH3 SCH 3  







Scheme 2.20 The synthesis of 4, 5-dioxopentanoic acid 91
However, the compound wasn’t fully characterized in the literature58’59’60, even in the
r o  1
original published paper . The authors only showed one complex H NMR, and
mentioned that the compound passed CHN analysis as a monohydrate compound. We
50
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
believe that the product is a mixture of at least three molecules as indicated in Scheme 
2.21. NMR showed that the hydrate form 92 is likely the dominant molecule. The 
monohydrate was used in our next step without further purification.
O
0  0  HCX?H 9
h '  y  ^  ' 0 H " —  H Y  0H
o  0
91 92
Scheme 2.21 Possible three molecules 
Compound 70 was synthesized by the condensation reaction as indicated in 
Scheme 2.22.
N ^ N  o o




N * NNH HN g  50-60 °C
'— ' 4 h
13 91 7%-13% 7Q
Scheme 2.22 The synthesis of 70 
Cyclen (13) and excess 4,5-dioxopentanoic acid monohydrate 91 were dissolved 
in CH3CN or MeOH, and the solution was heated to 50-60 °C for 4 hours. Solvent 
removal gave crude product which was subjected to chromatography to give pure product 
in, at best, 13% yield. The compound 70 was characterized by NMR, IR, and high 
resolution FAB mass spectrometry (HRFABMS).
Alkylation of tetracyclic bisaminal 70 with excess tert-butyl bromoacetate was 
attempted (Scheme 2.23).
51
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Scheme 2.23 Attempted synthesis of 69
Generally, CH3 CN is our first choice as the solvent of this kind of alkylation 
reaction in our group, but 70 has very poor solubility in CH3 CN and is more soluble in 
CH2 CI2 . Therefore, 70 and excess t-butyl bromoacetate was dissolved in CH2 CI2 and then 
the mixture was stirred for 3 days. Unfortunately, no precipitate was formed. Diethyl 
ether was added to form precipitate which was isolated and subjected to NMR analysis. 
The NMR spectra were complex, indicating a mixture. t-Butyl signals were present in 
both 'H NMR and 13C NMR spectra. The free carboxyl acid group likely caused this 
failure, so we decided to protect the carboxylic acid. In addition, the best yield of 
condensation reaction between cyclen and excess 91 was only 13%, and we hoped to 
increase the percent yield after protection of free carboxylic acid.
The methyl ester derivative 9561a was synthesized as indicated in Scheme 2.24. 
Benzylidene laevulinic acid 90 was dissolved in MeOH, a few drops of cone. H2 SO4  were 
added, and the mixture was refluxed for 0.75 hours. Solvent was removed under reduced 
pressure to give crude product which was recrystallized from a hot mixture of ethyl 
acetate and hexane (1:4, v:v) to yield crystalline product 9461b in 75% yield. Compound 
94 was converted to methyl 4, 5-dioxopentanoate 95 by ozonolysis.
52
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Scheme 2.24 The synthesis of 95 
Another alternative synthetic approach of compound 95 is indicated in Scheme 
2.25. Compound 99 was prepared in three steps by published methods , and then 
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Treatment o f laevulinic acid 96 with Br2 in refluxing methanol gave a mixture of 
methyl 5-bromolaevulinate (97), 3-bromolaevulinate (100), and 3,5-dibromolaevulinate 
(101).62a After column chromatography, we isolated the methyl 5-bromolaevulinate 97 in 
24% yield. Sn2 displacement by formate under basic conditions in benzene yielded the 
formyloxy compound 98 which was easily hydrolyzed to the 5-hydroxy methyl ester 99 
by passing it through a column of neutral alumina.62b The methyl 4, 5-dioxopentanoate 95 
was prepared by TPAP oxidation.
Interestingly, during one early attempt to synthesize 95 by ozonolysis, using H2 
and 10% Pd/C in the reductive workup instead of dimethyl sulfide, an unknown product 
was obtained. Comparison of the spectra of this product with those of methyl 5- 
hydroxylaevulinate 99, showed them to be the same (Scheme 2.26).
OCH,
1. 0 3, -78 °C
2. H2, 10% Pd/C 







Scheme 2.26 The synthesis of 99
Although the methyl 4,5-dioxopentanoate 95 was a known compound, 61 no NMR 
data were available in the literature. By searching the literature we found that there was a 
complex proton NMR spectrum of the ethyl 4,5-dioxopentanoate6 4  which was made by 
ozonolysis, and the authors mentioned that the compound was unstable, and used 
immediately without further purification.
54
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Scheme 2.27 The attempted synthesis of 102
Cyclen (13) and excess methyl 4,5-dioxopentanoate 93 were dissolved in CH3 CN or
MeOH, and the solution was heated to 50-60 °C for 4 hours. Solvent removal gave crude
product which was subjected to chromatography to give compound 102 in less than 7%.
1 1 ^But some extra peaks in both H NMR and C NMR were observed, the extra peaks 
were located in aromatic region.
As all of the attempts failed, an alternative strategy toward the BFC 40 is needed. 
Time constraints prevented the investigation of such an approach. We hope that some 
other member of the Weisman and Wong groups can finish the job in the future.
E. An Alternative Synthesis of 53
The precursor of BFC 39, di-t-butyl ester 53, had been synthesized and converted 
to compound 39 by Condon50 as indicated in Scheme 2.3.
We investigated the possibility of direct monoalkylation of cross-bridged cyclen 
17 with t-butyl bromoacetate, the pure mono-tert-butyl ester cross-bridged cyclen 73
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wasn’t obtained by direct alkylation of cross-bridged cyclen 17. Instead the pure di-tert- 
butyl ester cross-bridged cyclen 53 was obtained as indicated in Scheme 2.28.
n ~ \  . n ~ n C Y ° "Kl UM  * u ..* . J  u - _______ s ' \  \  II
I \ ^  .OH
HN. t-butyl bromoacetate (1 eq) f  '''i A ' r/ N 'vi N^i 11
Q J  — 5 = --------  V Ln U   * 9 L U
Or
' N H  N 4 9 0 /0
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'----- 1 HO '___ I ‘1TFA
53 39
Scheme 2.28 The formal synthesis of 39 
Cross-bridged cyclen 17 was dissolved in toluene, and anhydrous sodium 
carbonate and 1 equivalent of t-butylbromoacetate were added. The mixture was stirred 
for 24 h at room temperature. After solid KOH was used to adjust pH to 14, the organic 
layer was separated, dried (Na2 SC>4 ), and evaporated to dryness under reduced pressure to 
yield pure 53 as slightly yellow oil in 49% yield. At that time we didn’t recover the 
equivalent of starting material from aqueous phase. NMR spectra of 53 were consistent 
with spectra of authentic material.
F. The Synthesis and Characterization of 4.11-Bis-(carbo-tert-butoxvmethvO- 
1.4.8.11 -tetraazabicvclo 16.5.21 pentadecane (82).
As discussed in the Background of this chapter, the precursor Di-NH, cross­
bridged 14-ane-N4 34 was synthesized according to the procedure outlined by Hill 
(Scheme 2.9) . 19
The compound 82 was synthesized as indicated in Scheme 2.29.
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Scheme 2.29 The synthesis of 82
Treatment of di-NH, cross-bridged 14-ane-N4 34 with excess tert-butyl bromoacetate 
under basic conditions in MeCN gave crude product. After chromatography the pure 
compound 82 was obtained in moderate yield (55%).
Although time and sample quantity constraints prevented our conversion of 82 to 
the trifluoroacetic acid salt of 4,11-bis-(carboxymethyl)-1,4,8,11 -tetraazabicyclo[6.5.2]- 
pentadecane (42»nTFA), this will be carried out in the future as indicated in Scheme 2.27. 
The small sample of 82 that we prepared was provided to Professor Carolyn Anderson’s 
group at Washington University for conversion to 42 and subsequent labeling with 
6 4 Cu(II). The Weisman and Wong groups will scale this up and carry out cold Cu(II) 
coordination chemistry in the future.
G. Progress Toward Dibenzo BFC 44
The synthetic strategy which was outlined in Scheme 2.7 was used to approach 
the interesting BFC 44 (Figure 2.14).
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4 4
Figure 2.14 The Structure of BFC 44 
The compound 64 was synthesized as indicated in Scheme 2.30.65’66
Br Br





/ N k N
+
57
Scheme 2.30 The synthesis of 64 
Starting material 57 was synthesized by following the method that was developed 
by Condon (Scheme 2.6)50. Treatment o f 57 with 1 equivalent of tetrabutylammonium 
tribromide (TBABrs) in CHCI3 didn’t give exclusively the mono-para-brominated (para 
to aniline nitrogen) compound, but a mixture o f monobrominated compound 64, 
dibrominated compound 103 and starting material 57. When we used more than 1 
equivalent TBABr3 up to slight excess o f 2 equivalents TBABr3 , dibrominated 103 
became major product.
58
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From NMR spetra, approximately 40% of the product was mono-substituted 
product 64, which can be purified by chromatography. Unfortunately, the mono- and 
dibromination derivatives have very similar solubility, and both have very poor solubility 
in almost all solvents, which makes isolation very difficult. Small amounts of sample had 
to be dissolved in large amounts of solvent. By flash chromatography product of 
approximately 70% purity was obtained and this was subsequently used without further 
purification. A small amount of pure compound was acquired by repeated fl#sh 
chromatography (4 times). The compound 64 was characterized by NMR, IR, and high 
resolution FAB mass spectrometry (HRFABMS).
The compound 63 was synthesized from 64 by a Heck coupling reaction6 7  as 
indicated in Scheme 2.31.
COpBn






6 4  63
Scheme 2.31 The synthesis of 63
Treatment of monobrominated derivative 64 with NaOAc, tri(o-tolyl)phosphine, 
Palladium(II)acetate, and benzyl acrylate in DMF at 150 °C for 20 h gave crude product 
after workup and removal solvent. After chromatography, pure 63 was obtained in 21 %
59
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yield. 63 was characterized by NMR, IR, and high resolution FAB mass spectrometry 
(HRFABMS).
Hydrogenation of the olefin of 63 without debenzylation was attempted (Scheme 
2.32). A variety of conditions for hydrogenation of alkenes containing the
68 69 70 71hydrogenolysis-susceptible O-benzyl (Bn) group are reported in the literature. ’ ’ ’
63 62 
Scheme 2.32 The attempted synthesis of 62
Maki and coworkers71 had reported the use of Pd black as a catalyst to perform 












Scheme 2.33 An example of hydrogenolysis-ffee hydrogenation of olefin
Therefore, the chemoselective hydrogenation was attempted using the literature 
condition. Unfortunately, a mixture containing mostly starting material was obtained. As
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the attempted hydrogenation failed to afford compound 62, other metal catalysts or other 
methods are needed to overcome the problem. Time constraints prevented the 
investigation of such an attempt.
In his investigation of C2 dibenzoannelated dimethyl cross-bridged cyclam 59, 
Condon5 0  has found that dibenzo bisaminal 57 had a solubility limit toward alkylation: 
The formation of the bis-quatemized bisaminal was hampered by poor solubility of 57 in 
our typical reaction solvents (MeCN, MeOH, EtOH) for Sn2 alkylation. A possible 
solution to this problem involves appending flexible alkyl or alkaryl groups to this 
molecule. When we investigated the conditions for monobromination of 64, we found 
that dibrominated derivatives are easily prepared. That’s a good starting point for 
modification of this molecule.
The dibromo bisaminal 103 was synthesized by TBABr3 bromination as indicated 
in Scheme 2.34.
Treatment of dibenzoannelated bisaminal 57 with a slight excess of 2 equivalents of 
TBABr3 in refluxing CHCI3 gave crude product. Recrystallization from hot chloroform 





Scheme 2.34 The synthesis of 103
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(Figure 2.15), solved by Roger Sommers and Arnold Rheingold (Crystallography 
Laboratory, Department of Chemistry and Biochemistry, University o f Delaware), was 
similar to the structure of its parent compound 57. The crystal structure shows its C2 
symmetry and the flanking of the benzene rings about the cleft of this compound. 
Selected bond lengths and angles from the crystal structure of compound 103 are shown 
in Table 2.1.
Figure 2.15 The crystal structure of the dibromo bisaminal 103
62
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Table 2.1 Selected bond lengths and angles from the crystal structure of compound 103
N(l)-C(l) 1.447 A N(l)-C(3) 1.464 A N(l)-C(4) 1.453 A
N(2)-C(l) 1.476 A N(2)-C(2A) 1.467 A N(2)-C(10) 1.399 A
C(4)-N(l)-C(l) 109.74° C(4)-N(l)-C(3) 112.29° C(l)-N(l)-C(3) 111.46°
C(10)-N(2)-C(l) 116.54° C( 10)-N(2)-C(2A) 117.87° C(1)-N(2)-C(2A) 112.84°
fi 7The compound 106 was synthesized by a Heck coupling reaction as indicated in 
Scheme 2.35.










Scheme 2.35 The synthesis of 106 
Treatment of dibrominated derivative 103 with NaOAc, tri(o-tolyl)phosphine, 
palladium(II)acetate, and benzyl acrylate in DMF at 130 °C for 3 days gave crude product 
after workup and removal solvent. After chromatography, we got a white solid consisting 
of a mixture of two products: 106 and 107. The major product was the desired product 
106 and the minor product was 2-bromo-9-styryl-5,6,12,13,13b,13c-hexahydro-7H,14H-
63
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4b,6a,l lb ,l 3a-tetraazadibenzo[b,def]chrysene (107). The ratio of major to minor was 
4.7:1. The mixture was used for next step without further purification.
The compound 108 was synthesized by hydrogenation as indicated in scheme
2.36.
106 108 
Scheme 2.36 The synthesis of 108 
82% purity o f 106 was converted to product 108 by the standard conditions for 
hydrogenation using 10% Pd/C and atmospheric H2 in ethyl acetate. 108 was obtained in 
moderate yield (60%) after chromatography. 108 was characterized by NMR, IR, and 
high resolution FAB mass spectrometry (HRFABMS).
Two alkylating agents were used for the attempted alkylation of compound 108 as 
indicated in Scheme 2.37.
64
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Scheme 2.37 Two attempted alkylation of 108 
The solubility of 108 in CH3 CN, CH3 OH and EtOH is almost as poor as that of its 
parents, but the solubility in CHCI3 and CH2 CI2 is better than that of its parents. 
Therefore, CHCI3 was used for the alkylation. In the first reaction, the compound 108 
was treated with excess tert-butyl bromoacetate in CHCI3 , after 3 days at room 
temperature no precipitate was formed. Diethyl ether was added to the solution to 
precipitate out the contents, which proved to be starting materials determined by NMR.
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In the second reaction, 108 was allowed to react with an excess of benzyl bromide in 
CHCI3 . After 3 days at room temperature no precipitate was formed. Diethyl ether was 
added to the solution to precipitate out the contents, which had complex NMR spectra 
indicative of a mixture. Further investigation of this reaction seems warranted more 
conclusions here.
H. Attempted Synthesis of BFC 36 and Synthesis of Diamide 115 By a Short 
Synthetic Route
Since Condon5 0 has already synthesized BFC 39 by using a short synthetic route 
(Scheme 2.3), we hoped to use same strategy to approach the BFC 36. The retrosynthetic 
pathway for 36 is indicated in Scheme 2.38.
47
Scheme 2.38 Short retro-synthetic route for BFC 36 
The bisaminal compound 47 was reacted with excess t-butyl bromoacetate in a 
variety different solvents (CH3 CN, CH2 CI2 , CHCI3 and MeOH) (Scheme 2.39). No 
precipitate formed in any of these reactions. After diethyl ether was added to each
66
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reaction, a white precipitate formed. The precipitate was isolated, and analyzed by NMR. 
NMR spectra showed that it wasn’t the pure desired product, but a mixture.
t-butyl b rom oacetate (x s)  
solvent
Scheme 2.39 The attempted synthesis of 111
However, when cyclam glyoxal adduct 47 was allowed to react with excess ethyl 
bromoacetate in CH3 CN (Scheme 2.40), a small amount of white precipitate formed. This 
precipitate was isolated and shown to be pure product 1 1 2 , but the % yield was very poor 
(7%). When diethyl ether was added to the mother liquid, a white precipitate formed. The 
precipitate was isolated, and analyzed by NMR, which showed it to be a mixture.
ethyl b rom oacetate (xs)
CH3CN
7%
Scheme 2.40 The synthesis of 112 
When cyclam glyoxal adduct 47 was allowed to react with an excess ( 8  
equivalents) o f 2-bromoacetamide in CH3 CN for less than 5 days, the white precipitate 
that formed was isolated and shown to be the unexpected monoalkylated product 113 
(52% yield) (Scheme 2.41). 113 was characterized by NMR, IR, and high resolution FAB 
mass spectrometry (HRFABMS).
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N' ! ^ Nn  BrCH2CONH2(xs) ^  4 "  t Q
OH 3ON \ k| / | \ K|^N ■ N 0 N * N
f  H J  <5 days I J
^  52% ^  Br
47 113
Scheme 2.41 The synthesis of 113
When the heterogeneous cyclam glyoxal adduct 47 and an excessf8 T,equivalents) 
o f 2 -bromoacetamide reaction mixture was stirred for 15. days, the dialkylated product 
114 was obtained in 67% yield. 114 was characterized by NMR, IR, and high resolution 
FAB mass spectrometry (HRFABMS). 114 was then reductively ring-expanded to cross­
bridged compound 116 (Scheme 2.42), which had already been synthesized by Hill using 
a longer synthetic route12,19. NMR spectra o f 115 were consistent with spectra reported by 
Hill. 12 ,1 9
IT?!
BrCH2CONH2(xs) NaBH4 / N  N
N 'f  N CH»CN 96%BOH 1 W °
15 days -  57% H2N ^ ^ ^ |H 1 H2N'
67% 2Br
' N4 / n ^  RrT.H .r.nNH„^  '
° L ^ n J °  95% EtOHr S L l N.
J 
47 114 115
Scheme 2.42 The short pathway synthesis o f 115 
The success (113 and 114) and the failure (111 and 112) of alkylation of 47 show 
that the driving force for this kind of alkylation reaction is the precipitation/crystallization 
of product. If the right solvent or solvent mixture is chosen, it should be possible, in 
theory, to synthesize 1 1 1  and 1 1 2 .
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I. The Synthesis and Characterization of 4-Carbo-tert-butoxvmethvl-1.4.8.11- 
tetraazabicvclof6.6.21hexadecane (74).
Since we had already synthesized the mono, t-butyl ester cross-bridged cyclen 73 
(Scheme 2.16), naturally we thought that we could use same strategy to approach the 
mono, t-butyl ester cross-bridged cyclam 74 (Scheme 2.43).
N O f






I H r / v
(+1) °  
Bn" f  H I 2Br-
76
H l+- NJ^N
N i  N 
H
O or (+Nf N)N • N 
Bn" I H
H




Scheme 2.43 a retro-synthetic route for 74 
Synthesis of compound 77 was attempted by the alkylation reaction shown in 
Scheme 2.44.
^  ^  .0 -H
BrCH2COOCMe3
Nt N n| n'H I Br
solvent
47 77
Scheme 2.44 The attempted mono-alkylation of 47
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Treatment o f cyclam glyoxal adduct 47 with t-butyl bromoacetate in nonpolar solvents 
(Et2 0 , toluene, hexane) gave a precipitate product. Unfortunately the product that we 
isolated showed strange properties in different NMR solvents. In D2 O it appeared to be 
one pure compound 77 whose data fit the formulation. However, in other NMR solvents 
such as CDCI3 , CD3CN and CH2 CI2 the product exhibited two sets o f peaks. Our first 
thought was that the compound 77 could be partially protonated, but we couldn’t answer 
where the proton came from. Another possible explanation is that the product was a 
mixture o f mono- and dialkylated. When dissolved in D2.O, the product repeatedly 
dealkylated and realkylated; this made the NMR spectra appear to be one pure compound 
by coincidence. Of course more investigation is needed before we know exactly what’s 
going on.
According to our strategy we can either put on the t-butyl ester pendant-arm first, 
and then the benzyl group or put on the benzyl group first, and then t-butyl ester pendant- 
arm. Since we failed in the first route, we had to try the second. We started from 
compound 78, which was synthesized orginally by Hill. 1 2 ’19 Treatment o f the compound 
78 with t-butyl bromoacetate in different solvents (CH3 CN, CHCI3 , MeOH, DMF) 
(Scheme 2.41) gave no precipitate. After diethyl ether addition, precipitate formed, The 
precipitate was isolated by suction filtration to give white solid product. Unfortunately, 
the NMR spectra confirmed that it wasn’t the desired product, but a mixture (Scheme 
2.45).
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Scheme 2.45 The attempted synthesis of 76
As a result of the above investigation, it looked like it could be veiydifficult to 
use the same strategy as we used to synthesize the mono; t-butyl ester cross-bridged 
cyclen 73. In order to approach the mono, t-butyl ester cross-bridged cyclam 74. An 
alternative strategy was needed to synthesize critical synthetic intermediate 74.
As shown in Scheme 2.15, treatment of cross-bridged cyclam 35 with a slight 
excess (2.2 equivalents) of t-butyl bromoacetate gave pure product 51 after simple 
workup. We predicted that treatment of cross-bridged cyclam 35 with 1 equivalent of 
alkylating agent would give a mixture of monoalkylated, dialkylated, and starting 
material, and the mono-alkylated should be major product.
As predicted, treatment of 35 with 1 equivalent o f t-butyl bromoacetate gave a 
mixture of monoalkylated 74 (45%-50% from NMR), dialkylated 51, and starting 
material 35 as indicated in Scheme 2.46.
BrCH2C0 2C(CH3)3 (1 eq) .N
Scheme 2.46 The synthesis of 74
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Cross-bridged cyclam 35 was dissolved in dry MeCN, sodium carbonate was 
added in one portion, and 1 equivalent t-butyl bromoacetate was added in one portion by 
syringe. The solution was stirred for 14 hours at room temperature, and then solvent was 
removed under reduced pressure. Lucky, the mono-t-butyl cross-bridged cyclam can be 
isolated by flash chromatography (SiC>2 , MeOH : CH2 Cl2 = 1 .5 :1 0 ) to give product 74 as 
an oil in 39% yield. The compound 74 was characterized by NMR, IR, and high 
resolution FAB mass spectrometry (HRFABMS).
J. The Synthesis and Characterization of the Trifluoroacetic Acid Salt of 4- 
carboxvmethvl-l«4.8.11-tetraazabicvclol6.6.21hexadecane (116«2TFA).
With compound 74 in hand, we decided to convert the t-butyl ester 74 to the acid 




Schem e 2.47 The synthesis of 116«2TFA 
Compound 74 was stirred in CF3 CO2 H (TFA) for 15 hours. TFA removal gave 
product 116 as a TFA salt (2 equiv. TFA calculated on the basis of mass and *H NMR). 
NMR, IR, and HRFABMS data were consistent with this formulation.
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K. The Attempted Synthesis of Benzvl-S-ni-carbo-tert-butoxvmethvl-M.S.ll- 
tetraazabicvclolb.b.Zlhexadec^-ximethvD^-hvdroxvbenzoate (43)
BFC 43 was attempted by reductive alkylation as indicated in Scheme 2.48. When 
we treated mono, t-butyl ester cross-bridged cyclam 74 with 3-formyl-4-hydroxy-benzoic 
acid 85 and NaBFLCN in MeOH, it seemed that we synthesized the reductive alkylation 
product 43 on the basis of the NMR spectra, but we had difficulty isolating the amino 
acid 43. We attempted to solve the problem by protection of carboxylic acid prior to 
reaction.
chemoselective esterification of carboxylic acids using a CsF-Celite/alkyl halide/CFLCN 






Scheme 2.48 The attempted synthesis of 43 







c o 2h C 0 2Et
117 118
Scheme 2.49 CsF-Celite mediated chemoselective esterification of
phenolic carboxylic acid
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The benzoic acid benzyl ester compound 11973 was synthesized using the CsF- 









Scheme 2.50 The synthesis 119 
When benzoic acid derivative 85 was allowed to react with BnBr and CsF-Celite in 
CH3CN, pure product 119 was obtained in 32% yield after solvent removal and flash 
chromatography. NMR spectra were consistent with the structure.
With the benzoic acid benzyl ester derivative 119 and mono, t-butyl ester cross­









Scheme 2.51 The attempted synthesis o f 120 
74 was allowed to react with 119 and NaBH3CN or NaB(OAc)3H in MeOH. After 
solvent removal, basic extraction, and then solvent removal gave a solid, whose NMR 
spectra indicated that it could be the desired product, but there definitely was some
74
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dynamic process going on. The NMR spectra were so complex that more investigation is 
needed before we can draw a conclusion.
L. The Synthesis of three model compounds - 122. 124 and 126. and Synthesis of 4- 
(2-(l l-tert-ButoxvcarbonvlinethvP-1.4.8.1 l-tetraazabicvclol6.6.2lhexadec-4-vD- 
acetvlaminolbenzoic acid (45)
Before we tried to synthesize the desired BFC 45 (Figure 2.16), we first 
synthesized three model compounds for BFC 45.
COOH 45
Figure 2.16 The structure of 45
The first model compound 122 was synthesized as indicated in Scheme 2.52.
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100% H2N -^t f a
OH
122
Scheme 2.52 The synthesis of 122*2TFA
Treatment o f mono-tert-butyl ester cross-bridged cyclam 74 with an excess of 2- 
bromoacetamide in CH3 CN at room temperature yielded N-tert-butyl ester, N-acetamido 
cross-bridged cyclam 121 in 43% yield. 121 was characterized by NMR, IR, and high 
resolution FAB mass spectrometry (HRFABMS). 121 was subsequently stirred in a 1:1 
(v:v) solution of TFAiCThCh for 12 hours. Solvent removal gave product 122 as a TFA 
salt (2 equiv. TFA calculated on the basis of mass). NMR, IR, and HRFABMS were 
consistent with this formulation.
The second model compound 124 was synthesized as indicated in Scheme 2.53.
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.0
CICH2CONHCH3 (x s )
Na2C03, CH3CN 











Scheme 2.53 The synthesis of 124*2TFA
Treatment of compound 74 with 2-chloro-N-methylacetamide7 4  in CH3 CN at room 
temperature generated the product 123 in 98% yield. 123 was characterized by NMR, IR, 
and high resolution FAB mass spectrometry (HRFABMS). Compound 123 was then 
stirred in a 1:1 (v:v) solution of TFA:CH2 Cl2 for 12 h. Solvent removal gave product 124 
as a TFA salt (2 equiv. TFA calculated on the basis of mass), NMR, IR, and HRFABMS 
were consistent with this formulation.
The third model compound 126 was synthesized as indicated in Scheme 2.54.
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74
0  CICH2CONHC6H5 ( x s
Na2C03, CH3CN 










Scheme 2.54 The synthesis of 126*2TFA
Treatment of compound 74 with 2-chloro-N-phenylacetamide in CH3 CN at room 
temperature gave compound 125 in 73% yield. 125 was characterized by NMR, IR, and 
high resolution FAB mass spectrometry (HRFABMS). Compound 125 was then stirred in 
a 1:1 (v:v) solution of TFA:CH2 C12  for 12 h. Solvent removal gave product 126 as a TFA 
salt. NMR, IR, and HRFABMS were consistent with this formulation, and there are four 
TFAs according to the *H NMR.
With the synthesis of the three model compounds for BFC 45, it was envisioned 
that BFC 45 could be made in a similar fashion. The direct alkylation was first attempted 
as indicated in Schem e 2.55.
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o
h o 2c f  V nh . 0
127 0 Cl
NH N Na2C 0 3, CH3CN 
Kl, rt, 24 h
74
c o 2h
Scheme 2.55 The attempted synthesis of 45
When compound 7 4  was allowed to react with a slight excess of commercially 
available 4-(2-chloroacetomido) benzoic acid (1 2 7 )76 in CH3CN, solvent removal gave 
crude product. Purification by flash chromatography failed. We realized that the problem 
could be caused by unprotected carboxylic acid, so we decided to protect it as methyl 
ester. The Fischer esterification of compound 127  was carried out in a refluxing mixture 
of MeOH and cat. conc. H2 SO4 . The esterification went very well, but the amide 
functional group didn’t withstand these conditions, and was hydrolyzed as indicated in 
Scheme 2.56.
MeOH
Conc. H2S 0 4 (cat.)
O Cl reflux
127 128
S chem e 2 .56 The Fischer esterification o f  127
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Since the direct esterification of compound 127 failed to give the desired product 
129, an alternative preparation of compound 129 was needed. The approach taken is 
shown in Scheme 2.57.
r,— ^ chloroacetyl chloride r,—a
MeOzC—(/ 7— NH2 ------------------------------------ ► Me02C—\  Y - N H
c h 3c o 2h /Y A
O Cl
128 129
Scheme 2.57 The synthesis of 129
When 12877 which is commercially available was allowed to react with chloroacetyl 
chloride in acetic acid, the desired product 12978 was synthesized in good yield (98%).
With methyl 4-(2-chloroacetylamino)benzoate 129 in hand, the alkylation of 












Scheme 2.58 The synthesis of 130 
Treatment o f mono, t-butyl ester cross-bridged cyclam 74 in CH3 CN with the methyl 
benzoate derivative 129 gave product as a light yellow oil in 91% yield after workup. 130 
was characterized by NMR, IR, and high resolution FAB mass spectrometry 
(HRFABMS).
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Selective deprotection of the methyl ester in the present of the t-butyl ester wasn’t 
expected to be a problem, there are a few sets of conditions7 9 that can be used to 
deprotect the methyl ester, but not touch the t-butyl ester. The attempted conversion is 
indicated in Scheme 2.59.
Deprotection of methyl ester
C02Me C 02H
Scheme 2.59 The attempted synthesis of 45 
In the first attempt the compound 130 was allowed to react with IN NaOH in a mixture 
o f dioxane and H2 0 79a. After the mixture was stirred for 3 h, workup and solvent removal 
gave a product whose NMR indicated that both the methyl ester and the t-butyl ester were 
saponified. In the second attempt, the compound 130 was allowed to react with K.2 CO3 in 
mixture of MeOH and H2 0 79c. After the mixture was stirred for 16 h at room temperature, 
solvent removal gave a product whose NMR indicated that there was a mixture of desired 
product and product having both esters deprotected. Since our desired product is an 
amino acid, we decided to avoid the use of acid and base in the deprotection step. We 
decided to switch to a benzyl ester protecting group.
Although we failed to convert compound 130 to BFC 45 in our attempted 
synthesis (Scheme 2.60), 130 was converted to model compound 131 of BFC 45. The 
reaction is indicated in Scheme 2.60.
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130
C 02Me CC^Me
Scheme 2.60 The synthesis of 131«nTFA
Compound 130 was stirred in 1:1 (v:v) solution of TFA and CH2 CI2  for 16 h. Solvent 
removal gave product as a TFA salt. NMR and HRFABMS were consistent with this 
formulation, and there are 3.76 equivalents o f TFA according to the calculation based 
upon mass of the product. Compound 131 may be used as a model compound of BFC 45 
to test coordination chemistry.
With the synthesis of 130, it was envisioned that benzyl ester derivative 128 could 
be made in a similar fashion. But first we needed to synthesize benzyl 4-(2- 











Scheme 2.61 The synthesis of 134
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4-Aminobenzoic acid 132 was allowed to react with benzyl bromide in basic DMSO to
in 91% yield. The alkylating ageng 134 was characterized by NMR, IR, and high 
resolution FAB mass spectrometry (HRFABMS).
With the alkylating agent 134 in hand, cross-bridged BFC precursor 135 was 
synthesized by alkylation as indicated in Scheme 2.62.
Treatment of the mono-t-butyl ester cross-bridged cyclam 74 with the alkylation agent 
134, Na2 CC>3 , and KI in CH3 CN gave the desired product 135 in 99% yield. 135 was 
characterized by NMR, IR, and HRFABMS.
With the BFC precursor 135 in hand, the debenzylation was carried out in our 
glass hydrogenation apparatus designed for exclusion of O2 and for measurement o f H2 
uptake with maintenance of constant pressure. It was experimentally determined that the 
precursor was soluble in ethyl acetate. Thus the standard conditions for hydrogenolysis 
using 10% Pd/C and atmospheric H2 in ethyl acetate was carried out. After workup, the
regioselectively give desired product 13380 in 51% yield, Compound 133 was then
• • • • 81 allowed to react with chloroacetyl chloride in acetic acid to give the desired product 134
C02Bn
Scheme 2.62 The synthesis of 135
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Scheme 2.63 The synthesis of 45
M. The Synthesis and Characterization of 3-14-12-11 1-tert-Butoxvcarbonvlmethvl- 
1.4.8.11-tetraazabicvclol6.6.21hexadec-4-vB-ethvlsulfamovnphenvl)propionic Acid 
(46)
There are many possible strategies to synthesize BFC 46, Scheme 2.64 shows the 
approach that we used to synthesize the compound. When we disconnect the long arm, it 
will generate two fragments whose synthetic equivalents are mono-t-butyl ester cross­
bridged cyclam 74, which was previously synthesized and an aziridine derivative (e.g. 
136 or 137)
84




Scheme 2.64 Retro-synthetic route for 46
The aziridine derivative is not commercially available, however, there are a 
couple of strategies that we designed to approach the target. One of them which started 






Scheme 2.65 Retro-synthetic route for 137
Compound 139 was synthesized as indicated in Scheme 2.66.
85
so2ci
139 r  ll
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S02CI 66%














Scheme 2.66 The synthesis of 139
Compound 141 was allowed to react with 0.5 equiv ethanolamine in pyridine, After 
workup and recrystalization from hot CHCI3, the desired crystalline product 140 was 
obtained in good yield (6 6 %). The reaction condition was modeled on the method for the
characterized by NMR, IR, and HRFABMS. 140 was then treated with 20% KOH in 
benzene to give the desired aziridine derivative 139 in 8 6 % yield (the procedure was
compound was characterized by NMR, IR, and HRFABMS.
The next step of this synthetic strategy was attempted by Heck coupling reaction. 
However, when the aziridine 139 was allowed to react with benzyl acrylate under 
common Heck coupling condition, a surprising result was obtained. We didn’t get the 
desired product 138, but the 1,4-distyrylbenzene 14284 (Scheme 2.67). We didn’t predict 
that the aziridinesulfonyl group also was a leaving group for the Heck reaction. Literature
o9
synthesis of N-(2-((p-tolylsulfonyl)oxy)ethyl)-p-tolylsulfonamide . Compound 140 was
01
modeled on the method for the synthesis of N-(p-tolylsulfonyl)aziridine ). The
86
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didn’t show any example that sulfonamide group acted as leaving group in Heck reaction 







Bn02C C 0 2Bn
142
139
Scheme 2.67 The attempted synthesis of 138 
Since we failed to convert compound 140 to compound 138, another strategy to 












Scheme 2.68 Retro-synthetic route for 136 and 137
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136 was synthesized as indicated in Scheme 2.69. When compound 14585 was 
allowed to react with ethanolamine in pyridine, the desired product 143 was isolated in 
40% yield after workup and flash chromatography. The reaction condition was modeled 
on the method for the synthesis of N-(2-((p-tolylsulfonyl)oxy)ethyl)-p- 
tolylsulfonamide. 82 143 was characterized by NMR, IR, and HRFABMS. Treatment of 
compound 143 with 20% KOH in benzene gave desired aziridine derivative 136 in 89% 
yield. The procedure was modeled on the method for the synthesis of N-(p-.,r 
tolylsulfonyl)aziridine. 8 3 136 was characterized by NMR, IR, and HRFABMS. With the 
compound 136 in hand, it had been our intention to try the ring opening reaction with 
mono, t-butyl ester cross-bridged cyclam 74. However, our failure to synthesize the BFC 
45 by deprotection of a methyl ester in the final step (Scheme 2.59) convinced us to 
switch to a benzyl ester protecting group at this stage. The same strategy was used to 
synthesize the benzyl ester aziridine derivative 137.
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c o o c h 3
s o 2c i
H2N C H 2C H 2O H  (0 .5  eq)
pyridine 










C O O C H 3
136
C02Me
C O O C H 3
143
Scheme 2.69 The synthesis of 136 
Compound 137 was synthesized as indicated in Scheme 2.70. When 
hydrocinnamic acid 147 was allowed to react with the chlorosulfonic acid, after workup 
and recrystellization from hot benzene, the desired product 148 was obstained in 65% 
yield. 148 was converted to the corresponding benzyl ester derivative 146 by Fischer 
esterification. But at that time we were worried about the aqueous workup which may 
hydrolyze the sulfonyl chloride group to corresponding acid. The product of Fischer 
esterification was treated with thionyl chloride. Later on we learned that the step of 
treatment with thionyl chloride was not necessary by low resolution mass spectrometry 
(LRMS) and NMR spectra. Compound 146 was then allowed to react with 0.5 equiv 
ethanolamine in pyridine to give compound 144. The reaction condition (from 146 to 144) 
was modeled on the method for the synthesis of N-(2-((p-tolylsulfonyl)oxy)ethyl)-p- 
tolylsulfonamide. 8 2 137 was characterized by NMR, IR, and HRFABMS. 144 was then
89
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treated with 20% KOH in benzene to yield the benzyl ester aziridine derivative 137 in 
90% yield. The reaction condition (from 144 to 139) was modeled on the method for the
O'!

































Scheme 2.70 The synthesis of 137
Compound 149 was synthesized by the ring opening reaction as indicated in 
Scheme 2.71.
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137
COOBn
Scheme 2.71 The synthesis of 149
Treatment of the mono-t-butyl ester cross-bridged cyclam 74 with the aziridine derivative 
137 in CH3 CN gave the desired product 149 in good yield (77%). 149 was characterized 
by NMR, IR, and HRFABMS.







Scheme 2.72 The synthesis of BFC 46
91
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The debenzylation was carried out using standard conditions for 
hydrogenolysis: 10% Pd/C and atmospheric H2 in ethyl acetate. After workup, the desired 
BFC 46 was obtained in good yield (58%). The BFC 46 was characterized by NMR, IR, 
and HRFABMS. The proton of sulfonamide (SO2NH) is quite acidic (pKa~7), if the 
ligand forms a complex with Cu(II), these pendent arms will serve to fully envelop a six 
coordinate cation as well as neutralize a dicationic charge. The latter property is 
desirable for optimal 6 4 Cu(II) complex biodistribution and clearance characteristics. 1 2 ,4 3 ,4 4
N. The Synthesis and Characterization of Trifluoroacetic Acid Salt of (ll-(2- 
(Toluene-4-sulfonvlamino>ethvl)-1.4.8.11-tetraazabicvclol6.6.21hexadec-4-vBacetic 
acid (152«2TFA)
After we synthesized BFC 46, we needed to synthesize a model compound of 
BFC 46 for metal complexation study. Model compound 152 was synthesized as 
indicated in Scheme 2.73.
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Y 7
1:1 (v:v) TFA:CH2CI2
Scheme 2.73 The synthesis of 152*2TFA
To a solution of mono-tert-butyl ester cross-bridged cyclam 74 in CH3 CN, l-((4- 
methylphenyl)sulfony) aziridine 15086 was added. The mixture was refluxed for 18 hours. 
The solvent was removed under reduced pressure to give product 151 in good yield 
(-quant, >90% purity). 151 was then dissolved in a mixture of CF3 CO2 H (TFA) and 
CH2 CI2 (1:1, v:v) and solution was stirred for 16 hours at room temperature. Solvent was 
then removed under reduced pressure to give product 152 as TFA salt. On the basis of the 
mass and assuming a quantitative yield, the product is a di-TFA salt. 152 will act as a 
model compound of BFC 46 to study coordination chemistry.
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O. Conclusions
Di-carboxylic acid cross-bridged cyclam 36, a BFC whose HC1 salt originally had 
been synthesized by Hill12,19, has been synthesized as its di-TFA salt. Di-carboxyl acid 
cross-bridged cyclen 39, a BFC which originally had been synthesized by Condon50, has 
been formally synthesized by a different synthetic approach. The precursor 82 of di- 
carboxylic acid cross-bridged 13-ane-N4 42 has been synthesized and characterized 
successfully for the first time. Syntheses of BFC 41 and BFC 43 have been attempted, 
their NMR spectra showed that both BFC had been synthesized, but their isolation and 
purification still remains unsolved. The synthesis of C-substituted cross-bridged cyclen 
BFC 40 has failed to date. However, switching to a benzyl ester protecting group of 91 
may lead to future success. BFC 45 and BFC 46 have been synthesized and characterized 
successfully. Related model compounds have also been synthesized and fully 
characterized. Further research such as coordination chemistry studies and antibody 
labeling is in progress or will be done in the future. The synthesis of di-benzo BFC 44 
was attempted. Some progress was made toward this kind of BFC. The biggest challenge 
toward this kind of BFC is the solubility problem. Our studies shows that after we 
appended the phenethyl group, its solubility is better than its parent compound (at least in 
CHCI3 and CH2 CI2 ). One possible future direction toward this kind of dibenzo BFC (e.g. 
BFC 156) is shown in Scheme 2.74.
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N j^ N  palladium(ll) acetate h 2


















Scheme 2.74 One possible future direction toward this kind of dibenzo BFC 156
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Melting points (mp) were obtained on a Thomas Hoover capillary melting point 
apparatus and were uncorrected.
Infrared Spectra (IR) were run on a Nicolet MX-1 FT-IR spectrometer and 
absorptions are reported in wavenumber (cm'1).
*H NMR Spectra (*H NMR) were acquired on a Bruker AM360 FT-NMR 
spectrometer operating at 360.134 MHz, or a Varian Merrcury-400BB NMR 
spectrometer, or a Varian INOVA-500 NMR spectrometer. Chemical shifts are 
reported in parts per million (ppm) relative to internal Me4 Si (TMS) unless otherwise 
noted and coupling constants (J values) are in Hertz (Hz).
13C NMR spectra (l3C NMR) were acquired on a Bruker AM360 FT-NMR 
spectrometer operating at 90.556 MHz, a Varian Merrcury-400BB NMR 
spectrometer, or a Varian INOVA-500 NMR spectrometer. Chemical shifts are 
reported in parts per million (ppm) relative to internal Me4 Si (TMS) unless noted. 
Low-Resolution Mass Spectra (MS) were obtained on a Hewlett Packard 5988A 
GC/MS at the University Instrumentation Center of UNH.
High-Resolution Mass Spectra (HRMS) were obtained from Mass spectrometry 
Facility at the University of Notre Dame using a JEOL AX505HA high resolution 
mass spectrometer.
CHN Analysis (CH&N) were obtained on a perkin-Elmer Series IICHNS/O 
elemental analyzer model 240B at the University Instrumentation Center of UNH.
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X-Rav Crystallography (X-ray) was performed by Roger Sommers at the laboratory 
of Arnold Rheingold, Crystallography Laboratory, Department of Chemistry and 
Biochemistry, University of Deleware, Newark, DE.
II. Solvents
Absolute ethanol (EtOH) was obtained from AAPER Alcohol and Chemical Co. and 
was used without further purification.
Acetone was obtained from Pharmco products. It was used without further purification. 
Acetonitrile (CH3CN) was obtained from EM Science. It was distilled from CaPL and 
stored over 3A molecular sieves.
Benzene (C6H6 ) was obtained from J.T. Baker and was used without purification. 
Chloroform (CHCI3) was obtained form EM Science and was used without 
purification.
Deuterated NMR solvents were obtained from Cambridge Isotope Laboratories.
Diethvl ether (Et2 0 ) was obtained from Fisher Chemical Co.
Dichloromethane (CH2 CI2 ) was obtained from Pharmco Products. It was used without 
further purification
Dimethvlformamede (DMF) was obtained from J.T. Baker and used without 
purification.
Ethanol (95% EtOH) was obtained from AAPER Alcohol and Chemical Co. and was 
used without further purification.
Methanol (MeOH) was obtained from fisher Chemical Co. and was used without 
further purification.
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Methylene Chloride (CH2 CI2 ) was obtained form J. T. Baker. It was distilled from 
CaH2  and stored over 3A molecular sieves.
Tetrahvdrofuran (THF) was obtained form Fisher Chemical Co. and was distilled 
form Sodium prior to use.
Toluene (PhCFh) was obtained from EM Science. It was distilled from sodium prior 
to use.
III. Reagents
Acetic anhydride (AC2 O) was obtained from Fisher Chemical Co. and was used 
without further purification.
Aluminium trichloride was obtained from Aldrich Chemical Co. 
2-Aminobenzvlamine was obtained from Aldrich Chemical Co.
Benzyl bromide (PhCl^Br) was obtained from Aldrich Chemical Co.
Benzyl acrvlate was obtained from Lancaster Synthesis, Inc.
Benzaldehvde was obtained from Aldrich Chemical Co.
Benzyl alcohol was obtained from Fisher Scientific Company 
N.N’-Bis(2-HvdroxvethvlVethvlenediamine was obtained from Aldrich Chemical Co. 
Bromine was obtained from Aldrich Chemical Co. 
t-Butvlmalonate was obtained from Aldrich Chemical Co. 
t-Butvlbromoacetate was obtained from Aldrich Chemical Co.
2-Bromoacetamide was obtained from Aldrich Chemical Co. 
4-Bromobenzenesulfonvl chloride was obtained from Aldrich Chemical Co. 
Chloroacetvl chloride was obtained from Aldrich Chemical Co. 
4-f2-Chloroacetamido)benzoic acid was obtained from Aldrich Chemical Co.
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2-Chloro-N-phenvlacetamide was obtained from Aldrich Chemical Co.
2-Chloro-N-methvlacetamide was obtained from Aldrich Chemical Co.
Cesium carbonate was obtained from Cabot Chemical Co.
Calcium hvdride was obtained from Alfa Products Inc.
Diatomaceous earth (Celite) was obtained from Fischer Chemical Co.
Diethyl bromomalonate was obtained from Aldrich Chemical Co. 
1.8-Diazabicvcio[5.4.01undec-7-ene was obtained from Aldrich Chemical Co. 
Ethvlenediamine was obtained from Lancaster Synthesis, Inc.
Ethanol amine was obtained from Aldrich Chemical Co.
Formic acid was obtained from Aldrich Chemical Co.
Glvoxal (40 wt. % solution in H2O) was obtained from Aldrich Chemical Co. 
Hexamethvlenetetramine was obtained from Alfa Products Inc.
Hvdrocinnamic acid was obtained from Eastman Organic Chemicals. 
4-Hvdroxvberizoic acid was obtained from Aldrich Chemical Co.
Levulinic acid was obtained from Aldrich Chemical Co.
Lithium perchlorate was obtained from J.T. Baker Chemical Co.
Magnesium sulfate was obtained from Aldrich Chemical Co.
Methyl 3-(4-chlorosulphonvBphenvlpropionate was obtained from Lancaster 
Synthesis, Inc.
Methyl iodide was obtaind from Aldrich Chemical Co.
PalladiumOU acetate was obtained from Lancaster Synthesis, Inc.
Palladium Black was obtained from Alfa Products.
10% Palladium on carbon (10% Pd/C) was obtained from Aldrich Chemical Co.
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Piperidine was obtained from Aldrich Chemical Co.
3-Phenvlpropionic acid was obtained from Lancaster Synthesis, Inc.
1.10-Phenanthroline was obtained from Aldrich Chemical Co.
Potassium carbonate was obtained from Flinn Scientific Inc.
Potassium iodide was obtained from J. T. Baker Chemical Co.
Sodium borohvdride (NaBH4) was obtained from Lancaster Synthesis, Inc.
Sodium hydroxide (NaOH) was obtained from Fisher Scientific Company 
Sodium acetate anhydrous was obtained from Aldrich Chemical Co.
Sodium carbonate was obtained from Fisher Scientific Company.
Sulfuric acid was obtained from J.T. Baker Chemical Co.
Styrene was obtained from Aldrich Chemical Co.
1.4.7.10 -Tetraazacvclododecane (cyclen) was obtained from Strem Chemicals.
1.4.7.11 -Tetraazacvclotetradecane (cyclam) was obtained from Strem Chemicals. 
Tetrabutvlammonium tribromide was obtained from Fluka Chemie GmbH.
Thionyl chloride was obtained from Aldrich Chemical Co.
Triphenvlphosphine was obtained from Lancaster Synthesis, Inc.
Tri(0-tolvlphosphine was obtained from Lancaster synthesis, Inc. 
p-Toluenesulfonvl chloride was obtained from Aldrich Chemical Co.
IV. Column Chromatography Solid Supports
Alumina: Aluminum oxide powder (activated, basic, Brockmann 1,150 mesh) 
“suitable for chromatography’ was obtained from Aldrich Chemical Co.
Silica gel (60-200 mesh) “suitable for column chromatography” was obtained from 
J.T. Baker Chemical Co.
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V. Experimental Procedures
Note: All routine solvent evaporations were carried out on a standard rotary 
evaporator using aspirator pressure unless otherwise noted.
4-Methyl-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane (21): Hydrogenolysis o f 4- 
benzyl-10-methyl-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane (20) was carried out in a 
glass apparatus designed for the exclusion of O2 and for measurement o f H2 uptake with 
maintenance of constant pressure. Catalyst (250 mg, 10% Pd/C) and a 1% solution of 
conc.HCl in methanol (10 mL) were added to a 50 mL hydrogenation flask, which was 
connected to the apparatus. The system was evacuated by means of a water aspirator and 
flushed with N2 four times. After another evacuation the system was filled with 
hydrogen. The catalyst was equilibrated under H2 for 30 minutes. 4-Benzyl-10-methyl-
l,4,7,10-tetraazabicyclo[5.5.2]tetradecane (210 mg, 0.693 mmol) in methanol (2 mL) was 
then added and the mixture was stirred for 26 h under H2 at atmospheric pressure. The 
hydrogenolysis was stopped, the apparatus was evacuated and flushed with N2 , the 
hydrogenation flask was removed, the contents were filtered through Celite, and the 
catalyst and Celite were washed with methanol (3x2 mL). The filtrate and washings were 
concentrated under reduced pressure to give a light yellow oil which was dissolved in 
H2 O (2 mL), adjusted to pH 14 with solid KOH, and extracted with benzene (3x10 mL). 
The combined extracts were dried (Na2 S0 4 ), solvent was removed under reduced 
pressure, and the crude product was dissolved in a mixture of absolute EtOH (3 mL) and 
concentrated HC1 (3 mL). Mixing resulted in precipitation of a hydrochloride salt 
(stoichiometry unknown), which was filtered, washed with absolute EtOH (2 x 1 mL), and 
air-dried. The hydrochloride salt was recrystallized from hot absolute EtOH. The
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recrystallized material was dissolved in H2 O (10 mL), the pH was adjusted to 14 with 
solid KOH, and the aq solution was extracted with benzene (2x10 mL). The combined 
extracts were dried (Na2 S0 4 ), and solvent was removed under reduced pressure to give 
waxy solid product (43.8 mg, 0.207 mmol, 30%). ]H NMR (360 MHz, C6 D6) 5 2.21-2.42 
(m, 4H), 2.27 (s, 3H), 2.42-2.50 (m, 2H), 2.50-2.68 (m, 10H), 2.69-2.84 (m, 4H); '^ { 'H }  
NMR (90.6 MHz, C6 D6) 6  44.45, 48.04, 51.86, 52.32, 52.41, 56.69; IR(KBr) 3445, 2958, 
2936, 2847, 1663, 1575, 1559,1457, 1413, 1372, 1164 cm'1; MS, m/z 212(M+); 
HRFABMS, m/z (M+H)+ exact mass calcd for C n^sN *: 213.2079; Found: 213.2082 
(error +0 . 2  mmu/+l. 1 ppm).
4,10-Diacetyl-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane(22): 1,4,7,10- 
Tetraazabicyclo[5.5.2]tetradecane (100 mg, 0.515 mmol) was dissolved in acetic 
anhydride (5 mL), the mixture was stirred under N2  for 3 days, and then poured into water 
(2 mL), adjusted to pH 14 with solid KOH, and extracted with benzene (3x20 mL). The 
combined extracts were dried (Na2 S0 4 ) and solvent was removed under reduced pressure 
to give a solid (122 mg, 0.438 mmol, 85%). ‘H NMR (500 MHz, C6 D6) 5 1.73 (s, 6 H, 
COC//3 , major), 1.75 (s, 6 H, COC//3 , minor), 2.20-2.56 (m, 13H, major and minor), 2.66 
(dt, 1H, J=15.1, 2.4 Hz, major and minor), 2.92 (dt, 2H, J=14.9, 2.4 Hz, major), 2.92-2.99 
(m, 2H, minor), 3.33 (ddd, 2H, J=15.1, 10.3, 1.7 Hz, minor), 3.35-3.44 (m, 2H, major), 
3.92-3.98 (m, 2H, major), 4.01 (ddd, 2H, J=13.4, 3.7, 1.7 Hz, minor), the ratio of major 
and minor is 64/36; ^C l'H } NMR (100.5 MHz, C6 D6) 6  22.42 (major and minor),
54.92 (minor), 54.97 (major), 55.08 (major), 55.58 (minor), 56.06 (major), 56.36 (minor),
56.48 (minor), 56.93 (major), 57.55 (minor), 57.65 (minor), 57.70 (major), 169.87
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(minor), 170.16 (major). (There are 5 major peaks and 6  minor peaks in the mid-field 
region which indicates that the major conformation has time-averaged C2 symmetry and 
the minor conformation has time-averaged Cs symmetry); IR (KBr) 2924, 2834, 2802, 
1638.5, 1470, 1443, 1402, 1353, 1240, 1150, 1028 cm'1; HRFABMS m/z (M+H)+exact 
mass calcd for C 14H2 7N4 O2 : 283.2134; Found: 283.2138 (error +0.4 mmu/+1.3 ppm).
4,10-DibenzoyI-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane(23): 1,4,7,10- 
Tetraazabicyclo[5.5.2]tetradecane (50 mg, 0.26 mmol) was dissolved in CH2 CI2 (1 mL), 
and PhCOCl (89 mg, 0.53 mmol) was added in one portion. The mixture was stirred for 
12 h at room temperature and then poured into water (2 mL), adjusted to pH 14 with solid 
KOH, and extracted with benzene (3 x 20 mL). The combined extracts were dried 
(Na2 S0 4 ) and solvent was removed under reduced pressure to give a solid. The crude 
product was recrystallized from acetone to give white crystals (24 mg, 0.13 mmol, 50%): 
‘H NMR (500 MHz, CDCI3 ) 5 2.56-2.80 (m, 5H), 2.81-2.96 (m, 4H), 3.08-3.30 (m, 5H), 
3.42-3.54 (m, 2H), 3.57-3.68 (m, 2H), 4.14 (dd, J=13.2, 2.7 Hz, major) & 4.20 (dd,
J=13.4,2.9 Hz, minor) (total integration 2H), 7.33-7.46 (m, 10H), the ratio of major and 
minor conformations is 55/45; 13C{'H} NMR (100.5 MHz, CDCI3 ) 8  54.20, 54.47,
54.70, 55.03, 55.26, 55.60, 55.70, 56.42, 57.12, 57.25, 57.50, 126.17, 128.53, 128.55,
129.07, 129.11, 137.63,137.71, 172.29, 172.46; IR (KBr) 2945, 2933, 2833, 1608,1575, 
1469, 1445, 1409, 1375, 1351, 1303, 1123, 743, 709 cm-1; Anal Calcd for C2 4 H3oN4 0 2:
C, 70.91; H, 7.44; N, 13.78. Found: C, 70.54; H, 7.58; N, 13.81.
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4-Acetyl-10-methyl-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane (24): 4-Methyl- 
1,4, 7,10-tetraazabicyclo[5.5.2]tetradecane 21 (70.0 mg, 0.336 mmol) was dissolved in 
acetic anhydride (1 mL) and the mixture was stirred under N2  for 14 h. The reaction 
mixture was then poured into water (2 mL), adjusted to pH 14 with solid KOH, and 
extracted with benzene (3x20 mL). The combined extracts were dried (Na2 S0 4 ) and 
solvent was removed under reduced pressure to give product as a light yellow oil (67.2 
mg, 0.269 mmol, 80%): ]H NMR (360 MHz, C6 D6) 8  1.79 (s, 3H, COCH&2.20 (s, 3H, 
NC//3), 2.24-2.33 (m, 2 H), 2.39-2.81 (m, 13H), 2.84-3.06 (m, 3H), 3.51-3.62 (m, 1 H), 
4.06-4.17 (dm, 1H, J=13.0 Hz); 13C{!H} NMR (90.6 MHz, C6 D6) 5 22.39, 45.60, 54.89 
(br), 54.95, 56.06, 56.32 (br), 56.97 (br), 57.03 (br), 57.22 (br), 57.53 (br), 59.71, 60.16, 
170.32 (CO); IR(neat) 3020,2975, 2929, 2875, 2834, 2803, 1627, 1417, 1372, 1215 cm'1; 
HRFABMS, m/z (M+H)+ exact mass calcd for C13H27N40: 255.2185; Found: 255.2199 
(error +1.5 mmu/+5.7 ppm).
4-Benzoyl-10-methyl-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane (25): 4-
Methyl-1, 4,7,10-tetraazabicyclo[5.5.2]tetradecane 21 (31.0 mg, 0.149 mmol) was 
dissolved in CH2 CI2  (1 mL) and PhCOCl (178 mg, 1.26 mmol) was added in one portion. 
The mixture was stirred for 12 h at room temperature, and then poured into water (2 mL), 
adjusted to pH 14 with solid KOH, and extracted with benzene (3x20 mL). The combined 
extracts were dried (Na2 S 0 4) and solvent was removed under reduced pressure to give  
product as a light yellow oil (46.0 mg, 0.148 mmol, 99%): *H NMR (360 MHz, C6 D&)
8  2.18 (s, 3H, N C//3), 2.22-3.20 (m, 20H), 3.26-3.40 (dm, 1H, J=14.6 Hz), 3.72 (br dd,
1H, J=14.6, 10.4 Hz), 4.20-4.30 (dm, 1H, J=12.2 Hz), 7.00-7.15 (m, 3H), 7.25-7.48 (m,
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2H); 13C{‘H} NMR (90.6 MHz, C6 D6) 6  45.07 (NCH3), 54.55 (br), 54.88 (br), 56.11(2C, 
one br), 56.46 (br), 56.77, 56.78 (br), 57.90 (br), 59.34 (br), 60.15 (br), 127.13,128. 80,
129.01,139.70, 172.09 (NCO); IR (neat) 3020, 2966, 2930, 1619, 1602, 1216, 758, 6 6 8  
cm'1; MS, m/z 316 (M+); HRFABMS, m/z (M+H)+ exact mass calcd for C 18H2 9N4 O: 
317.2341; Found: 317.2352 (error+1.1 mmu/+3.3 ppm).
4-Formyl-10-methyl-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane (26). 4-
Benzyl-10 methyl-1,4,7,10-tetraazabicyclo[5.5.2]tetradecane 21 (130 mg, 0.432 mmol) 
was dissolved in methanol solution containing 4.4% HCOOH (10 mL), and 10% Pd/C 
catalyst (200 mg) was added in one portion. The mixture was stirred under N2  for 14 h, 
the contents were filtered through Celite, and the solvent was removed under reduced 
pressure. The residual solid was dissolved in H2 O (10 mL), pH was adjusted to 14 with 
solid KOH, and the aqueous solution was extracted with benzene (3x20 mL). The 
combined extracts were dried (Na2 S0 4 ) and solvent was removed under reduced pressure 
to give product as a white solid (85.2 mg, 0.363 mmol, 84%, >95% purity): ]H NMR 
(360 MHz, C6 D6) 5 2.15 (s, 3H, NC//3 ), 2.20-2.84 (m, 20H), 2.90 (dt, 1H, J=14.4, 2.4 
Hz), 3.33 (app. ddd, 1H, J=15.5, 11.1,2.2 Hz), 3.74-3.3.84 (dm, 1H, J=13.1 Hz), 8.01 (s, 
1H, NC//0); 1 3C{'H} NMR (90.6 MHz, C6D6) 5 45.00 (NCH3), 51.28, 52.87 (br), 55.59, 
56.12 (2C), 56.39, 56.55, 58.90, 59.71, 59.93, 164.03 (NCHO); IR (KBr) 3450 (H2 0), 
3055, 2922, 2900, 2875, 2834, 2800, 2773, 1673, 1451, 1426, 1383, 1177, 1151 cm'1; 
HRFABMS m/z (M+H)+ exact mass calcd for C 12H2 5N4 O: 241.2028; Found: 241.2011 
(error -1.7 mmu/-7.2 ppm).
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General Procedure for complex formation: Equimolar amounts of ligand 26 
and metal salt were heated to reflux in methanol solution, the solvent was removed , and 
the coordination compound was recrystallized from methanol and diethyl ether diffusion.
l,4,8,ll-Tetraazabicyclo[6.5.2]pentadecane (34):The compound was prepared 
according to the procedure of Hill13,19. The hydrogenolysis was carried out in a glass 
apparatus designed for the exclusion of O2 and for measurement of H2 uptake with 
maintenance of constant pressure. Catalyst (100 mg, 10% Pd/C) and acetic acid (4 mL) 
were added to a 50 mL hydrogenation flask, which was connected to the apparatus. The 
system was evacuated by means of a water aspirator and flushed with N2 four times.
After another evacuation the system was filled with hydrogen. The mixture of 10% Pd/C 
and acetic acid was equilibrated under H2 for 1.5 h. 4,11-Dibenzyl-1,4,8,11- 
tetraazabicyclo[6.5.2]- pentadecane 81 (70.0 mg, 0.178 mmol) in acetic acid (1 mL) was 
then added and the mixture was stirred for 16 h under H2 . The hydrogenolysis was 
stopped, the apparatus was evacuated, flushed, and the hydrogenation flask was removed 
from the apparatus. The contents were filtered through Celite, and the catalyst and Celite 
were washed with acetic acid (2x5 mL). The filtrate and washings were concentrated 
under reduced pressure to give a light yellow oil which was dissolved in H2 O (3 mL), 
adjusted to pH 14 with solid KOH, and extracted with benzene (3 x 25 mL). The 
combined extracts were dried (Na2 S0 4 ), and solvent was removed under reduced pressure 
to give product as oil (35.0 mg, 0.165 mmol, 92 %), which contained minor impurities 
and was directly used for the next step. NMR spectra were consistent with spectra of 
authentic material.
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Bis-trifluoroacetate salt of 4,ll-bis-(carboxymethyl)-l,4,8,ll-tetraaza- 
bicyclo[6.6.2]hexadecane (36-2TFA-H20). 4,11 -Bis-(carbo-/ert. -butoxymethyl)-
1,4,8,1 l-tetraazabicyclo[6.6.2]hexadecane (51) (1.183 g, 2.602 mmol) was dissolved in a 
1:1 (vol:vol) mixture of CF3 COOH (TFA) and CH2 CI2  (5 mL). The mixture was stirred 
under N 2  at room temperature for 48 h. Solvent was removed under reduced pressure to 
give an oil, which crystallized after removal of residual solvent under vacupjn to yield 
1.510 g (2.566 mmol, 99%) of product as the di-TFA salt monohydrate: mp 165-169 °C;
'H NMR (400 MHz, CD3CN, CD2//CN central peak set to 1.94 ppm) 8  1.64-1.74 (dm, 
2H, J=16.8 Hz, CH2 C//eqHaxCH2), 2.18-2.34 (~qm, 2H, J~13 Hz, CH2 CHe£//axCH2), 
2.57-2.67 (dm, 2H, J=13.6 Hz), 2.89-3.14 (m, 12H), 3.31 (td, 2H, J=13.0, 3.3 Hz), 3.43-
3.48 (AA'BB', 4H, NC//2 Ci/2N cross-bridge), 3.46 (d, 2H, J=17.0 Hz, NCHAHxC 0 2),
4.14 (d, 2H, 1=17.0 Hz, NCHAHxC 02), (Note: N-H/CO2 H fast-exchange signal 
broadened into baseline. In other spectra, broad signals integrating for up to 4H were 
observed in the range 8.9-12 ppm); 13C NMR (100.5 MHz, CD3 CN, CD3 CN central peak 
set to 1.39 ppm) 8  20.63, 49.20, 48.48, 48.48, 54.35, 56.28, 59.09, 60.81, 172.69 (O C O ); 
IR (KBr) 3408, 2960, 2886, 2529, 1723, 1708, 1628, 1433,1281, 1242, 1198, 1132, 722 
cm’l; Anal Calcd for Ci6 H3 0N4 O4 -2TFA- H2 0 : C, 40.82; H, 5.82; N, 9.52. Found: C, 
41.14; H, 5.91; N, 9.62.
4-(2-(ll-tert-Butoxycarbonylmethyl)-l,4,8,ll-tetraazabicycIo[6.6.2]hexadec- 
4-yl)-acetylamino)benzoic acid (45). Hydrogenolysis of benzyl 4-(2-(l 1-tert- 
butoxycarbonylmethyl)-l ,4,8,11 -tetraaza-bicyclo[6.6.2]hexadec-4-yl)-
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acetylamino)benzoate 135 was carried out in a glass apparatus designed for the exclusion 
of O2  and for measurement of H2 uptake with maintenance of constant pressure. Catalyst 
(40.0 mg, 10% Pd/C) and ethyl acetate (20 mL) were added to a 50 mL hydrogenation 
flask, which was connected to the apparatus. The system was evacuated by means of a 
water aspirator and flushed with N2 four times. After another evacuation the system was 
filled with hydrogen. The mixture of 10% Pd/C and ethyl acetate solution was 
equilibrated under H2 for 30 minutes. 135 (65.2 mg, 0.107 mmol) in ethyl acetate (5 mL) 
was then added and the mixture was stirred for 16 h under H2 . The hydrogenolysis was 
stopped, the apparatus was evacuated and flushed with N2 at atmospheric pressure. The 
contents of the hydrogenation flask were filtered through Celite, and the product, the 
catalyst and Celite were washed with ethyl acetate (2x50 mL). The ethyl acetate filtrate 
and washings were discarded. The product was then washed out with CH3 CN (6x50 mL), 
the washings were combined, and dried (Na2 SC>4 ). The solvent was removed under 
reduced pressure to yield product (45.0 mg, 0.0869 mmol, 81%): 'H NMR (500 MHz, 
CD3 CN, C//D 2 CN central peak set to 1.94) 8  1.42 (s, 9H), 1.60-1.80 (m, 4H), 2.43 (br s, 
H2 0), 2.70-3.20 (m, 16H), 3.34-3.45 (m, 2H), 3.50-3.62 (m, 2H), 3.33 & 3.34 (AB, 2H, 
J=17.1 Hz), 3.53 & 3.60 (AB, 2H, J=16.3 Hz), 7.79-7.84 (XX’ of AA’XX’, 2H), 7.91- 
7.96 (AA’ of AA’XX’, 2H), 10.17 (br s, 1H), 10.22 (br s, 1H); *H NMR (500 MHz, 
CD3 OD, CM )2OD peak set to 4.87) 8  1.44 (s, 9H), 1.62-1.80 (m, 3H), 1.83-1.95 (m, 1H), 
2.66-2.80 (m, 4H), 2.80-3.02 (m, 7H), 3.03-3.13 (m, 4H), 3 .16-3 .26 (m, 3H), 3.27 & 3.36  
(AB, 2H, J=17.3 Hz), 3.33 & 3.54 (AX, 2H, J=16.1 Hz), 3.52-3.63 (m, 1H), 3.69-3.80 (m, 
1H), 7.56-7.61 (XX’ of AA’XX’, 2H), 7.90-7.96 (AA’ of AA’XX’, 2H); ' ^ { ‘H } NMR 
(125.7 MHz, CD3 CN, CD3CN central peak set to 1.39) 8  24.67, 25.47, 28.46, 51.43,
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51.92, 53.26(br), 53.61 (br), 54.89 (br), 56.22, 56.35, 56.75, 57.41, 57.66 (br), 58.98 (br),
119.75,127.67 (br), 131.54,143.90,168.26,171.09,171:67; ' ^ { ‘H } NMR (125.7 MHz, 
CD3OD, CD3OD central peak set to 49.15) 8  24.98, 25.91, 28.59, 51.84, 51.85 (br), 52.57, 
53.86 (br), 54.10 (br), 55.58 (br), 56.78, 57.00, 57.03, 58.32 (br), 58.43, 59.67, 82.67 (br), 
119.97, 131.36, 134.93, 141.69, 171.234, 172.45, 174.92; IR(CH3CN) 3649, 3629, 3164, 
3002, 2944, 1717, 1683, 1455, 1419, 1375, 1039, 918 c m 1; HRFABMS, m/z (M+H)+ 
exact mass for C27H44N5O5: 6518.3342; Found: 518.3330 (error -1.2 mmu/«2.4 ppm)
3-(4-(2-(l 1-tert-Butoxycarbonylmethyl-1,4,8? 11 -tetraazabicyclo [6.6.2] - 
hexadec-4-yl)-ethylsulfamoyl)phenyl)propionic acid (46). Hydrogenolysis of benzyl-3- 
(4-(2-(l 1 -carbo-tert-butoxymethyl-1,4,8,11 -tetraaza-bicyclo[6.6.2]hexadec-4-yl)- 
ethylsulfamoyl)- phenyl) propionate 149 was carried out in a glass apparatus designed for 
the exclusion of O2  and for measurement of H2 uptake with maintenance of constant 
pressure. Catalyst (150 mg, 10% Pd/C) and ethyl acetate (50 mL) were added to a 200 
mL hydrogenation flask, which was connected to the apparatus. The system was 
evacuated by means of a water aspirator and flushed with N2 four times. After another 
evacuation the system was filled with hydrogen. The mixture of 10% Pd/C and ethyl 
acetate solution was equilibrated under H2  for 30 minutes. 149 (40.0 mg, 0.0583 mmol) 
in ethyl acetate (2 mL) was then added and the mixture was stirred for 16 h under H2 . The 
hydrogenolysis was stopped, the apparatus was evacuated and flushed with N2 at 
atmospheric pressure. The contents of the hydrogenation flask were filtered through 
Celite, and the product, the catalyst and Celite were washed with ethyl acetate (2x25 
mL). The ethyl acetate filtrate and washings were discarded. The product was then
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washed from the Celite with CH3 CN (3x30 mL), the washings were combined, and dried 
(Na2 SC>4 ). The solvent was removed under reduced pressure to yield product (20.0 mg, 
0.0336 mmol, 58%, >90% purity): *H NMR (500 MHz, CD3 CN, C//D2CN central peak 
set to 1.94) 6  1.48 (s, 9H), 1.52-1.63 (m, 2H), 1.64-1.76 (m, 2H), 2.39 (br s, H2 0), 2.36-
2.70 (m, 6 H), 2.72-3.00 (m, 16H), 3.00-3.06 (m, 2H), 3.10-3.17 (m, 2H), 3.19-3.29 (m, 
2H), 3.20 & 3.33 (AB, 2H, J=17.6 Hz), 3.75-3.84 (m, 1H), 7.40-7.45 (XX’ of AA’XX’, 
2H), 7.74-7.78 (AA’ of AA’XX’, 2H), 10.15 (br s, 1H); '^ { 'H }  NMR (125.7 MHz, 
CD 3 CN, CD3CN central peak set to 1.39) 5 22.61 (impurity), 24.55, 25.69, 28.48, 33.08, 
39.38, 40.81, 50.82 (br), 51.86 (br), 52.26, 52.34 (br), 53.80, 54.74 (br), 54.99, 55.74 (br),
55.93, 56.40 (br), 56.68, 59.38 (br), 82.28, 127.75, 130.15,139.19, 149.41, 171. 65, 
176.99; IR(CH3 CN) 33370, 3281, 3093, 2924, 2853,1653,1636, 1559, 1038, 832 cm'1; 
HRFABMS, m/z (M+H)+ exact mass for C2 9 H5 0N 5 O6 S: 596.3482; Found: 596.3478 
(error -0.3 mmu/-0.6 ppm).
4,ll-Bis-(carbo-terr-butoxymethyl)-l,4,8,l l-tetraazabicyclo[6.6.2]hexadecane 
(51). Anhydrous sodium carbonate (1.18 g, 11.1 mmol) and t-butyl bromoacetate 35 
(2.17 g, 11.1 mmol) was added to a solution of 1,4,8,1 l-tetraazabicyclo[6.6.2]hexadecane 
(1.12 g ,4.95 mmol) in acetonitrile (30 mL) .The mixture was stirred under N2  and heated 
to 50° C for 48 h. Solvent was then removed under reduced pressure and residual material 
was dissolved in 20% aq NaOH (20 mL) at ice bath temperature (0-5 °C). The aqueous 
layer was extracted with cold (0-5 °C) toluene (3 x 20 mL), combined extracts were dried 
(Na2 SC>4 ), and solvent was removed under reduced pressure to give a oil which solidified 
upon standing (2.08 g, 4.58 mmol, 93%): mp 39-40 °C; 'H NMR (400 MHz, C6 D6)
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8  1.21-1.46 (m, 4H), 1.40 (s, 18H, (CH3)i), 2.23 (ddd, 2H, J=13.5, 3.9,1.9 Hz), 2.29 
(ddd, 2H, J=13.1, 4.9, 2.5 Hz), 2.42-2.56 (XX' o f AA'XX', 2H, NCHA77XCHA>//XN 
cross-bridge), 2.60-2.94 (m, 10H), 3.01 and 3.17 (AB, 4H, J=16.4 Hz, N-C//a/ /b-C 02), 
3.24-3.40 (AA' of AA'XX', 2H, NC//AHXC//A’HX’N cross-bridge), 3.69 (td, 2H, J=11.9, 
4.2 Hz); 13C NMR (100.5 MHz, C6D6) 8  28.10, 28.20, 50.87, 53.32, 55.96, 56.31, 57.24, 
60.13, 79.67, 171.08; IR (KBr) 2976, 2917, 2819, 2784, 1739, 1728, 1477, 1392, 1367, 
1323, 1165, 1122 cm'1; HRFABMS, m/z (M+H)+ exact mass for C2 4 H4 7 O4N4 : 455.3597; 
Found: 455.3600 (error +0.2 mmu/+0.5 ppm).
4.10-Bis(carbo-tert-butoxymethyl)-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane 
(53). l,4,7,10-Tetraazabicyclo[5.5.2]tetradecane (17) (51.0 mg, 0.263 mmol) was 
dissolved in toluene (4 mL), anhydrous sodium carbonate (28.0 mg, 0.264 mmol) was 
added in one portion, and a solution of t-butylbromoacetate (51.0 mg, 0.263 mmol) in 
toluene (1 mL) was added over 1 minute. The mixture was stirred for 24 h at room 
temperature, and then poured into ice-water (2 mL). Solid KOH was used to adjust pH to 
14. The organic layer was separated, dried (Na2 SC>4 ), and evaporated to dryness under 
reduced pressure to yield product as slightly yellow oil (54.0 mg, 0.128 mmol, 49%): 
NMR spectra were consistent with spectra of authentic material. 50
2.3.9.10-Dibenzo-l,5,8,12-tetraazacycIotetradeca-4,l 1-diene (55): The
compound was prepared according to procedure of Betakis, Piesch, and Ried51. Dry 
toluene (450 mL), ethylene diamine (182 mL, 2.72 mol), Cu powder (28.4 g, 0.50 mol), 
and formic acid (9 mL) were combined in a dry 1L round-bottom flask under N2 to give a
1 1 1
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blue mixture, which was refluxed for 35 min. The mixture was allowed to cool (rt) and a 
solution of 2-chlorobenzaldehyde (50 mL, 0.44 mol) in toluene (50 mL) was added 
dropwise with stirring over 1 h. The mixture was refluxed for 4 h to give a green mixture 
that was hot filtered to remove solids. The filtrate separated into two phases. The upper 
green organic phase was isolated, and the blue aqueous phase was extracted with toluene 
(2 x 1 OOmL). The combined organic phase and toluene extracts were dried (Na2 SC>4 ) and 
the solvent was removed under reduced pressure to give crude product. This was 
recrystallized from hot 95% EtOH to yield pure product as a yellow solid (24.2 g, 82.8 
mmol, 37%). NMR spectra were consistent with spectra of authentic material.
2, 3, 9 ,10-Dibenzo-l, 5, 8 , 12-tetraazacyclotetradecane (56): The compound 
was prepared according to procedure of Condon. 5 0  2, 3, 9, 10-Dibenzo-l, 5, 8 , 12- 
tetraazacyclotetradeca-4,11-diene 55 (6.51 g, 22.3 mmol) was dissolved in dry THF (440 
mL). The solution was stirred under N2  and cooled (ice/water). NaBEU powder (33.5 g, 
0 . 8 8 6  mol) was added batchwise over 1 0  min and the resultant mixture was refluxed for 
43.5 h. The mixture was cooled (ice/water) and the pH was adjusted to 1 by slow addition 
of 3 M aq HC1 (208 mL) with stirring. Rotary evaporation gave an aqueous mixture. The 
pH was adjusted to 14 by solid KOH addition, and the solution was extracted with 
chloroform (4 x 200 mL). The combined extracts were dried (Na2 SC>4 ) and the solvent 
was removed under reduced pressure to give crude product which was washed with 
boiling MeOH (100 mL) to give product as a white solid (4.70 g, 15.8 mmol, 71%).
NMR spectra were consistent with spectra of authentic material.
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(13ba, 13ca)-5,6,7,12,13,13b,13c,14-Octahydro-4b,6a,llb,13a- 
tetraazadibenzo[b,def]chrysene (57). The compound was prepared according to 
procedure of Condon. 5 0  2, 3, 9, 10-Dibenzo-l, 5, 8 , 12-tetraazacyclotetradecane 56 (2.51
g, 8.46 mmol) was dissolved in MeOH (180 mL) in a round-bottom flask under N2 . 40% 
Aq glyoxal (1.2 mL, 11 mmol) was added dropwise with stirring, and then the mixture 
was stirred for 14 h at room temperature. The precipitate formed was isolated by suction 
filtration and washed with MeOH (3 x 20 mL). Removal of solvent gave product as a 
white solid (2.25 g, 7.08 mmol, 84%). NMR spectra were consistent with spectra of 
authentic material.
Benzyl-(E)-(13ba, 13ca)-3-(5,6,7,12,13,13b,13c,14-Octahydro-4b,6a,Hb,13a- 
tetraazadibenzo[b,def]chrysenzyl)acrylate(63): NaOAc (44.0 mg, 0.537 mmol), tri(o- 
tolyl)phosphine (26.0 mg, 0.0854 mmol), palladium(II) acetate (13.6 mg, 0.0606 mmol), 
and benzyl acrylate (8 6 . 6  mg, 0.534 mmol) were added to a solution of (13ba, 13ca)-2- 
bromo-5,6,7,12,13,13b, 13c, 14-octahydro-4b,6a, 11 b, 13a-tetraazadibenzo[b,def)chrysene 
64 (214 mg, 0.535 mmol) in DMF (20 mL). The mixture was maintained at 150 °C for 20
h, then poured into a flask with ice ( 2 0 0  g) to generate white precipitate which was 
collected by suction filtration. This was dissolved in CHCI3 (100 mL), the solution was 
washed with water (2 x 200 mL), brine (200 mL), and dried (Na2 SC>4 ). Solvent was 
removed under reduced pressure to give crude product, which was subjected to flash 
chromatography (SiC>2 , hexane: ethyl acetate = 1 : 1) to give product as white solid (50.0 
mg, 0.111 mmol, 21%): ]H NMR (400 MHz, CDC13) 5 2.64-2.74 (m, 2H), 2.95-3.13 (m, 
2H), 3.14-3.35 (m, 2H), 3.66 (2 overlapping d, 2H, J-16.8 Hz), 3.83-3.94 (m, 2H), 4.22
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(d, 1H, unresolved J, (N)2 C//CH(N)2), 4.31 (d, 1H, J=2.3 Hz, (N)2 CHC//(N)2), 4.51 (d, 
1H, J=17.0 Hz), 4.55 (d, 1H, J=17.0 Hz), 5.24 (s, 2H), 6.30 (d, 1H, J=16.0 Hz), 6.72-6.79 
(m, 1H), 6.81 (d, 1H, J=8 . 6  Hz), 6.85 (br d, 1H, J - 8 . 8  Hz), 6.95 (br d, 1H, J-7.0 Hz),
7.10-7.18 (m, 2H), 7.29-7.45 (m, 6 H), 7.63 (d, 1H, J=16.0 Hz); ^C l'H } NMR (100.5 
MHz, CDC13) 8  44.87, 45.21, 45.92, 46.22, 54.92, 55.14, 66.27, 70.33, 70.40, 112.53,
112.93, 113.73, 118.81,120.44, 120.57,124.39, 127.34, 127.86, 128.33, 128.40, 128.54, 
128.77, 136.57, 144.54, 145.32,146.88,167.66; IR (KBr) 3066, 2963, 2940, 2859, 1708, 
1603,1493,1308, 1155, 1144,1120, 1105, 1084, 802,747 c m 1.
(13ba, 13ca)-2-Bromo-5,6,7,12,13,13b,13c,14-octahydro-4b,6a,llb,13a- 
tetraazadibenzo[b,def|chrysene (64).Tetrabutylammonium tribromide (TBABrs) (159.0 
mg, 0.3300 mmol) was added to a stirred solution of (13ba, 13ca)-5,6,7,12,13,13b,13c, 
14-octahydro-4b,6a,l lb,13a-tetraazadibenzo[b,def]chrysene 57 (100.0 mg, 0.3140 mmol) 
in CHCI3 (20 mL), and the mixture was stirred for 36 h at room temperature. The mixture 
was diluted with additional CHCI3 (200 mL), and the organic solution was washed with 
aq. sodium thiosulfate (2 x 100 mL), water ( 2  x 100 mL), aq saturated NaCl (2 x 40 mL), 
dried (Na2 SC>4 ), and evaporated to dryness. Crude product was purified by flash 
chromatography (Si02, MeOH: CH2C12=1:15) to yield white solid product (52.2 mg, 
about 70% pure by NMR), which was subsequently used without further purification. A 
small amount of pure compound was acquired by repeated (4 times) flash 
chromatography (2 mg from 16 mg of 70% pure product): 'H NMR (500 MHz, CDCI3)
8  2.60-2.71 (m, 2H), 2.96-3.03 (m, 2H), 3.24 (td, 1H, J=11.5, 3.4 Hz), 3.29 (td, 1H,
J=11.7, 3.7 Hz), 3.61 (d, 1H, J=16.9 Hz), 3.65 (d, 1H, J=16.9 Hz), 3.80-3.84 (dm, 1H,
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J=11.7 Hz), 3.86-3.92 (dm, 1H, J=11.7 Hz), 4.18 & 4.21 (AB, 2H, J=2.4 Hz), 4.50 (d, 1H, 
J=16.9 Hz), 4.55 (d, 1H, J=16.6 Hz), 6.71 (d, 1H, J=9.0 Hz), 6.76 (td, 1H, J=7.3, 1.0 Hz), 
6.85 (br d, 1H, J=8.3 Hz), 6.94 (d, 1H, J=7.3 Hz), 7.04-7.06 (m, 1H), 7.12-7.17 (~tm, 1H, 
J=8.3 Hz), 7.21 (ddd, 1H, J=9.0, 2.9, 0.5 Hz); '^ { 'H }  NMR (125.7 MHz, CDCI3 , CDC13 
central peak set at 77.23) 8  45.25 (2C), 46.11, 46.31, 54.70, 55.09, 70.40, 70.46, 110.51, 
112.87, 114.58, 118.74, 120.17, 122.75,127.32, 127.83, 129.80, 130.44,143.87, 144.61; 
IR(KBr) 3080, 2964, 2859, 2859, 2835, 2805, 1602, 1488, 1377,1330, 1303, 1261, 1229,
1127, 1047, 1029, 907, 817, 799, 747 cm 1; HRFABMS, m/z (M+H)+ exact mass for 
C2 oH2 2N4 Br: 397.1028; Found: 397.1026 (error-0.2 mmu/-0.4 ppm)
cis-Decahydro-8b-carboxylethyl-2a,4a,6a,8a-tetraazacyclopent[fg]- 
acenaphthylene (70). A solution of 4,5-dioxopentanoic acid 91 (190.0 mg, 1.283 mmol) 
and 1,4,7,10-tetraazacyclododecane (13) (200.0 mg, 1.161 mmol) in 20 mL of MeCN 
were stirred for 1 h at room temperature, and then for 4 h at 50-60 °C. After the reaction 
mixture was cooled to room temperature, the solvent was removed under reduced 
pressure. Purification by flash chromatography (SiC>2 , MeOH) yielded solid product (41.0 
mg, 0.154 mmol, 13%): 'H NMR (CD3 CN, 400 MHz, CD2HCN central peak set at 1.94 
ppm) 8  1.92-1.96 (m, 2H), 2.33 (ddd, 2H, J=10.9, 5.1, 2.3 Hz), 2.46-2.52 (m, 2H), 2.54- 
2.62 (m, 2H), 2.88-3.05 (m, 7H), 3.05-3.12 (m, 2H), 3.18 (td, 2H, J=10.5, 6.2 Hz), 3.36-
3.45 (m, 2H); *H NMR (CDC13, 500 MHz) 8  1.95-2.02 (m, 2H), 2.38-2.44 (m, 2H), 2.60-
2.71 (m, 4H), 2.92-3.04 (m, 4H), 3.04-3.10 (m, 2H), 3.06 (s, 1H), 3.14-3.24 (m, 4H),
3.33-3.41 (m, 2H); ,3 C{'H] NMR (CD3 CN, 90.56 MHz, CD3CN central peak set at 
1.37) 8  27.98, 31.38, 43.14, 43.67, 48.71, 52.00, 77.27, 79.67, 176.74; IR(KBr)
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3405(COOH), 2954,2938,1560 (C=0), 1447, 1438,1414,1200 cm'1; LREIMS, m/z 
266(M+); HRFABMS, m/z (M+H)+ exact mass for C 1 3H2 3N4 O2 : 267.1821; Found: 
267.1809 (error-1.2 mmu/-4.4 ppm).
Notes: Assignment of the 1.92-1.96 (m, 2H) in the !H NMR spectrum (C D 3 CN), as well 
as some other assignments, were based upon a gHMQC spectrum. No COOH  signal was 
observed in either of the *H NMR spectra (CD 3 CN & C D O 3 ). A HRFABMS peak 
corresponding to sodium salt molecular ion was observed in addition to thatof the title 
compound.
4-(Carbo-tert-butoxymethyl)-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane (73).
Hydrogenolysis o f 4-(tert-butylcarboxymethyl)-l0-(phenylmethyl)-l ,4,7,10- 
tetraazabicyclo[5.5.2]tetradecane 72 was carried out in a glass apparatus designed for the 
exclusion of O2 and for measurement of H2  uptake with maintenance of constant 
pressure. 10% Pd/C (1 lOmg), conc. HC1 (0.2 mL), and EtOH (20mL) were added to a 
125 mL hydrogenation flask which was connected to the hydrogenator. The system was 
evacuated (by means of a water aspirator) and flushed with nitrogen four times. After 
another evacuation and flushing with hydrogen, the system was filled with hydrogen. The 
catalyst was equilibrated with stirring under hydrogen for 0.5 h. To the reaction flask was 
added a solution of 4-(tert-butylcarboxymethyl)-10-(phenylmethyl)-l,4,7,10- 
tetraazabicyclo[5.5.2]tetradecane 72 (110 mg, 0.273 mmol) in EtOH (5 mL). The mixture 
was stirred for 3 hours under H2 (1 atm). The theoretical H2 uptake for this reaction was
6.1 mL; the measured uptake was 4.8 mL, which is 78% of the theoretical value. The 
hydrogenation apparatus was evacuated and flushed with N2 four times. The reaction
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flask was removed from the apparatus, the contents were filtered through celite, and the 
catalyst and celite were washed with EtOH ( 2 x 5  mL). The filtrate and washings were 
combined and concentrated under reduced pressure to give a white solid, which was 
dissolved in H2 O (4 mL), adjusted to pH 14 with solid KOH (with cooling), and extracted 
with benzene (2 x 25 mL). The combined extracts were dried (Na2 S0 4 ) and solvent was 
removed under reduced pressure to give product as a light yellow oil (74.4 mg, 0.238 
mmol, 87%): *H NMR (C6 D6, 360.15 MHz) 1.38(s, 9H, C(C//3)3), 2.39-3.78 (m, 21H), 
3.29 (s, 2H, N 0 / 2 C(0)); l3C NMR (C6 D6, 90.56 Hz) 28.25(C(CH3)3), 48.04, 52.22,
52.66, 53.06, 55.29, 56.95, 79.96 (C(CH3)3), 171.43 (C=0); IR(neat) 1154, 1216, 1368, 
1735(C=0), 2804, 2909, 2974, 3193, 3222 (NH) cm’1; HREIMS m/z (M+) exact mass 
calcd for Ci6H3 2N4 0 2 : 312.2525; Found: 312.2523 (error 0.2 mmu).
4-Carbo-tert-butoxymethyl-l,4,8,ll-tetraazabicyclo|6.6.2]hexadecane (74).
1,4,8,1 l-Tetraazabicyclo[6.6.2]hexadecane 35 (100 mg, 0.441 mmol) was dissolved in 
dry MeCN (4 mL), sodium carbonate (47.0 mg, 0.441 mmol) was added in one portion, 
and t-butyl bromoacetate (0.065 mL, 0.44 mmol) was added in one portion by syringe.
The solution was stirred for 14 h at room temperature, and then solvent was removed 
under reduced pressure. Purification by flash chromatography (SiC>2 , MeOH :
CH2 C12 =1.5:10) yielded an oil which was dissolved in water (4 mL), adjusted to pH 14 
(solid KOH), and extracted with benzene (3 x 5 0  mL). The combined extracts were dried 
(Na2 S0 4 ) and solvent was removed under reduced pressure to yield product as a light 
yellow oil (60.0 mg, 0.172 mmol, 39%): 'H NMR (C6D6, 500 MHz) 5 1.20-1.32 (m, 2H), 
1.38 (s, 9H, C(Ctf3)3), 1.41-1.52 (m, 2H), 1.94-2.01 (dm, 1H, J=15.6 Hz), 2.08-2.14 (dm,
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1H, J=14.7 Hz), 2.19 (ddd, 1H, J=13.4, 10.0, 3.4 Hz), 2.24-2.29 (dm, 1H, J=12.9 Hz), 
2.30-2.40 (m, 3H), 2.45 (td, 1H, J=13.2, 3.7 Hz), 2.53 (td, 1H, J=11.5, 5.4 Hz), 2.58-2.65 
(ddm, 1H, J=13.4, 5.9 Hz), 2.65-2.80 (m, 5H), 2.85-2.94 (m, 1H), 2.97-3.04 (m, 1H), 
3.00 & 3.11 (AB, 2H, J=16.4 Hz), 3.15-3.26 (m, 2H), 3.41-3.48 (m, 1H), 4.69 (m, 1H, 
NH); 1 3C{'H} NMR (C6 D6, 100.5 MHz) 5 25.73, 28.21 (C(CH3)3), 28.35, 48.79, 49.03,
49.07, 50.20, 53.67, 55.63, 55.71, 57.36, 57.59, 59.37, 60.75, 79.92 (OC(CH3)3), 171.24 
(C=0); IR (neat) 1158, 1214, 1255, 1296, 1366, 1391, 1458, 1492, 1736(C^O), 2801, 
2914, 3236 (NH) cm'1; HRFABMS (M+H)+ exact mass calcd for Ci8 H3 3 N4 0 2: 341.2917; 
Found: 341.2915 (error-0.1 mmu/-0.3 ppm).
cis-Decahydro-5H-2a,4a,7a,9a-tetraazacyclopenta [cd] phenalene. (79): The
compound was prepared according to the procedure of Hill1319. 40% Aq glyoxal (0.30 
mL, 0.38 g, 2.6 mmol) was added dropwise over 1 h to a stirred solution of 1,4,7,10- 
tetraazacyclotridecane (33) (310 mg, 1.67 mmol) in MeCN (10 mL). The mixture was 
heated to 60 °C for 6  h. Solvent was removed to give a yellow oil, which was dissolved 
in chloroform (20 mL) and dried (Na2 S0 4 ), and then solvent was removed under reduced 
pressure to give crude product. This was purified by flash chromatography on basic 
alumina (10% EtOH/Et2 0 ) to give a clear oil which crystallized upon standing at room 
temperature (178 mg, 0.864 mmol, 52%). NMR spectra were consistent with spectra of 
authentic material.
(9ba, 9ca)-Decahydro-2a,7a-bis(phenylmethyl)-5H-4a,9a-diaza-2a,7a- 
diazoniacyclopenta|cd]phenalene dibromide (80). The compound was prepared
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according to the procedure of Hill13,19. To a stirred solution of cis-decahydro-5H- 
2a,4a,7a,9a-tetraazacyclopenta[cd]phenalene 79 (178 mg, 0.864 mmol) in MeCN (5 mL) 
at room temperature, was added benzyl bromide (1.10 mL, 1.58 g, 9.24 mmol). The 
mixture was stirred at room temperature for 20 days. Precipitate was collected by suction 
filtration, washed with MeCN (2 x 30 mL), and then CH2 CI2 ( 3x15  mL). Residual 
solvent was removed under vacuum to give product as white powder (300 mg, 0.545 
mmol, 63%). NMR spectra were consistent with spectra of authentic material.
4.11-Bis(phenylmethyl)-l,4,8,ll-tetraazabicyclo|6.5.2]pentadecane (81): The
compound was prepared according to the procedure of Hill13,19. NaBfL (1.31 g, 0.0340 
mol) was added in small portions over 20 min to a stirred solution of (9ba, 9ca)- 
Decahydro-2a,7a-bis(phenylmethyl)-5H-4a,9a-diaza-2a,7a-diazoniacyclopenta[cd]- 
phenalene dibromide 80 (300 mg, 0.545 mmol) in 95% EtOH (7.5 mL). The mixture was 
stirred for 10 days at room temperature. Excess NaBH4 was then decomposed by slow 
addition 15 mL of 3 M HC1. Evaporation of solvent gave a white solid which was 
dissolved in water (3 mL), adjusted to pH 14 with solid KOH, and extracted with benzene 
(3 x 45 mL). The combined extracts were dried (Na2 S0 4 ), and solvent was removed 
under reduced pressure to yield product as a viscous oil (70.0 mg, 0.178 mmol, 33%). 
NMR spectra were consistent with spectra of authentic material.
4.11-Bis-(carbo-tert-butoxymethyI)-l,4,8,ll-tetraazabicyclo[6.5.2]- 
pentadecane (82). To a stirred solution of 1,4,8,1 l-tetraazabicyclo[6.5.2]pentadecane 34 
(35.0 mg, 0.165 mmol) in MeCN ( 8  mL), sodium carbonate (50.0 mg, 0.472 mmol) was
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added in one portion, followed by tert-butyl bromoacetate (0.050 mL, 0.34 mmol) via 
syringe. The mixture was stirred for 3 days at room temperature. Solvent was removed 
under reduced pressure to yield crude product, which was subjected to flash 
chromatography (Si0 2 , CH2 CI2 : MeOH=10:l) to yield product as light yellow oil (40.0 
mg, 0.0909 mmol, 55%): ‘H NMR (500 MHz, C6D6) 6  1.30-1.46 (m, 2H), 1.40 (s, 18H), 
2.25 (dt, 1H, J=13.9, 2.9 Hz), 2.50-2.62 (m, 5H), 2.72-2.88 (m, 10H), 2.88-2.95 (m, 1H), 
2.96-3.03 (m, 1H), 3.09 & 3.17 (AB, 2H, J=16.4 Hz), 3.20 (br s, 2H), 3.24-3.31 (m, 1H), 
3.59 (ddd, 1H, J= 12.5, 9.8, 4.9 Hz); ’^ { ’H} NMR (125.7 MHz, C6 D6) 8  28.36, 28.60, 
28.61, 51.24, 53.34, 55.08, 55.82, 56.86, 57.39, 57.52 (2C), 57.66, 57.74, 59.84, 60.22, 
80.17, 80.22, 171.52, 172.08; IR(neat) 2976, 2924, 2852, 2800, 1734, 1719, 1457, 1367,
1152,1124; HRFABMS, m/z (M+H)+ exact mass for C2 3 H4 5N4 O4 : 441.3441; Found:
441.3456 (error +1.5 mmu/+0.3 ppm)
4-(ter/-Butvlcar boxy methyl)-! 0-(2 -hv dr oxv benzyl)-1,4,7,10-
tetraazabicyclo[5.5.2]- tetradecane (83): 4-(tert-Butylcarboxymethyl)-l,4,7,10- 
tetraazabicyclo[5.5.2]- tetradecane 73 (60.0 mg, 0.192 mmol), salicylaldehyde (71.0 mg, 
0.582 mmol), acetic acid (69.0 mg, 1.15 mmol) were dissolved in 1,2-dichloroethane (10 
mL). Sodium triacetoxyborohydride (82.0 mg, 0.387 mmol) was added to the above 
solution and the reaction mixture was stirred at room temperature under N2  for 16 hours. 
The reaction mixture was then treated with additional sodium triactoxyborohydride (41.0 
mg, 0.194 mmol). After stirring for an addition 8  hours, the reaction was made basic with 
1 N NaOH, and product was extracted with EtOAc (2 x 50 mL). The combined EtOAc 
extracts were dried (Na2 SC>4 ) and solvent was removed under reduced pressure to give an
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oil, which was dissolved in water (2 mL), adjusted to pH 3 by addition of 3 M HC1, and 
extracted with Et2 0  (2 x 25 mL). The aqueous solution Was then adjusted to pH 13 (solid 
KOH), extracted with benzene (2 x 25 mL), the combined extracts were dried (Na2 S0 4), 
and solvent was removed under reduced pressure to yield product as an oil (32.0 mg, 
0.0766 mmol, 40%): ’H NMR (C6 D6, 360 MHz) 1.38 (s, 9H, C(CH3)3), 2.34-2.40 (m, 
4H), 2.55-2.90 (m, 18H), 3.08 (s, 2H), 3.45 (s, 2H), 6.74-6.80 (m, 1H), 6.85-6.89 (m,
1H), 7.05-7.22 (m, 2H); '^ { 'H }  NMR (C6D6, 90.56 Hz) 28.24 (C(CH3)3)^6 .70 , 56.73, 
56.76, 57.29, 58.32, 58.91, 62.54, 80.05 (C(CH3)3), 116.60,119.09,123.42, 128.83, 
129.26, 159.20, 171.49 (C=0); IR(KBr) 3485, 3400-2400 (br), ,3060, 2975, 2930, 2854, 
1733,1669, 1457, 1393,1368, 1253, 1223, 1153, 755 cm'1; HREIMS, m/z (M+H)+ exact 
mass calcd for C23H3gN40 3: 418.2944; Found: 418.2930 (error +1.4 mmu)
4-Formyl-10-(terz‘-butylcarboxymethyl)-l,4,7,10-tetraazabicycIo[5.5.2]-
tetradecane (86). 4-Benzyl-10-(tert-butylcarboxylmethyl)-1,4,7,10- 
tetraazabicyclo[5.5.2]tetradecane 72 (100 mg, 0.248 mmol) was dissolved in a solution of
4.4 % HCOOH (v:v) in MeOH (10 mL) and 10% Pd/C (100 mg) was added in one 
portion at room temperature. The mixture was then stirred for 18 h under N2 at room 
temperature. The contents were filtered through Celite, catalyst and Celite were washed 
with MeOH (2 x 5  mL), and the filtrate and washings were combined and concentrated 
under reduced pressure to give a white solid. This solid was dissolved in water (2 mL), 
the solution pH was adjusted to 14 (solid KOH with cooling) and the aq solution was 
extracted with benzene (2 x 25 mL). The combined extracts were dried (Na2 S0 4) and 
solvent was removed under reduced pressure to give product as a light yellow oil (84.0
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mg, 0.246 mmol, 99%, >93% purity by 13C NMR): 'H NMR (C6 D6, 360.15 MHz) 1.39 
(s, 9H, C(CH3)3), 2.23-2.89 (m, 18H), 3.10 (s, 2H, CH2 CO), 3.26-3.38 (m, 1H), 3.73-3.84 
(dm, 1H, J—13.1 Hz), 7.97 (s, CHO); ^C^H } NMR (C6 D6, 90.56 Hz) 28.57 (C(CH3)3), 
51.53, 53.09, 55.73, 56.48, 56.77, 56.81, 57.29, 58.25, 58.81, 58.84, 59.17, 80.45 
(C(CH3)3), 163.98 (CHO), 171.76 (COO); IR (neat) 2974, 2916, 2818,1734,1674,1456, 
1392, 1369, 1217, 1150, 1122, 1032 cm'1; HRFABMS, m/z (M+H)+ exact mass calcd for 
Ci7H3 2N4 0 3: 341.2553; Found: 341.2527 (error-2.5 mmu/-7.4 ppm)
4-Carboxymethyl-l,4,7,10-tetraazabicyclo[5.5.2]tetradecane • nHCl (87» 3HC1).
4-(ter/-Butylcarboxymethyl)-l 0-formyl-l ,4,7,10-tetraazabicyclo[5.5.2]tetradecane (86) 
(50.0 mg, 0.147 mmol) was dissolved in 6  M aq HC1 (10 mL), the solution was refluxed 
for 3 days, and then the solvent was removed under reduced pressure to give white solid 
product as hydrochloride salt (3 equiv. HC1 calculated on the basis of mass; 56.8 mg):]H 
NMR (D2 0 , 360 MHz, DOH peak set to 4.80) 2.96-3.14(m, 8 H), 3.16-3.30 (m, 4H),
3.33-3.44 (m, 6 H), 3.68 (s, 2H), 3.68-3.80 (m, 2H); ^Ci'H } NMR (D2 0 , 90.6 MHz) 
47.52, 49.62, 55.48, 55.97, 58.47, 59.18, 179.96 (C=0); IR(KBr) 3389, 2989, 2828, 
2634,2615, 2506, 2413, 1763, 1736, 1488, 1433, 1421, 1407, 1309, 1236,1194, 1144, 
1091,1027, 981 cm'1; HRFABMS, m/z (M+H)+ exact mass calcd for Ci2H2 sN4 0 2: 
257.1978; Found: 257.1974 (error-0.4 mmu/-1.4 ppm).
5-Benzylidene laevulinic acid (90): The compound was prepared by the 
published method58. Laevulinic acid (29.0 g, 0.250 mol) and benzaldehyde (26.5 g, 0.250 
mol) were dissolved in dry benzene (200 mL). Acetic acid (30 mL) and dry piperidine
122
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(10 mL) were also added to the mixture. This solution was then refluxed for 72 h over a 
Dean-Stark trap. After the solution was cooled, water (100 mL) was added, and the 
aqueous phase was extracted with ether (3 x 200 mL). The combined extracts were then 
washed with water (2 x 200 mL) and dried (Na2 SC>4 ). Removal of solvent under reduced 
pressure afforded white crystalline product (41.3 g, 0.203 mol, 81%): 'H NMR (400 MHz, 
CDCI3) 8  2.75 (t, 2H, J=6 . 6  Hz), 3.02 (t, 2H, J=6 . 6  Hz), 6.76 (d, 1H, J=16.2 Hz), 7.35-
7.45 (m, 3H), 7.50-7.60 (m, 2H), 7.60 (d, 1H, J=16.4 Hz); ^C l'H } NMR (TOO.5 MHz, 
CDCI3) 8  28.17, 35.16, 125.87, 128.55, 129.16, 130.81,134.51, 143.38, 178.90,198.05.
4 ,5-dioxopentanoic acid (91): The compound was prepared by the published
c o
method . 8 -Benzylidene laevulinic acid 90 (10 g, 0.049 mol) was dissolved in dry 
methanol (150 mL) and cooled to -70 °C in acetone/dry ice bath. Ozone was passed 
through the solution until the excess ozone caused the solution to acquire a slight bluish 
color. The solution was allowed to warm to -10 °C, when the temperature reached -10 °C, 
dimethyl sulfide (DMS) (4.2 g, 6 8  mmol) was added in one portion, the temperature was 
maintained for 1 h and warmed to room temperature, the solvent was removed under 
reduced pressure, the residue was dissolved in water (50 ml) and extracted with ether (4 x 
50 ml) to remove benzaldehyde, the aqueous layer was removed to produce monohydrate 
product as green oil (6.5 g, 44 mmol, 90%): b C{‘H} NMR (125.7 MHz, DMSO)
8  27.40, 31.07, 90.72, 173.96, 207.43. The material was used directly in the next reaction.
Methyl 5-Benzylidene laevulinic acid (94): 8 -Benzylidene laevulinic acid 90 
(2.0 g, 9.8 mmol) was dissolved in MeOH (150 mL), and conc. H2 SO4  (0.5 mL) was
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added. The mixture was refluxed for 0.75 h. The solvent was removed under reduced 
pressure, the residue was dissolved in CHCI3 (50 mL), and the solution was washed with 
aq saturated NaHCC>3 (2 x 25 mL) and water (2 x 30 mL), and dried (Na2 SC>4 ). The 
solvent was removed under reduced pressure to give crude product which was 
recrystallized from a hot mixture of ethyl acetate (0.4 mL) and hexane (1 . 6  mL) to yield 
crystalline product ( 1 . 6  g, 7.4 mmol, 75%). NMR spectra were consistent with reported 
spectra. 6 " 5
Attempted preparation of Methyl 4, 5-dioxo-pentanoate (95). Actual 
synthesis of methyl 5-hydroxylaevulinate (99): A stream of Ozone was passed through 
a stirred solution of methyl benzyl-laevulinate 94 (500 mg, 2.29 mmol) in dry methanol 
(30 ml) at -10 °C. On completion of reaction (TLC analysis) the resulting light green 
solution was purged with N2 for 0.5 h, the solution was hydrogenated at room 
temperature and atmospheric pressure over 10% Pd/C (500 mg) for 4 h, the Pd/C was 
filtered off and the solvent was evaporated to dryness. The residue was dissolved in water 
(2 ml) and washed with hexane (2 x 25 ml) to remove the benzaldehyde. The aqueous 
layer was evaporated to yield product as light green oil (167 mg, 1.14 mmol, 50%):
NMR spectra are consistent with reported data for methyl 5-hydroxylaevulinate 9962b
Methyl 4, 5-dioxo-pentanoate (95): This procedure was modeled on the method
f O
for the preparation of 4, 5-dioxopentanoic acid of Cook and coworkers . A steam of 
Ozone was passed through a stirred solution of methyl benzyl-laevulinate 94 (620 mg, 
2.84 mmol) in dry methanol (30 ml) at -40 °C. On completion of reaction (TLC analysis)
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the resulting solution was purged with N2 for 1 h, warmed to -10 °C, DMS (0.25 ml, 2.8 
mmol) was added in one portion, the temperature was kept for lh  and warmed to room 
temperature, the solvent was removed under reduced pressure, the residue was dissolved 
in water (5 ml) and extracted with hexane (2 x 20 ml) to remove benzaldehyde, the 
aqueous layer was removed to produce product as an unstable light green oil (240 mg,
1.67 mmol, 59%): NMR (100.5 MHz, CDC13) 8  28.81, 28.87, 51.81,172.906,
175.46, 187.89. The material was used directly in the next reaction. Alternative method: 
The procedure was modeled the procedure of the published paper by Griffith and Ley63. 
Tetra-n-propylammonium perruthenate (TPAP)(5 mol%, 12 mg) was added in one 
portion to a stirred mixture of 5-hydroxy-4-oxopentanoic acid methyl ester 99 (100 mg, 
0.680 mmol), 4-methyl morpholine N-oxide (NMO)(190 mg, 1.02 mmol), 4A molecular 
sieves (500 mg) in CH2 CI2  (1.5 ml). The reaction was following by TLC , when 
completion, the mixture was filtered through a pad of silica, eluting with CH2 CI2 , the 
filtrate was evaporated to yield product as green oil (97 mg, 0.673 mmol, 99%).
Methyl 5-bromolaevulinate (97): The compound was prepared by a literature 
method623. A solution of laevulinic acid (96) (2.00 g, 0.0172 mol) in MeOH (20 mL) was 
stirred at room temperature while bromine (2.76 g, 0.0173 mol) was added in one portion. 
After 3.5 h, the Kl-Starch test was negative and the solution was refluxed for 1.5 h. After 
removal of methanol, the residue was stirred with ether (20 mL) and water (10 mL) while 
sodium bicarbonate (10 g) was added. The ether layer was washed with aqueous saturated 
sodium bicarbonate (20 mL), dried (Na2 S0 4 ), and then solvent was removed under 
reduced pressure to give crude product which was subjected to flash chromatography
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(SiC>2 , hexane: ethyl acetate=4:l) to yield product as a colorless oil (850 mg, 4.07 mmol, 
24%): 'H NMR (400 MHz, CDC13) 5 2.53 (t, 2H, J=6.4 Hz), 2.85 (t, 2H, J=6.4 Hz), 3.56 
(s, 3H), 3.90 (s, 2H); 13C NMR (100.5 MHz, CDCI3 ) 5 27.93, 34.31, 34.35, 51.78, 172.64,
200.44.
Methyl 5-formyloxylaevulinate (98): The compound was prepared by a 
published method62b. l,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) (512.7 mg, 3.369 mmol) 
was added slowly at 0 °C to a mixture of methyl 5-bromolaevulinate (97) (500.0 mg„
2.392 mmol) and formic acid (149.7 mg, 3.249 mmol) in benzene (10 mL). After 2 h at 
room temperature, water (20 mL) was added and the mixture was extracted with CH2CI2 
(3 x 20 mL). The organic phase was washed with 0.1 M HC1 (2 x 25 mL) and water (2 x 
25 mL). Drying (T^SCU), filtration, and evaporation of the solvent under reduced 
pressure afforded crude formyloxy compound which was subjected to flash 
chromatography (SiC>2 , ethyl acetate: hexane=l :2 ) to give pure formyloxy compound 
(308 mg, 1.77 mmol, 74%). NMR spectra were consistent with reported spectra.
Methyl 5-hydroxylaevulinate (99): The compound was prepared by the 
published method62b. Methyl 5-formyloxylaevulinate 98 (1.40 g, 8.05 mmol) was 
deformylated by being subjected to flash chromatography (neutral AI2 O3 ,
CH2Cl2 :M eO H =l: 1) to yield pure product (1.11 g, 7.60 mmol, 94%). NM R spectra were 
consistent with reported spectra.62b
(13ba, 13ca)-2,9-Dibromo-5,6,7,12,13,13b, 13c, 14-octahydro-4b,6a, 11 b, 13 a- 
tetraazadibenzo[b,defjchrysene (103). Tetrabutylammonium tribromide (TBABr3 ) (370.0
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mg, 0.7670 mmol) was added to a stirred solution of (13ba, 13ca)- 
5,6,7,12,13,13b, 13c, 14-octahydro-4b,6a, 11 b, 13a-tetraazadibenzo[b,def]chrysene 57 
(110.0 mg, 0.3460 mmol) in CHCI3 (20 mL). The mixture was refluxed for 3 days, 
diluted with additional CHCI3 (300 mL), and the organic solution was washed with water 
( 2  x 100 mL), aq saturated NaCl (2 x 40 mL), dried (Na2 SC>4 ), and evaporated to dryness. 
Recrystallization from hot CHCI3 gave x-ray quality crystals (84.0 mg, 0.175 mmol, 
50%): mp 132-134 °C (dec); 'H NMR (400 MHz, CDC13) 8  2.67 (ddd, 2H, J=11.0, 3.7,
1.7 Hz), 2.98 (td, 2H, J=11.7, 3.9 Hz), 3.27 (td, 2H, J=11.7, 3.7 Hz), 3.60 (d, 2H, J=17.0 
Hz), 3.81 (ddd, 2H, J=11.7, 3.4,2.0 Hz), 4.17 (s, 2H), 4.49 (d, 2H, J=17.0 Hz), 6.71 (d, 
2H, J=8 . 8  Hz), 7.03-7.06 (m, 2H), 7.21 (ddd, 2H, J=9.0, 2.7, 0.7 Hz); 13C{'H} NMR 
(100.5 MHz, CDCI3 , CDCI3 central peak set at 77.23) 8  45.20, 46.09, 54.68, 70.26, 
110.68, 114.66, 122.73, 129.83, 130.49, 143.74; IR(KBr) 2948, 2906, 2862, 2827, 1588, 
1487, 1449, 1407, 1380, 1322, 1300, 1241, 1130, 907, 801 cm’1; HRFABMS, m/z 
(M+H)+ exact mass calcd for C2 oH2 iN4 Br2 : 475.0133; Found: 475.0113 (error-2.0 
mmu/-4.3 ppm)
(13ba, 13ca)-2,9-Dibromo-5,6,7,12,13,13b,13c,14-octahydro-4b,6a,llb,13a- 
tetraazadibenzo[b,def]chrysene (103). Tetrabutylammonium tribromide (TBABra) 
(370.0 mg, 0.7670 mmol) was added to a stirred solution of (13ba, 13ca)- 
5,6,7,12,13,13b, 13c, 14-octahydro-4b,6a, 11 b, 13a-tetraazadibenzo[b,def)chrysene 57 
(110.0 mg, 0.3460 mmol) in CHCI3 (20 mL). The mixture was refluxed for 3 days, 
diluted with additional CHCI3 (300 mL), and the organic solution was washed with water 
( 2  x 100 mL), aq saturated NaCl (2 x 40 mL), dried (Na2 SC>4 ), and evaporated to dryness.
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Recrystallization from hot CHCI3 gave x-ray quality crystals (84.0 mg, 0.175 mmol, 
50%): mp 132-134 °C (dec); ‘H NMR (400 MHz, CDC13) 5 2.67 (ddd, 2H, J=11.0, 3.7,
1.7 Hz), 2.98 (td, 2H, J=11.7, 3.9 Hz), 3.27 (td, 2H, J=11.7, 3.7 Hz), 3.60 (d, 2H, J=17.0 
Hz), 3.81 (ddd, 2H, J=11.7, 3.4, 2.0 Hz), 4.17 (s, 2H), 4.49 (d, 2H, J=17.0 Hz), 6.71 (d, 
2H, J=8 . 8  Hz), 7.03-7.06 (m, 2H), 7.21 (ddd, 2H, J=9.0, 2.7, 0.7 Hz); ‘^ { 'H }  NMR 
(100.5 MHz, CDCI3 , CDCI3 central peak set at 77.23) 6  45.20, 46.09, 54.68, 70.26,
110.68,114.66, 122.73,129.83,130.49, 143.74; IR(KBr) 2948, 2906, 2862^2827, 1588, 
1487,1449, 1407, 1380, 1322, 1300, 1241, 1130, 907, 801 cm 1; HRFABMS, m/z 
(M+H)+ exact mass calcd for C2 oH2 iN4 Br2 : 475.0133; Found: 475.0113 (error-2.0 
mmu/-4.3 ppm)
(13ba, 13ca)-2,9-Bis((E)-styryl)-5,6,7,12,13,13b,13c,14-octahydro- 
4b,6a,llb,13a-tetraazadibenzo[b,def]chrysene (106): To a solution of (13ba, 13ca)-
2,9-dibromo-5,6,7,12,13,13b, 13 c, 14-octahydro-4b,6a, 11 b, 13 a-
tetraazadibenzo[b,def]chrysene 103 (67.0 mg, 0.140 mmol) in DMF (10 mL) was added 
NaOAc (23.0 mg, 0.280 mmol), tri(o-tolyl)phosphine (27.2 mg, 0.0894 mmol), 
palladium(II) acetate (5.0 mg, 0.022 mmol), and styrene (60.0 mg, 0.576 mmol). The 
mixture was maintained at 130 °C for 3 days. The mixture was then poured into a flask 
containing ice (300 g) to generate white precipitate which was collected by suction 
filtration and then dissolved in CHCI3  (200 mL). The solution was washed with H 2 O (2 * 
200 mL) and dried (Na2 SC>4 ). The solvent was removed under reduced pressure to give 
crude product which was subjected to flash chromatography (SiC>2 , CH2 CI2 : MeOH = 30: 
1) to give 27.2 mg of white solid consisting of a mixture of two products. The major
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product was (13ba, 13ca)-2,9-bis((E)-styryl)-5,6,7,12,13,13b,13c,14-octahydro- 
4b,6a,l lb,13a-tetraazadibenzo[b,def]chrysene 106 (0.0516 mmol, 37% by NMR 
integration) and the minor product was 2-bromo-9-styryl-5,6,12,13,13b,13c-hexahydro- 
7H,14H-4b,6a,l lb,13a-tetraazadibenzo[b,def]chrysene (107) (0.0109 mmol, 8 % by 
NMR integration). The ratio of major to minor was 4.7:1. Major product: 'H NMR (500 
MHz, CDCI3 ) 5 2.66-2.76 (dm, 2H, J=10.0 Hz), 3.06 (td, 2H, J=11.7, 3.7 Hz), 3.31 (td, 
2H, J=11.7, 3.7 Hz), 3.70 (d, 2H, J=16.8 Hz), 3.88-3.96 (dm, 2H, J=10.7 Hz), 4.27 (s, 2H, 
NC//N), 4.58 (d, 2H, J=16.6 Hz), 6.85 (d, 2H, J=8.5 Hz), 6.94 & 7.02 (AB, 4H, J=16.4 
Hz), 7.14 (s, 2H), 7.20-7.25 (tm, 2H, J=7.1 Hz), 7.28-7.32 (dm, 2H, J=7.1 Hz), 7.28-7.32 
(dm, 2H, J=9.0 Hz), 7.35 (t, 4H, J=7.6 Hz), 7.48 (d, 4H, J=7.8 Hz); '^ { 'H }  NMR (125.7 
MHz, CDCI3 ) 5 45.26,46.20, 55.15, 70.55, 112.99, 120.68, 125.30, 125.77, 126.34,
126.45, 127.21, 127.92, 128.50, 128.85, 138.09, 144.42.
(13ba, 13ca)-2,9-Diphenethvl-5,6,7,12,13,13b,13c,14-octahydro- 
4b,6a,llb,13a-tetraazadibenzo[b,def)chrysene (108). Hydrogenolysis of(13ba, 13ca)-
2,9-distyryl-5,6,7,12,13,13b, 13c, 14-octahydro-4b,6a, 11 b, 13a-
tetraazadibenzo[b,def]chrysene (106) was carried out in a glass apparatus designed for 
the exclusion of O2 and for measurement of H2 uptake with maintenance of constant 
pressure. Catalyst (60 mg, 10% Pd/C) and ethyl acetate (50 mL) were added to a 100 mL 
hydrogenation flask, which was connected to the apparatus. The system was evacuated by 
means of a water aspirator and flushed with N2  four times. After another evacuation the 
system was filled with hydrogen. The mixture of 10% Pd/C and ethyl acetate solution 
was equilibrated under H2 for 30 minutes. 106 (20.0 mg, 0.0659 mmol) in ethyl acetate (2
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mL) was then added and the mixture was stirred for 24 h under H2 . The hydrogenolysis 
was stopped, the apparatus was evacuated and flushed with N2 , the hydrogenation flask 
was removed from the apparatus, the contents were filtered through Celite, and the 
catalyst and Celite were washed with ethyl acetate (2x25 mL). The filtrate and washings 
were combined, dried (Na2 SC>4 ), and the solvent was removed to yield product ( 1 2 . 0  mg, 
0.0228 mmol, 60%): *H NMR (500 MHz, CDCI3) 5 2.64-2.73 (dm, 2H, J=9.1 Hz), 2.75-
2.92 (AA’BB’, 4H), 2.99 (td, 2H, J=11.7, 3.2 Hz), 3.31 (br t, 2H, J=11.5Hb), 3.62 (d, 2H, 
J=16.6 Hz), 3.81-3.93 (dm, 2H, J=10.7 Hz), 4.18 (s, 2H), 4.54 (d, 2H, J=16.6 Hz), 6.72- 
6.82 (m, 4H), 6.97 (br d, 2H, J=8 . 8  Hz), 7.15-7.40 (m, 10H); '^ { 'H }  NMR (125.7 MHz, 
CDCI3, CDCI3 central peak set at 77.23) 5 37.27, 38.35, 45.55,46.42, 55.11 , 70.77,
112.94, 120.59, 126.06, 127.21, 127.63, 128.53, 128.67, 131.91, 142.28, 142.86; IR(KBr) 
3054, 2987, 1422, 1265, 896, 739, 705 cm'1; HRFABMS, m/z (M+H)+ exact mass for 
C3 6 H39N4 : 527.3175; Found: 527.3171 (error-0.3 mmu/-0.6 ppm).
(10ba,l 0ca)-Decahydro-3a-acetamido-l H,6H-3a,5a,8a,l Oa-tetraazapyrenium 
bromide (113). cis-Decahydro-lH,6H-3a,5a,8a,10a-tetraazapyrene 47 (200 mg, 0.900 
mmol) was dissolved in dry MeCN (15 mL), 2-bromoacetamide (1.02 g, 7.40 mmol) was 
added in one portion to the solution, and the solution was stirred for 6  days at room 
temperature under nitrogen. The white precipitate which had formed was collected by 
suction filtration under a blanket o f nitrogen and the filtercake was washed with MeCN 
( 2 x 5  mL) to yield product as a white solid (170 mg, 0.472 mmol, 52%): 'H NMR (D2 O, 
400 MHz, refCH3CN set at 2.06) 6  1.36-1.44 (dm, 1H, J=14.2 Hz), 1.82-1.91 (dm, 1H,
J=16.4 Hz), 2.09-2.30 (m, 1H), 2.26-2.57 (m, 5H), 2.90-3.09 (m, 7H), 3.40-3.51 (m, 1H),
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3.64-3.72 (dm, 1H, J=12.7 Hz), 3,80 (td, 1H, J=13.3,4.1 Hz), 3.90-3.97 (m, 1H), 4.00 (br 
s, 1H), 4.05 (d, 1H, J=2.3 Hz), 4.28-4.39 (m, 1H), 4.33 & 4.58 (AB, 2H, J=15.1 Hz); 13C 
NMR (D2 0 , 100.5 MHz, ref CH3CN set at 1.47) 5 18.19, 18.82, 42.12, 46.44, 50.62,
51.46, 52.18, 53.47, 53.93, 58.12, 61.53, 69.57, 82.96,166.04(00); IR(KBr) 3457,
3380, 3316,3150, 3031,2953,2869, 2838, 2796, 1694, 1457, 1352, 1145, 1118 cm '1; 
HRFABMS, m/z (M-Br)+ exact mass for C 14H2 6N5O: 280.2137; Found: 280.2119 (error -  
1.9 mmu/-6 . 6  ppm).
(10ba,10ca)-Decahydro-3a,8a-bis-(acetamido)-lH,6H-3a,5a,8 a,1 Oa- 
tetraazapyrenium dibromide (114). cis-Decahydro-lH,6H-3a,5a,8a,10a-tetraazapyrene 
47 (30.0 mg, 0.225 mmol) was dissolved in dry MeCN (3.7 mL), 2-bromoacetamide (256 
mg, 1 . 8 6  mmol) was added in one portion to the stirred solution, and the solution was 
stirred for 15 days at room temperature. The white precipitate which had formed was 
isolated by suction filtration under a blanket of nitrogen. The filter cake was washed with 
MeCN (2 x5 mL) to yield product as a white solid (75.0 mg, 0.151 mmol, 67%): ’H 
NMR (D2 0, 400 MHz, ref CH3CN set at 2.06) 8  1.89-1.98 (dm, 2H, J=15.4 Hz), 2.36- 
2.51 (m, 2H), 2.78 (td, 2H, J=12.7, 3.3 Hz), 3.13-3.30 (m, 4H), 3.32-3.39 (m, 2H), 3.45 
(br s, 2H, impurity hypothesized to be 1 eq. strongly complexed H2 0 ), 3.63 (dd, 2H,
J=13.1, 2.0 Hz), 3.86-4.02 (m, 4H), 4.44 & 4.60 (AB, 4H, J=16.2 Hz, NCHAHBCO), 4.64 
(td, 2H, J=12.9, 4.3 Hz), 5.34 (s, 2H); l3C NMR (D2 0 , 100.5 MHz, ref CH3CN set at 
1.47) 6  18.78 (CH2 C//2 CH2 ), 46.77, 49.98, 51.45, 58.17, 62.33, 76.28, 165.80(C=O); IR 
(KBr) 3468, 3316, 3150, 3058, 2964, 2857, 1697,1310, 1137 cm'1; HRFABMS, m/z (M-
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Br)+ exact mass for C^fboNgC^Br: 417.1614; Found: 417.1632 (error +1.8 mmu/+4.4 
ppm).
1,8-Bisacetamido-1,4,8,11-tetraazabicyclo [6.6.2] hexadecane (115).
(1 Oba, 10ca)-Decahydro-3a,8a-bis-(acetamido)-1 H,6H-3a,5a,8a, 1 Oa-tetraazapyrenium 
dibromide 114 (100 mg, 0.201 mmol) was dissolved into a mixture of 95% EtOH (20 mL) 
and H2 O (1 mL). NaBFLt (100 mg, 2.70 mmol) was added in small portions over 5 
minutes. The mixture was stirred for 14 days at room temperature. Excess NaBFLt was 
then decomposed by slow addition of 10 mL of 3M aq HC1. Evaporation of solvent under 
reduced pressure gave white solid, which was dissolved in H2 O (5 mL). The solution was 
adjusted to pH 14 by addition of solid KOH, extracted with CHCI3 (3 x 50 mL), the 
combined extracts were dried (Na2 S0 4 ), and solvent was removed under reduced pressure 
to give white solid product (43.0 mg, 0.128 mmol, 64%). NMR spectra were consistent 
with those of authentic compound. 12
4-Carboxy methyl-1,4,8,11-tetraazabicv do 16.6.2] hexadecane *2TFA 
(116«2TFA). 4-Carbo-tert-butoxymethyl-l,4,8,l l-tetraazabicyclo[6.6.2]hexadecane 74 
(44 mg, 0.13 mmol) was dissolved in CF3CO2 H (TFA) (5 mL), and the solution was 
stirred for 15 h at room temperature. Solvent was then removed under reduced pressure to 
give product as TFA salt (2 equiv. TFA calculated on the basis of mass and 'H NMR; 6 6  
mg): 'H NMR (400 MHz, CD3CN, CHD2CN central peak set at 1.94) 8  1.60-1.72 (m,
2H), 2.16-2.37 (m, 2H), 2.45-2.57 (m, 2H), 2.64-2.76 (m, 2H), 2.80-2.92 (m, 2H), 2.93-
3.05 (m, 3H), 3.06-3.40 (m, 10H), 3.41-3.64 (m, 4H), 4.08 (A of AX, J=16.8 Hz), 8.78
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(br s, 1H), 11.14 (br s, 2H); NMR (D2 0 , 100.5 MHz, ref CH3CN set at 1.47)
8  18.70, 19.47, 41.68, 47.95, 48.88,49.06, 49.15, 54.86, 55.24, 55.79, 57.98, 58.55, 58.92,
116.91 (q, JC-f =323.2 Hz), 163.46 (t, JC-f= 39.8  H z), 172.28; IR (CH3 CN) 3164, 3003, 
2944, 1650, 1445, 1376, 1199, 1039 cm'1; HRFABMS, m/z (M+H)+ exact mass calcd for 
C 14H2 9N4 O2 : 285.2291; Found: 285.2289 (error-0.1 mmu/-0.5 ppm).
4-Acetamido-ll-carbo-tert-butoxymethyl-l,4,8,ll-tetraazabicyclo[6.6.2]- 
hexadecane (121). 4-Carbo-tert-butoxymethyl-l,4,8,l l-tetraazabicyclo[6.6.2]hexadecane 
74 (30 mg, 0.086 mmol) was dissolved in dry MeCN (4 mL), sodium carbonate (9.2 mg, 
0.086 mmol) was added in one portion, and 2 -bromoacetamide ( 1 2  mg, 0.086 mmol) was 
added in one portion. The mixture was stirred for 14 h at room temperature., and then 
solvent was removed under reduced pressure. The residue was dissolved in water (2 mL), 
adjusted to pH 14 (solid KOH) with cooling, and the aq solution was extracted with 
benzene (2 x 20 mL). The combined extracts were dried (Na2 S0 4 ) and solvent was 
removed under reduced pressure to give product as an oil (15.0 mg, 0.0372 mmol, 43%): 
*H NMR (C6 D6, 400 MHz) 8  1.01-1.40 (m, 4H), 1.39 (s, 9H, C(CH3)i), 2.00 (dt, 1H, 
J=12.3, 4.1 Hz), 2.05-2.68 (m, 13H), 2.68-2.86 (m, 3H), 2.79 & 3.04 (AX, 2H, J=16.4 
Hz), 3.02 & 3.14 (AB, 2H, J=16.4 Hz), 3.20 (td, 1H, J=8.0,4.1 Hz), 3.36 (td, 1H, J=12.1,
4.5 Hz), 4.08 (ddd, 1H, J=13.3, 8.2, 3.9 Hz ), 6.37 (br s, 1H), 6.42 (br s, 1H); 13C{'H} 
NMR (C6D6, 100.5 MHz) 8  28.04, 28.22, 28.40. 51.67, 52.27, 53.46, 53.86, 55.89, 56.76, 
57.24, 57.52, 57.55, 58.65, 59.94, 61.06, 79.96, 171.18, 174.44; IR (CC14) 3448, 2978, 
2922, 2809, 1739, 1689, 1368, 1155, 1125 cm'1; HSFABMS (M+H)+ exact mass calcd 
for C2 0 H4 0 O3N5 : 398.3131; Found: 398.3106 (error -2.5 mmu/-6.3 ppm)
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4-Acetamido-ll-carboxymethyl-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecane 
•2TFA (122*2TFA). 4-Carbo-tert-butoxymethyl-l l-acetamido-1,4,8,11- 
tetraazabicyclo[6.6.2]- hexadecane 121 (15 mg, 0.0372 mmol) was dissolved in a mixture 
o f TFA and CH2 CI2 (TFA : CH2 CI2 =1:1,6 mL) and the solution was stirred for 14 h at 
room temperature. Solvent was then removed under reduced pressure to give product as 
TFA salt (2 equiv TFA calculated on the basis of mass; 20 mg): *H NMR (D2 0 , 400 MHz, 
DOH peak set to 4.80) 5 1.72-1.80 (dm, 2H, J=17.4 Hz), 2.30-2.45 (m, 2H), 2.70-2.84 
(m, 2H), 3.00-3.36(m, 16H), 3.42-3.72 (m, 4H), 3.56 & 4.08 (AX, 2H, J=17.4 Hz), 3.63 
& 4.08 (AX, 2H, J=16.1 Hz); 13C NMR (D20 , 100.5 MHz) 5 19.46, 19.47, 47.56, 47.82, 
48.20, 48.30, 52.91, 53.23, 54.98, 55.11, 58.11, 58.13, 58.70, 58.93,116.4 (q, J=291.4 Hz, 
CF3 COOH), 163.1 (q, J=35.2 Hz, CF3 COOH), 170.05, 171.77; IR (CH3 CN) 3681, 3540, 
3164, 3003, 2944, 1694, 1444, 1422, 1376, 1202, 1039, 918 cm'1; HRFABMS, m/z 
(M+H)+ exact mass for C 16H3 5N 5 O3 : 342.2505; Found: 342.2500 (error-0.5 mmu/-1.4 
ppm).
4-Carbo-tert-butoxymethyl-l l-(N-methylacetamido)-l,4,8,l 1- 
tetraazabicyclo[6.6.2]- hexadecane (123). 4-Carbo-tert-butoxymethyl-l,4,8,11- 
tetraazabicyclo[6.6.2]hexadecane 74 (18 mg, 0.052 mmol) was dissolved in dry MeCN (4 
mL), sodium carbonate (13 mg, 0.1226 mmol), potassium iodide (23 mg, 0.1385 mmol), 
and 2-chloro-N-methyl acetamide (13 mg, 0.1209 mmol) were added in portions, and 
then the solution was stirred for 14 h at room temperature. Solvent was removed under 
reduced pressure to yield solid product, which was dissolved in water (2 mL) and
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adjusted to pH 3 by addition of 3 M aq HC1 (with cooling). The aq phase was extracted 
with benzene (2 x 25 mL), the organic layer was discarded, and the aqueous layer was 
adjusted to pH 14 with solid KOH (with cooling). The basic aq phase was extracted with 
benzene (2 * 25 mL), combined extracts were dried (Na2S04), and solvent was removed 
under reduced pressure to yield product an oil (21 mg, 0.051 mmol, 98%, >92% purity by 
13C NMR): *H NMR (C6D6, 400 MHz) 8 1.05-1.40 (m, 4H), 1.40 (s, 9H, C(C//3)3 ), 2.02- 
2.16 (m, 2H), 2.17-2.36 (m, 2H), 2.36-2.66 (m, 8H), 2.64 (d, 3H, J=5.1 Hz),; 2.68-2.94 
(m, 5H), 2.86 & 3.07 (AB, 2H, J=16.2 Hz), 3.02 & 3.15 (AB, 2H, J=16.4 Hz), 3.24 (td, 
1H, J=12.1, 4.3 Hz), 3.40 (td, 1H, J=11.9, 4.3 Hz), 4.11 (ddd, 1H, J=16.6, 10.0, 4.3 Hz), 
6.59 (br s, 1H, NH); ^ C f’H} NMR (C6D6, 100.5 MHz) 8 25.77, 28.32, 28.53, 28.58. 
51.96, 52.70, 53.83, 54.02, 56.29, 57.18, 57.76, 57.95, 58.81, 60.23, 61.58,.80.34, 171.53 
171.69; IR(CC14) 3407, 2918, 2809, 1739, 1684, 1559, 1457, 1368, 1155, 1125 cm '1; 
HSFABMS (M+H)+ exact mass calcd for C 2 1 H4 2 N 5 O3 : 412.3288; Found: 412.3274 (error 
-1.4 mmu/-3.3 ppm).
(11 -M ethylcar bamoylmethyl-1,4,8,11 -tetraazabicyclo [ 6.6.2] hexadec-4-yl)- 
acetic acid •2TFA (124*2TFA). 4-(Carbo-tert-butoxymethyl)-l l-(N-methylacetamido)-
1,4,8,1 l-tetraazabicyclo[6.6.2]hexadecane 123 (14 mg, 0.034 mmol) was dissolved in a 
mixture o f CF3C 02H (TFA) and CH2C12 (TFA: CH2C12 =1:1,8 mL), and the solution was 
stirred for 16 h. Solvent was then removed under reduced pressure to yield product (20 
mg): ]H NMR (400 MHz, D20 , DOH  peak set at 4.80) 8 1.70-1.80 (dm, 2H, J=17.0 Hz), 
2.30-2.46 (m, 2H), 2.70-2.85 (m, 2H), 2.74 (s, 3H, NC//3), 3.00-3.38 (m, 14H), 3.44-3.76 
(m, 4H), 3.57 & 4.11 (AX, 2H, J-17.4 Hz), 3.58 & 4.06 (AX, 2H, J=16.1Hz); ' ^ { ‘H}
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NMR (100.5 MHz, D2 0 ) 8  19.41 (2C), 25.95,47.51, 47.87,48.26,48.32, 52.82, 53.29, 
55.13 (2C), 58.07 (2C), 58.61, 58.93, 116.43 (q, JCF=292.2 Hz, CF3COOH), 163.05 (q, 
J c f -3 5 .2  H z, CF3 COOH), 167.65,171.74; IR (CH3 CN) 3638-3538 (br), 3164, 3002, 
2944, 1682, 1444, 1418, 1376, 1201, 1132, 1039 cm'1; HRFABMS, m/z (M+H)+ exact 
mass for C 17H3 4N 5 O3 : 356.2662; Found: 356.2664 (error +0.2 mmu/+0.5 ppm). On the 
basis of the mass and assuming a quantitative yield (no evidence of impurities), the 
product is a di-TFA salt.
4-(Carbo-tert-butoxymethyl)-l l-(N-phenylacetamido)-l,4,8,l 1- 
tetraazabicyclo|6.6.2)hexadecane (125). 4-(Carbo-tert-butoxymethyl)-l,4,8,l 1- 
tetraazabicyclo[6.6.2]hexadecane 74 (20 mg, 0.058 mmol) was dissolved in dry MeCN (4 
mL), sodium carbonate (74 mg, 0.698 mmol), potassium iodide (13.4 mg, 0.0807 mmol), 
and 2-chloro-N-phenylacetamide (37 mg, 0.218 mmol) were added in single portions.
The solution was stirred for 14 h at room temperature and solvent was removed under 
reduced pressure to yield a solid. This was dissolved in water (2 mL), the solution was 
adjusted to pH 3 by addition of 3 M aq HC1 (with cooling), and the acidic solution was 
extracted with benzene (2 x 25 mL). The organic phase was discarded. The aqueous 
phase was adjusted to pH 14 (solid KOH with cooling), extracted with benzene (2 x 25 
mL), combined extracts were dried (Na2 SC>4 ), and solvent was removed under reduced 
pressure to yield product as an oil (20 mg, 0.042 mmol, 73%): 'H NMR (C6 D6 , 500 MHz) 
8  1.03-1.40 (m, 4H), 1.40 (s, 9H, C(CH3)3), 2.00-2.03 (m, 2H), 2.08 (dt, 1H, J=13.0, 3.9 
Hz), 2.12-2.23 (m, 2H), 2.24-2.35 (m 2H), 2.48-2.55 (m, 2H), 2.55-2.66 (m, 4H), 2.71(td, 
1H, J=8 .8 , 3.6 Hz), 2.76-2.86 (m, 2H), 2.85 & 3.09 (AX, 2H, J=16.4 Hz), 2.97 (td, 1H,
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J=11.7, 4.2 Hz), 3.01 & 3.13 (AB, 2H, J=16.4 Hz), 3.25 (td, 1H, J=13.2,4.6 Hz), 3.33 (td, 
1H, J=12.0, 4.4 Hz), 4.17-4.24 (m, 1H), 6.92 (tt, 1H, J=8 .6 , 1.0 Hz), 7.14-7.22 (m, 2H),
7.91 (dd, 2H, J=8 .6 , 1.0 Hz), 9.12 (br s, 1H, NH); 13C{]H} NMR (C6 D6, 100.5 MHz)
5 28.30, 28.57(C(CH3)3), 28.69, 51.87, 52.49, 53.84, 54.10, 56.13, 57.22, 57.46, 58.03,
58.36, 59.43, 60.40, 62.44, 80.39,119.31, 124.24, 129.84,139.48, 169.63, 171.49; IR 
(neat) 703, 739,1126, 1156, 1265, 1368, 1443, 1521, 1601, 1684, 1732, 2818, 2925, 2979, 
3053, 3308 cm'1; HSFABMS (M+H) exact mass calcd for C2 6 H4 4 N 5 O3 : 474.3444;
Found: 474.3440 (error -0.4 mmu/-0.8 ppm).
(ll-PhenylcarbamoylmethyH,4,8,ll-tetraazabicyclo[6.6.2]hexadec-4-yl)- 
acetic acid «4TFA (126»4TFA). 4-(Carbo-tert-butoxymethyl)-l l-(N-phenyl acetamido)-
1,4,8,1 l-tetraazabicyclo[6.6.2]hexadecane 125 (140 mg, 0.296 mmol) was dissolved in a 
mixture of CF3 CO2H (TFA) and CH2 C12  (TFA: CH2 C12 =1:1, 20 mL), and the solution 
was stirred for 16 h. Solvent was then removed under reduced pressure to yield product 
(255 mg, quant; no impurities by NMR): 'H NMR (CD3 CN, 500 MHz, CHD2CN central 
peak set to 1.94) 5 1.63-1.72 (m, 2H), 2.20-2.34 (m, 2H), 2.68-2.76 (dm, 2H, J=12.5 Hz), 
2.94-3.02 (dm, 2H, J=14.7 Hz), 3.03-3.22 (m, 12H), 3.27 (td, 1H, J=12.9, 3.2 Hz), 3.40- 
3.61 (m, 4H), 3.62-3.72 (m, 2H), 4.05 (A of AX, 1H, J=16.6 Hz), 4.23 (A of AX, 1H, 
J=16.6 Hz), 7.12-7.17 (m, 1H), 7.31-7.36 (m, 2H), 7.57-7.61 (m, 2H), 10.02 (s, 1H, NH), 
10.90 (br s, 2H), 11.06 (br s, 3H); '^ { 'H }  NMR (CD3 CN, 125.7 MHz, CD3CN central 
peak set to 1.39) 6  20.73, 20.81, 48.77, 48.98, 49.39, 49.43, 53.73, 53.91, 56.66, 57.70, 
59.42, 60.40, 117.25 (q, JCF=290.5 Hz, CF3 C 02), 121.24, 125.88, 129.94, 138.79, 160.95 
(q, JCf=36.4  Hz, CF3 C 02), 166.73, 171.91; IR (CH3 CN) 3648, 3607, 3550, 3002, 2944,
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1680,1632,1446, 1428,1375, 1201,1039,918, 749 cm’1; HSFABMS (M+H)+ exact 
mass calcd for C2 2 H3 6N 5O3 : 418.2818; Found: 418.2811 (error-0.7 mmu/ -1.7 ppm).
Methyl-4-(2-(ll-(carbo-tert-butoxymethyl)-l,4,8,ll-tetraazabicyclo[6.6.2]- 
hexadec-4-yl)-acetylamino]-benzoate (130). To a solution of 4-(carbo-tert- 
butoxymethyl)-l,4,8,l l-tetraazabicyclo[6.6.2]hexadecane 74 (14.0 mg, 0.0412 mmol) in 
CH3 CN (4 mL), KI (14.0 mg, 0.0843 mmol), Na2 C 0 3 (9.0 mg, 0.085 mmol) were added 
first, and then methyl-4-(2-chloroacetylamino)benzoate 129 (20.0 mg, 0.0879 mmol) was 
added. The mixture was stirred for 12 h at room temperature. After removal o f the 
solvent, the residue was dissolved in water (2 mL), adjusted pH 3 by careful addition of 3 
M HC1 and washed with benzene (2 x 25 mL), and then adjusted to pH 14 by addition of 
solid KOH and extracted with benzene (3 x 3 5  mL). The combined extracts were dried 
(Na2 SC>4 ) and the solvent was removed under reduced pressure to give product as light 
yellow oil (20.0 mg, 0.0377 mmol, 91%): ‘H NMR (400 MHz, C6 D6) 5 1.00-1.42 (m, 
4H), 1.40 (s, 9H), 1.92-2.02 (m, 2H), 2.02-2.27 (m, 4H), 2.31 (dt, 1H, J=13.4, 4.9 Hz), 
2.44-2.64 (m, 6 H), 2.71 (td, 1H, J=15.4, 3.9 Hz), 2.66-2.94 (m, 3H), 2.80 & 3.02 (AB,
2H, J=16.4 Hz), 3.02 & 3.15 (AB, 2H, J=16.4 Hz), 3.20-3.38 (m, 2H), 3.50 (s, 3H), 4.16- 
4.26 (m, 1H), 7.84-7.90 (XX’ of AA’XX’, 2H), 8.15-8.21 (AA’ of AA’XX’, 2H), 9.22 
(br s, 1H, NH); i3 C{’H} NMR (100.5 MHz, C6 D6) 5 28.25, 28.51, 28.57, 51.81, 51.89, 
52.59, 53.83, 53.89, 56.15, 57.19, 57.62, 57.90, 58.16, 59.06, 60.29, 62.32, 80.41, 118.63, 
126.31, 131.85, 143.12, 166.56, 169.96, 171.47.
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Methyl-4-(2-(ll-carboxymethyl-l,4,8,ll-tetraazabicyclo[6.6.2]hexadec-4-yl)- 
acetylamlno)benzoate «nTFA (131«nTFA): Methyl-4-(2-( 11-carbo-tert-butoxymethyl- 
l,4,8,ll-tetraaza-bicyclo[6.6.2]hexadec-4-yl)-acetylamino)benzoate 130 (10.0 mg,
0.0188 mmol) was dissolved in a mixture of CF3 CO2 H (TFA) (3 mL) and CH2 CI2 (3 mL) 
The solution was stirred for 16 h at room temperature, and the solvent was removed 
under reduced pressure to give product as a TFA salt (17.0 mg, quant (no impurities by 
NMR)): ‘H NMR (400 MHz, D2 0 ) 5 1.72-1.82 (dm, 2H, J=16.8 Hz), 2.30-2.48 (m, 2H), 
2.85-2.98 (m, 2H), 3.00-3.42 (m, 14H), 3.45 & 4.12 (AX, 2H, J=17.3 Hz), 3.54-3.68 (m, 
3H), 3.66 & 4.13 (AX, 2H, J=16.4 Hz), 3.84 (td, 1H, J=13.4, 3.9 Hz), 3.91 (s, 3H), 7.62- 
7.68 (XX’ of AA’XX’, 2H), 8.00-8.05 (AA’ of AA’XX’, 2H); '^ { 'H }  NMR (100.5 
MHz, D2 0 ) 5 19.65, 19.72, 47.57, 47.73, 48.01, 48.08, 52.71, 53.10, 53.18* 55.81, 56.66, 
57.73, 58.08, 59.45, 59.48, 116.44 (q, JCf=291.4 H z), 120.00, 125.87,130.78, 141.51, 
163.09 (q, JCf=35.2 Hz), 167.59, 168.95,172.09; HRFABMS, m/z (M+H)+ exact mass 
calcd for C2 4 H3 8N 5 O5 : 476.2873; Found: 476.2856 (error -1.7 mmu/-3.6 ppm). There are 
3.76 equivalents o f TFA (by calculation based upon mass of product).
4-Benzyloxycarbonylaniline (133). The mixture of powdered KOH (1.0 g, 18 
mmol) in DMSO (20 mL) was vigorously stirred for 30 minutes at room temperature. To 
this slurry was added a solution of 4-aminobenzoic acid 132 (1.64 g, 12.0 mmol) in 
DMSO (20 mL) and the resulting mixture was stirred for 15 minutes. After the addition 
of benzylbromide (2.00 mL, 16.8 mmol), the mixture was stirred for a further 2.7 hours at 
room temperature, and then added a mixture of ice-water, the resulting solution was 
extracted with ethyl acetate (150 mL), the extract was washed with aq. saturated Na2 C0 3
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(100 mL), aq. saturated NaCl (100 mL), dried (Na2 S0 4 ), the solvent was removed under 
reduced pressure to give crude product, which was purified by flash chromatography 
(SiC>2 , hexane: ethyl acetate=3:l) to give pure product as white solid (1.38 g, 6.08 mmol, 
51%). NMR spectra were consistent with reported spectra
Phenylmethyl 4-(2-chloroacetylamino)benzoate (134). Phenylmethyl 4- 
aminobenzoate 133 (140 mg, 0.617 mmol) was dissolved in acetic acid (16 mL), 
chloroacetyl chloride (0.083 mL, 0.12 g, 1.0 mmol) was added by syringe, and the 
solution was stirred for 24 hours at room temperature. Solvent was then removed under 
reduced pressure, the residue was treated with saturated NaHCOs solution (50 mL), 
extracted with Et2 0  (120 mL), and the organic layer was washed with saturated aq 
NaHCC>3 (30 mL), water (50 mL), and saturated aq NaCl (100 mL), and dried (Na2 SC>4 ). 
The solvent was removed under reduced pressure to yield white solid product (180 mg, 
0.593 mmol, 96%). ‘H NMR (500 MHz, CDC13, CHCh peak set at 7.27) 5 4.19 (s, 2H), 
5.37 (s, 2H), 7.34-7.48 (m, 5H), 7.66 (d, 2H, J=8 . 8  Hz), 8.08 (d, 2H, J=8 . 8  Hz), 8.46 (br s, 
1H, NH); l3 C{’H} NMR (125.7 MHz, CDC13, CDC13 central peak set to 77.23) 8  43.04, 
66.90,119.37, 128.33, 126.68, 128.45, 128.78, 131.17, 136.14, 141.11, 164.25, 165.93; 
IR(KBr) 3293, 3209,3132, 3082, 3035, 1783, 1733, 1674, 1603, 1513, 1411, 1382, 1334, 
1299,1253,1174, 1130, 1120, 1015, 857, 772, 766 cm’1; HRFABMS, m/z (M+H)+ exact 
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tetraazabicyclo[6.6.2]hexadecane 74 (34 mg, 0.10 mmol) was dissolved in CH3 CN (4 
mL), KI (25 mg, 0.15 mmol) and Na2 CC>3 (26 mg, 0.25 mmol) were added, and benzyl 4- 
(2-chloroacetylamino)benzoate 134 (45 mg, 0.15 mmol) was added in one portion. The 
solution was stirred for 16 h at room temperature, solvent was removed, and the residue 
was dissolved in water (2 mL). The pH was adjusted to 3 with aq 3 M HC1 and the acidic 
solution was extracted with benzene (2 x 25 mL). The aq phase was adjusted to pH 14 
(solid KOH), extracted with benzene (3 x 35 mL), combined extracts weredried 
(Na2 S0 4 ), and solvent was removed under reduced pressure to yield product as a light 
yellow oil (60 mg, 0.99 mmol, 99%): ’H NMR (400 MHz, CDC13) 6  1.40-1.60 (m, 4H), 
1.48 (s, 9H), 2.31 (dt, 1H, J=13.1, 4.3 Hz), 2.35-2.48 (m, 2H), 2.52-2.88 (m, 13H), 2.96-
3.06 (m, 1H), 3.04 & 3.30 (AB, 2H, J=17.0 Hz), 3.08 & 3.22 (AB, 2H, J=16.5 Hz), 3.45 
(td,' 1H, J=12.3, .4.7 Hz), 4.45-4.55 (m, 1H), 5.36 (s, 2H), 7.31-7.48 (m, 5H), 7.64-7.68 
(XX’ of AA’XX’, 2H), 8.05-8.10 (AA’ of AA’XX’, 2H), 9.51 (br s, 1H); ’^ { 'H }  NMR 
(100.5 MHz, CDCI3 , CDCI3 central peak set at 77.23) 8  27.53, 28.15, 28.43, 51.87, 52.35,
53.08, 53.65, 55.97, 56.56, 57.23, 57.69, 57.94, 58.76, 59.06, 61.96, 66.75, 80.81, 118.40, 
118.48, 125.58, 128.30, 128.39, 128.77, 131.34, 136.34, 142.10, 166.10,170.72, 171.83; 
IR(CH3 CN) 3164, 3002, 2944, 1717, 1700, 1602, 1458, 1436, 1375, 1272, 1039 cm’1; 
HRFABMS, m/z (M+H)+ exact mass for C3 4 H5 0N5 O5 : 608.3812; Found: 608.3809 (error 
-0.3 mmu/-0.6 ppm).
Methyl-3-(4-(aziridine-l-sulfonyl)phenyl)propionate (136). A solution of 20% 
aq KOH solution (3 mL) was added to methyl-3-(4-(2-(4-(2-benzyloxycarbonylethyl)- 
benzensulfonyloxy)ethylsulfamoyl)phenyl)propionate 143 (40.0 mg, 0.0753 mmol) in
141
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benzene (15 mL), the two phases mixture was stirred for 0.5 h at room temperature. The 
mixture was shaken with water (2 x 40 mL), aq saturated NaCl (2 x 30 mL), and the 
organic phase was dried (Na2 S0 4 ) and solvent was removed under reduced pressure to 
yield product as light yellow oil (18.0 mg, 0.0669 mmol, 89%): !H NMR (500 MHz, 
CDCI3 ) 5 2.39 (br s, 4H), 2.68 (app. t, 2H, J=7.6 Hz), 3.05 (app. t, 2H, J=7.6 Hz), 3.69 (s, 
3H), 7.37-7.43 (XX’ of AA’XX’, 2H), 7.86-7.92 (AA’ of AA’XX’, 2H); 13C NMR 
(125.7 MHz, CDCI3 , CDCI3 central peak set at 77.23) 6  27.71, 30.94, 35.14, 52.02, 
128.46, 129.32, 136.11, 147.21, 172.89; IR(CH2 C12) 3055,2987, 1735, 1438, 1326, 1265, 
1165, 909, 739, 704 cm'1; HRFABMS, m/z (M+H)+ exact mass for Ci2Hi6NC>4 S: 
270.0800; Found: 270.0810 (error +1.0 mmu/+3.7 ppm).
Benzyl-3-(4-(aziridine-l-sulfonyl)phenyl)propionate (137). A solution of 20% 
aq. KOH solution (5 mL) was added to Benzyl-3-(4-(2-(4-(2-benzyloxycarbonylethyl) 
benzensulfonyloxy)ethylsulfamoyl) phenyl)propionate 144 (120 mg, 0.180 mmol) in 
benzene (25 mL) and the two phases mixture was stirred for 1 h. The mixture was shaken 
with water (2 x 40 mL) and aq saturated NaCl solution (2 x 30 mL), and then the organic 
phase was dried (Na2 S0 4 ) and evaporated to dryness to yield product as yellow oil (60.0 
mg, 0.174 mmol, 97%): 'H NMR (400 MHz, CDC13) 5 2.38 (br s, 4H), 2.73 (app. t, 2H, 
J=7.5 Hz), 3.06 (app. t, 2H, J=7.6 Hz), 5.12 (s, 2H), 7.28-7.40 (m, 7H), 7.82-7.88 (m, 2H); 
13C NMR (100.5 MHz, CDCI3 , CDCI3 central peak set at 77.23) 6  27.67, 30.90, 35.30, 
66.71, 128.39, 128.49, 128.56,128.77, 129.30, 135.81, 136.00, 147.06, 172.21;
IR(CHC13) 3428, 3035, 2959, 2928, 1733, 1325, 1240, 1158, 908, 732 cm'1; HRFABMS,
142
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
m/z (M+H)+ exact mass for C 18H2 0 NO4 S: 446.1113; Found: 346.1133 (error +2.0 
mmu/+5.8 ppm).
l-((4-Bromophenyl)sulfony)aziridine (139). The procedure was modeled on the 
method for the synthesis of N-(p-tolylsulfonyl)aziridine83. A solution of 20% aq KOH 
solution (3 mL) was added to ethyl (2-(4-bromophenylsulfonylamino))-4- 
bromophenylsulfonate 140 (154.5 mg, 0.3096 mmol) in benzene (40 mL), and the two 
phases mixture was stirred for 1 h at room temperature. The organic phase was then 
washed with H2 O (3 x 100 mL), aq saturated NaCl (2 x 100 mL), and dried (Na2 S0 4 ). 
The solvent was removed under reduced pressure to give product as white solid (70.0 mg, 
0.267 mmol, 8 6 %): 'H NMR (400 MHz, CDCI3 ) 6  2.41 (br s, 4H), 7.67-7.73 (XX’ of 
AA’XX’, 2H), 7.79-7.85 (AA’ of AA’XX’, 2H); 13C NMR (100.5 MHz, CDCI3 , CDC13 
central peak set at 77.23) 8  27.89, 129.07, 129.64, 132.63, 137.17; IR(KBr) 3093, 3010, 
1573, 1468, 1388, 1323, 1276, 1241, 1180, 1156, 1096, 1082, 1065, 1010,916,816, 750, 
705, 661, 608 cm'1; HRFABMS, m/z (M+H)+ exact mass calcd for CgHgNBrSC^: 
261.9537; Found: 261.9556 (error+1.8 mmu/+7.0 ppm).
(2-(4-BromophenylsuIfonylamino)ethyl)-4-bromophenylsulfonate (140). The
procedure was modeled on the method for the synthesis of N-(2-((p- 
tolylsulfonyl)oxy)ethyl)-p-tolylsulfonamide70. To a stirred suspension of 4- 
bromobenzylsulfonylchloride 141 (5.365g, 21.00 mmol) in pyridine (25 mL) cooled to -  
40 °C was added dropwise a solution of 2-aminoethanol (0.600 mL, 9.97 mmol) in 
pyridine (10 mL). After the addition was complete, the temperature was raised to -10  °C
143
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for 1 hour, and then to 0 °C for 12,hours. After crushed ice was added, the precipitate 
formed was filtered off, washed with water (2 x 50 mL), dissolved in CHCI3 (150 mL), 
washed with water (2 x 200 mL), dried (Na2 SC>4 ). Solvent was removed under reduced 
pressure to yield crude product, which was purified by recrystallization from hot CHCI3 
to yield white crystalline product (3.300 g, 6.613 mmol, 6 6 %): 'H NMR (400 MHz, 
CDCI3 ) 5 3.29 (q, 2H, J=5.3 Hz), 4.11 (t, 2H, J=5.1 Hz), 5.01 (br t, 1H, J=6.4 Hz, NH), 
7.64-7.78 (m, 8 H); '^ { 'H }  NMR (100.5 MHz, CDC13, CDC13 central peakset at 77.23)
8  42.37, 69.19, 128.29, 128.73, 129.59, 129.89, 132.81, 133.06, 134.40, 138.89; IR (KBr) 
3268, 3097, 1575, 1472,1436, 1392, 1371, 1327, 1278, 1186, 1155, 1081, 1066, 1009, 
973, 814, 761, 732, 667, 650 cm’1; HRFABMS, m/z (M+H)+ exact mass for 
Ci4 Hi4 Br2NOsS2 : 497.8680; Found: 497.8682 (error +0.2 mmu/+0.4 ppm).'
(E,E)-Dibenzyl 1 ,4-phenylenediacrylate (142): To a solution of l-(4- 
(bromophenyl) sulfonyl) aziridine 139 (140 mg, 0.534 mmol) in DMF (10 mL), were 
added anhyd. NaOAc (44.0 mg, 0.536 mmol), tri(o-tolyl)phosphine (13.0 mg, 0.0428 
mmol), palladium(II) acetate (2.4 mg, 0.011 mmol), and benzyl acrylate (8 6 . 6  mg, 0.534 
mmol). The mixture was maintained at 150 °C for 5 h. The solvent was removed under 
reduced pressure to give crude produce which was subjected to flash chromatography 
(SiC>2 , hexane: ethyl acetate = 6 : 1 ) to give product as yellow solid (49.0 mg, 0.131 mmol, 
49%); ‘H NMR (500 MHz, CDC13) S 5.27 (s, 4H), 6.53 (d, 2H, J=16.1 Hz), 7.33-7.45 (m, 
10 H), 7.54 (s, 4H), 7.71 (d, 2H, J= 16.1 Hz); ' ^ { ‘H} NMR (125.7 MHz, CDCI3 )
8  66.73, 119.26, 128.54,128.80, 128.85, 136.16, 136.39, 144.19, 166.75. The product has 
been reported in the literature84, but NMR data has not been reported.
144
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Methyl-3-(4-(2-(4-(2-methyloxycarbonylethyl)benzensulfonyIamino)- 
ethoxysulfonyl) phenyl)propionate(143). To a stirred suspension of methyl 3-(4- 
chlorosulfonyl) phenylpropionate 145 (1.10 g, 4.19 mmol) in pyridine (12 mL) cooled to 
-40  °C, was added dropwise a solution of 2-aminoethanol (128 mg, 2.09 mmol) in 
pyridine (5 mL). After the addition was completed, the temperature was raised to -10 °C 
for 1 h, and then maintained at 0 °C for 12 h. After pyridine was removed under reduced 
pressure, CHCI3 (200 mL) was added, and the solution was washed with 0.1 M HC1 (100 
mL), water (2 x 200 mL), aq saturated NaCl solution (2 x 200 mL), and dried (Na2 SC>4 ). 
The solvent was removed under reduced pressure to give crude product which was 
purified by flash chromatography (SiC>2 , hexane: ethyl acetate = 1 :1 ) to give, white solid 
product (430 mg, 0.838 mmol, 40%): 'H NMR (500 MHz, CDCI3 ) 8  2.67 (t, 2H, J=7.8 
Hz), 2.69 (t, 2H, J=7.8 Hz), 3.03 (t, 2H, J=7.6 Hz), 3.06 (t, 2H, J=7.6 Hz), 3.25 (q, 2H, 
J=5.4 Hz), 4.08 (t, 2H, J=5.1 Hz), 4.89 (t, 1H, J=6.4 Hz, NH), 7.34-7.38 (XX’ of 
AA’XX’, 2H), 7.40-7.43 (XX’ of AAXX’, 2H), 7.73-7.76 (AA’ of AA’XX’, 2H), 7.78- 
7.82 (AA’ of AA’XX’, 2H); 1 3C{!H} NMR (125.7 MHz, CDC13, CDC13 central peak set 
at 77.23) 8  30.82, 30.89, 34.98, 35.12, 42.34, 52.00, 52.04, 69.03, 127.47, 128.41, 129.44, 
129.64, 133.38, 137.75, 146.42, 147.92,172.84, 172.94.
Benzyl-3-(4-(2-(4-(2-benzyloxycarbonyIethyl)benzensulfonyloxy)- 
ethylsulfamoyl) phenyl)propionate (144). To a stirred suspension of benzyl 3-(4- 
. chlorosulfonyl)- phenylpropionate 146 (1.43 g, 4.22 mmol) in pyridine (10 mL) cooled to 
—40 °C was added dropwise a solution of 2-aminoethanol (0.126 mL, 1.40 g, 2.10 mmol)
145
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in pyridine (5 mL). After the addition was complete, the temperature was raised to -10 °C 
for 0.5 h, and then maintained at 0 °C for 12 h. After pyridine was removed under 
reduced pressure, CHCI3 (200 mL) was added, and the solution was washed with water (2 
x 200 mL), aq saturated NaCl solution (2 x 200 mL), and dried (Na2 SC>4 ). The solvent 
was removed under reduced pressure to give crude product which was purified by flash 
chromatography (SiC>2 , hexane: ethyl acetate = 1 :1 ) to yield white solid product (1.28 g,
1.92 mmol, 46%): mp 67-68 °C; ‘H NMR (400 MHz, CDCI3) 6  2.70 (t, 2H, J=7.6 Hz),
2.72 (t, 2H, J=7.4 Hz), 3.03 (t, 2H, J=7.6 Hz), 3.05 (t, 2H, J=7.8 Hz), 3.22 (app. q, 2H, 
J=5.6 Hz), 4.05 (t, 2H, J=5.2 Hz), 4.88 (t, 1H, J=6.3 Hz, NH), 7.27-7.39 (m, 12H), 7.69- 
7.78(m, 2H); 13C NMR (100.5 MHz, CDC13, CDC13 central peak set at 77.23)
8  30.78,30.85, 35.15, 35.29, 42.25, 6 6 .6 6 , 66.71, 68.99, 127.40, 128.33,128.44,128.46, 
128.52, 128.54, 128.74 (degenerate), 129.40, 129.60, 133.30, 135.77, 135.81, 137.70, 
146.22, 147.72, 172.17, 172.28; IR(KBr) 3288, 3033, 2953, 2927, 1731, 1362,1326,
1188, 1168, 1095, 1008, 915, 756, 700 cm"1; HRFABMS, m/z (M+H)+ exact mass for 
C3 4 H36NO9 S2 : 666.1832; Found: 666.1817 (error-1.4 mmu/-2.2 ppm).
Benzyl 3-(4-chlorosulfony]phenyl)propionate (146): A solution o f 3-(4- 
chlorosulfonylphenyl)-propionic acid 148 (1.70 g, 6.84 mmol), benzyl alcohol (960 mg, 
8.85 mmol), and p-toluenesulfonic acid monohydrate (23.0 mg, 0.121 mmol) in benzene 
(150 mL) was refluxed for 18 h under a Dean-Stark trap. The solution was then washed 
with 0.1 M HC1 (250 mL), water (200 mL), and brine (200 mL), and subsequently dried 
(Na2 SC>4 ). The solvent was removed under reduced pressure to give product (2.08 g, 6.14 
mmol, 90%, >95% purity): 'H NMR (500 MHz, CDCI3 ) 8  2.71 (t, 2H, J=7.3 Hz), 3.05 (t,
146
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2H, J=7.3 Hz), 5.09 (s, 2H), 7.22-7.34 (m, 5H), 7.35-7.40 (XX5 of AA’XX’, 2H), 7.85- 
7.89 (AA’ of AA’XX’, 2H); 1 3C{*H} NMR (125.7 MHz, CDC13) 6  30.65, 34.68, 66.38,
127.08, 128.20, 128.28, 128.50,129.67, 135.62, 142.09, 149.06,171.69; MS, m/z, 338 
(M+). The compound was used without further purification.
3-(4-chlorosulfonylphenyl)-propionic acid (148): Gradual addition of 
hydrocinnamic acid 147 (2.7 g, 18 mmol) to chlorosulfonic acid (7.00 mL, 12.3 g, 106 
mmol) at 0 °C gave a solution which was maintained at 65 °C for 1.5 h, and then poured 
on ice (200 g). The precipitate was collected by suction filtration to give crude product 
which was recrystallized from hot benzene to give crystalline product (1.9 g, 7.7 mmol, 
43%): 'H NMR (400 MHz, CDC13) 5 2.77 (t, 2H, J=7.4 Hz), 3.09 (t, 2H, J=7.4 Hz), 7.48 
(d, 2H, J=8.4 Hz), 7.98 (d, 2H, J=8 . 6  Hz); 13C NMR (100.5 MHz, CDC13) 8  30.58, 34.70, 
127.58, 129.86, 142.79, 148.76, 177.79.86
Benzyl-3-(4-(2-(l l-carbo-tert-butoxymethyl-1,4,8,11-tetraaza- 
bicyclo[6.6.2]hexadec-4-yI)-ethylsulfamoyl)phenyl)propionate (149). 4-(Carbo-tert- 
butoxymethyl)-l,4,8,l l-tetraazabicyclo[6.6.2]hexadecane 74 (30 mg, 0.091 mmol) was 
dissolved in dry CH3CN (5 mL), Na2 C0 3 (9.6 mg, 0.091 mmol) and N-(4-(benzyl 3- 
propionate) phenylsulfonyl) aziridine 137 (31.4 mg, 0.0909 mmol) were added, and the 
mixture was stirred for 16 h at 80 °C under N2. After cooling to room temperature, the 
contents were filtered through Celite, and the filtrate was evaporated to dryness to yield 
product (48 mg, 0.070 mmol, 77%): 'H NMR (400 MHz, CD3CN, CD2//CN central peak 
set at 1.94) 8  1.22-1.50 (m, 4H), 1.43 (s, 9H), 2.20-2.73 (m, 20H), 2.70 (t, 2H, J=7.4 Hz),
147
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2.73-2.95 (m, 2H), 3.00 & 3.19 (AB, 2H, J=17.0 Hz), 3.00 (t, 2H, J=7.1 Hz), 3.14-3.24 
(m, 1H), 3.34-3.58 (m, 1H), 3.58 (br s, 1H), 5.07 (s, 2H), 7.27-7.38 (m, 5H), 7.36-7.42 
(XX’ of AA’XX’, 2H), 7.70-7.76 (AA’ of AA’XX’, 2H); ' ^ { ’H} NMR (100.5 MHz, 
CD3 CN, CD3CN central peak set at 1.37) 5 24.52 (br), 25.65 (br), 28.44 ((CH3 )3 C), 31.31, 
35.81, 40.88 (br), 50.66 (br), 51.78, 52.24 (br), 53.80 (br), 54.80 (br), 55.00, 56.01, 56.24 
(br), 56.67, 59.63 (br), 66.95, 82.34, 128.10,129.06, 129.15, 129.58, 130.20, 137.52,
139.36, 146.99, 171.66, 173.22; IR(CH3 CN) 3400 (br), 3164, 3033, 2981, 2941, 2853, 
1734, 1437, 1374, 1159 cm’'; HRFABMS, m/z (M+H)+ exact mass for C^HseNsOftS: 
686.3951; Found: 686.3958 (error +0.6 mmu/+0.9 ppm).
4-(Carbo-tert-butoxymethyl)-l l-(2-(tosylamino)ethyl)-l,4,8,l 1- 
tetraazabicyclo-[6.6.2]hexadecane (151): To a solution of 4-(carbo-tert-butoxymethyl)-
1,4,8,1 l-tetraazabicyclo[6.6.2]hexadecane 74 (45.0 mg, 0.132 mmol) in CH3CN (10 mL), 
l-((4-methylphenyl)sulfony) aziridine 150 (26.1 mg, 0.132 mmol) was added. The 
mixture was refluxed for 18 h. The solvent was removed under reduced pressure to give 
product (71.1 mg, 0.132 mmol, -quant, >90% purity): 'H NMR (500 MHz, CD3 CN, 
CD2HCN central peak set at 1.94) 5 1.20-1.44 (m, 4H), 1.43 (s, 9H), 2.26-2.78 (m, 16H), 
2.41 (s, 3H), 2.80-2.92 (m, 2H), 2.92-3.24 (m, 5H), 2.98 & 3.18 (AB, 2H, J=16.6 Hz),
3.44 (td, 1H, J=11.7, 4.2 Hz), 3.66-3.76 (m, 1H), 7.35-7.39 (XX’ of AA’XX’, 2H), 7.69-
7.73 (AA’ of AA’XX’, 2H); ^C l'H } NMR (125.7 MHz, CD3CN, CD3CN central peak 
set at 1.37) 8  21.55, 28.28, 28.47, 42.68, 52.54 (br), 52.55, 54.23, 55.08, 55.10, 56.65, 
56.88 (br), 57.03 (br), 57.78, 58.11, 58.82 (br), 59.72 (br), 81.08, 127.94, 130.71, 138.64,
144.36.
148
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(ll-(2-(Toluene-4-sulfonylamino)ethyl)-l ,4,8,1 l-tetraazabicyclo[6.6.2]- 
hexadec-4-yl)-acetic acid «2TFA (152«2TFA): tert-Butyl-(l 1-(2-(toluene-4- 
sulfonylamino)ethyl)-l,4,8,l l-tetraazabicyclo[6.6.2]hexadec-4-yl)acetate 151 (71.1 mg, 
0.132 mmol) was dissolved in a mixture of CF3 CO2 H (TFA) (10 mL) and CH2 CI2 (10 
mL). The solution was stirred for 16 h at room temperature. Solvent was then removed 
under reduced pressure to give product (94.0 mg, quant): ’H NMR (400 MHz, CD3CN, 
CD2HCN central peak set at 1.94) 5 1.62-1.71 (dm, 1H, J=17.0 Hz), 1.71-1.82 (dm, 1H, 
J=16.8 Hz), 2.18-2.38 (m, 2H), 2.42 (s, 3H), 2.38-2.49 (m, 1H), 2.51-2.82 (m, 4H), 2.84- 
3.70 (m, 19H), 3.59 & 4.08 (AB, 2H, J=17.3 Hz), 6.90 (br s, 1H), 7.00-7.70 (br s, 3H), 
7.36-7.43 (XX’ of AA’XX’, 2H), 7.72-7.77 (AA’ of AA’XX’, 2H); 13C{]H} NMR 
(100.5 MHz, CD3 CN, CD3CN central peak set at 1.37) 5 20.31, 20.80 (br), 21.60, 38.32, 
49.10, 49.15,49.48 (br), 49.68, 54.28, 54.54, 55.32 (br), 56.34 (br), 56.75, 58.05 (br), 
58.83, 58.98, 117.38 (q, JCf=290.7 Hz, CF3 C 02), 128.06, 130.95, 137.29, 145.22, 161.01 
(q, Jcf=35.1 Hz, CF3 CO2 ), 172.14. There are 2 TFA based upon mass calculation.
149
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Appendix
150
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Spectral Index
151
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